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ABSTRACT 
 
Rheumatoid arthritis is an autoimmune disease in which various mediators of immune 
function play a vital role in the pathological process, influencing its development, 
progression and severity. 
 
The aim of this study was to investigate the relationship between markers of immune 
dysfunction and the disease process. One of the main objectives was to identify key 
biomarkers involved in early RA (<1 year) and their association with disease measures and 
development of established disease (>5 years). Another objective was to determine the 
relationship between biomarkers of the peripheral circulation and the synovial joint, and to 
investigate the association of markers from both environments with disease activity and 
severity. The influence of smoking on biomarker expression and its relationship with 
disease activity and severity was also investigated. 
 
Using ELISAs and bead-based multiplex assays, 41 mediators were analysed in the sera of 
early RA (n=86), established RA (n=77), OA (n=20), PsA (n=34) and ReA (n=26) patients 
as well as in paired sera and synovial fluid of 52 RA patients. Data were analysed using a 
variety of statistical methods including hierarchical clustering, principal component 
analysis, regression analysis and ROC analysis. 
 
This study demonstrated the involvement of numerous interleukins, matrix remodelling 
mediators and pro-inflammatory mediators in the disease process in both early and 
established RA, and enabled its differentiation from other arthritides. In addition, 
biomarkers from both the synovial fluid and the peripheral circulation were found to be 
 V 
associated with disease activity and severity. Cigarette smoking influenced biomarker 
expression in both the systemic and local environment, and a smoking associated 
biomarker profile was associated with worse disease. 
 
This study reveals that RA is an extremely heterogeneous disease involving many 
mediators in a complex network which may include various pathological routes. Many of 
these biomarkers could potentially become new targets for disease intervention. 
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INTRODUCTION 
 
 2 
1.1.1 Arthritis Overview 
 
Arthritis originates from the Greek word arthro- meaning joint, and –itis meaning 
inflammation. It is a group of damaging musculoskeletal disorders affecting the synovial 
joints through inflammation. There are over 100 conditions of arthritis which include 
reactive arthritis (ReA), gout, Lyme disease and numerous others. This research focuses 
primarily on rheumatoid arthritis (RA). However, investigation into reactive arthritis 
(ReA), psoriatic arthritis (PsA) and osteoarthritis (OA) were also undertaken to make 
comparisons between different arthritic diseases and RA. 
 
1.1.2 Rheumatoid arthritis, an introduction 
 
Rheumatoid arthritis is an autoimmune disease, where the immune system is in 
dysfunction and initiates an inappropriate immune response against components of the host 
body which is termed as “self”. This gives rise to the attack of its own targeted cells or 
tissues which are normally present in their body as it perceives it as a ‘”non-self” or 
foreign antigen. RA is a systemic disease which affects many tissues and organs but 
primarily affects the synovial joints. RA currently has no known cure, however the disease 
is managed with various drug therapies which will be discussed later (Section 1.1.12 RA 
Treatment). RA can affect both males and females of all ages and ethnicity. It 
predominantly occurs in individuals 40-50 years of age, particularly in females. The 
precise aetiology of the disease is still unknown, though a multi-factorial combination of 
both environmental and genetic factors is considered to be integral to the onset of RA. 
 
 3 
Immune function in RA disease is thought to be highly dysregulated, involving a persistent 
and excessive expression of immunomodulatory and inflammatory mediators. This results 
in chronic inflammation which leads to the destruction of the synovial joints in a 
symmetrical manner. This is a distinguishing characteristic of the disease. The majority of 
RA cases progressively become more severe over time, which ultimately leads to disability 
and functional impairment. The disease is said to be extremely heterogeneous in terms of 
developmental course, disease characteristics, range of outcomes (mild with limited bone 
damage to severe with deformity, disability and premature mortality), and therapeutic 
responses, with the majority of cases becoming progressively more severe over time (van 
der Pouw Kraan et al., 2003). Remission of the disease can occur in rare cases, but 
disability and deformity of the disease is however permanent. Therefore the inflammatory 
response is critical to the pathogenesis of RA, as well as its severity and progression. 
 
The specific pathologic mechanisms leading to the onset and development of RA have yet 
to be understood. Therefore, the role of inflammatory mediators and their complex 
interaction network is crucial to further understanding of the disease. 
 
1.1.3 History of RA 
 
The presence of RA was first observed in the skeletal remains of Native American Indians 
dated to 8000 BC, and 4500 BC, in Tennessee (Rothschild and Woods, 1990, Aceves-
Avila et al., 2001). Other evidence of RA was discovered (Aceves-Avila et al., 2001), in 
pre-historic individuals living in 500BC in India, and 100BC in Italy. In both instances, 
descriptions of the disease by its characteristic deformities and symmetrical arthritis were 
observed. RA may also have been observed in the late 15th Century where Flemish artists 
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illustrated swelling and deformity of the metacarpophalangeal (MCP) joints of their 
subjects’ hands. In 1578 the first distinction of RA was identified in Mexico (Aceves-Avila 
et al., 2001). In 1676 a joint disease was described by characterizing its chronicity and 
deformities (Aceves-Avila et al., 2001). In 1800, Dr Landre-Beauvias published the first 
definitive description of RA (Landré-Beauvais, 2001). Finally, in 1859, Sir Alfred Garrod 
documented a case in an individual and gave the disease its current name of Rheumatoid 
arthritis. 
 
1.1.4 RA Classification 
 
Since the first recording of RA, the definition of the disease is now more detailed and 
specific compared to Garrod’s initial description. Until 2009, the accepted classification of 
RA was the 1987 American College of Rheumatology (ACR) revised criteria (Arnett et al., 
1988), where a minimum of 4 out of 7 criteria must be met to be diagnosed as Rheumatoid 
arthritis (Table 1.1.4a).  
 
Table 1.1.4a: The 1987 American College of Rheumatology (ACR) revised criteria set for 
the classification of rheumatoid arthritis (RA). 
Criteria Qualifying parameters 
1. Morning stiffness Duration > 1 hour before maximal improvement for 6 weeks 
2. Arthritis of > 3 joints* Soft tissue swelling over 6 weeks determined by a physician 
3. Arthritis of hand joints Swelling of the wrist, PIP or MCP joints over 6 weeks 
4. Symmetrical arthritis Same joints affected on both sides of the body over 6 weeks 
5. Rheumatoid nodules Subcutaneous nodules determined by a physician 
6. Rheumatoid factor Positive by a method where 95% of normal control subjects are negative 
7. Radiographic changes 
Bone erosion or decalcification observed on posteroanterior hand and 
wrist radiographs 
* Possible joints: left or right PIP (proximal interphalangeal), MCP (metacarpophalangeal), wrist, elbow, 
knee, ankle and MTP (metatarsophalangeal) joints. Table reproduced from (Arnett et al., 1988). 
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In 2010 a new classification criteria for RA was set (Table 1.1.4b) (Aletaha et al., 2010), 
which focuses on early disease characteristics that are associated with chronic or erosive 
RA, rather than defining it using established disease charactersitics. This system is based 
on an algorithm scoring system, where individuals must score >6 out of 10, with at least 1 
“B” and 1 “C” criteria to be defined for the presence of definite RA. This new RA 
classification criteria can confirm early unconfirmed RA diagnoses, and thus effective drug 
therapy can be administered at an earlier stage of their disease. 
 
Table 1.1.4b: The 2010 American College of Rheumatology (ACR)/European League 
Against Rheumatism (EULAR) criteria for RA. 
The 2010 ACR/EULAR criteria for RA Score 
Target population, patients who:  
1. Have at least 1 joint with definite clinical synovitis  
2. with synovitis not explained by another disease  
  
Classification criteria for RA (score-based algorithm)  
A. Joint involvement  
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without large joint involvement) 2 
4-10 small joint (with or without large joint involvement) 3 
>10 joints (with at least 1 small joint) 5 
  
B. Serology (at least 1 test result is needed for classification)  
Negative RF and negative anti-CCP 0 
Low-positive RF or low positive anti-CCP 2 
High-positive RF or high-positive anti-CCP 3 
  
C. Acute-phase reactants (at least 1 test result is needed for classification)  
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
  
D. Duration of symptoms  
<6 weeks 0 
>6 weeks 1 
Reproduced from (Aletaha et al., 2010). 
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1.1.5 Epidemiological morbidity: prevalence and incidence rates 
 
Rheumatoid arthritis can affect both males and females of any age, although it 
predominantly occurs between the ages of 40 to 50 years old. The disease is also more 
prevalent in females than in males, with a 3:1 ratio (Majithia and Geraci, 2007). Females 
also exhibit a more severe and progressive disease along with a worse long-term outcome. 
This appears to be increased further in female smokers (Criswell et al., 2002). The reason 
for females commonly having worse disease than males is unknown, although it has led to 
the suggestion that sex hormones may be involved (Da Silva and Hall, 1992). 
 
It is estimated that up to 1% of the world population is affected with RA. Although the 
disease can affect any ethnicity, the prevalence rate can differ quite significantly between 
some populations. A few Native American tribes have a 5-6% higher prevalence rate of 
RA, such as the Pima Indians (5.3%), and the Chippewa Indians (6.8-7.1%) (Silman and 
Pearson, 2002, Ferucci et al., 2004). The high prevalence rates in Native American Indians 
suggest a major genetic influence in these populations (Peschken and Esdaile, 1999, 
Ferucci et al., 2004). 
 
Low prevalence of RA are found in southern Europe with a rate of 0.3-0.7%. Similarly, 
populations in south-east Asia (China and Japan), show also low prevalence rates (0.2-
0.3%) (Alamanos and Drosos, 2005). Reports from developing countries also show low 
rates, ranging from 0.1-0.5% and where African ancestry populations (Carribean, Nigerian 
and South African) indicate very little presence of RA (Silman and Pearson, 2002). 
Though genes play a major role in RA, environmental and lifestyle factors also contribute 
to the onset of the disease. 
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The mean annual incidence rate of RA is estimated to be 0.02-0.05% in North American 
and North European countries (Alamanos and Drosos, 2005). In the UK, a study in 1994 
determined the annual disease incidence to be 0.014% in males and 0.036% in females 
(Symmons et al., 1994). Another study in 1999 estimated that the annual rate of RA 
incidence in the UK could be in the region of 0.012% for males and 0.03% for females 
(Wiles et al., 1999). These small numbers of RA incidence studies, along with a lack of 
incidence rate studies in developing countries make its very difficult to determine precise 
incidence figures (Alamanos et al., 2006). 
 
1.1.6 Aetiology 
 
The exact aetiology of RA is still currently unknown, however it is a general consensus 
that the disease is thought to be triggered by a combination of both environmental and 
genetic factors. The contribution of the genetic component is thought to constitute 
approximately up to 60% towards RA susceptibility. This was shown from a study of 
monozygotic and dizygotic twins, using two published nationwide population studies 
(Macgregor et al., 2000). Additionally, familial inheritance also increases the risk of RA 
(Deighton et al., 1992, Grant et al., 2001). Therefore a large proportion of RA 
susceptibility, approximately 40%, arises from environmental factors influencing disease 
development. 
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1.1.6.1 Genetic factors 
 
Comprehensive RA genetic research has demonstrated a genetic susceptibility for the 
development of the disease in certain individuals. The genetic contribution to RA is 
extensive and will be discussed in a separate section (Section 1.2.1 RA genetics). This 
section of RA aetiology will continue to discuss the role of environmental factors. 
 
1.1.6.2 Environmental factors 
 
As of yet, no specific environmental factors have been conclusively identified, although 
there are numerous environmental factors that have been suggested that contribute to RA 
onset and development such as pathogenic infections. 
 
1.1.6.2.1 Pathogens 
 
A number of studies have proposed the role of micro-organisms as a potential RA onset 
trigger. A few viruses and bacteria have been detected within RA patients, including the 
Epstein Barr Virus (EBV), rubella, parvovirus B19, cytomegalovirus (CMV), bacterial 
DNA and peptidoglycan (PG) -a major bacterial cell wall component in gram-positive 
bacteria. Additionally, the association of bacteria as the cause of onset and development of 
Reactive Arthritis as well as the various animal models of arthritic disease induced by 
bacteria, supports the notion that bacteria may play a role in disease development, although 
most probably within a specific subset of patients. 
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Although the mechanism behind the roles of pathogens in RA aetiology is unclear, there 
have been two suggested mechanisms. One is “molecular mimicry”, where a viral or 
bacterial antigen mimics a structure within the joint, creating an immune response towards 
the antigen but also the synovium as a consequence. Another possible mechanism is the 
“carrier effect” mechanism. A foreign antigenic peptide cross-reacts and conjugates with 
an endogenous synovial peptide. The immune system directs its response towards the 
foreign antigen, as well as inappropriately recognizing the host peptide, initiating 
autoimmunity. 
 
1.1.6.2.2 Other factors 
 
Numerous other environmental factors have been investigated, including coffee 
consumption, climate, atmospheric toxins, pollution and cigarette smoking. Of these, 
cigarette smoking has been identified to be the most important contributing factor to RA in 
terms of both onset risk and disease severity (Heliovaara et al., 1993, Gorman, 2006). 
However the extent of cigarette smoking needed to trigger RA onset is unclear, as well as 
the mechanisms behind it. 
 
It is perhaps not surprising that cigarette smoking is involved in RA pathogenesis as it is 
widely known that smoking is hazardous to health, contributing to other diseases such as 
cancer, chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD) and 
asthma. Tobacco smoke contains over 4000 chemicals of which 50 are carcinogenic. 
Therefore it is quite plausible that any of these toxins could be responsible for the 
development of RA. The effect of cigarette smoking on RA patients and its interactions 
will be discussed further in detail in Section 1.2.2. 
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1.1.7 Mortality and Co-Morbidity 
 
Rheumatoid arthritis is a systemic inflammatory disease that affects many organs and 
tissues, though the joints are the principal targets of attack. The mortality rate is increased 
a minimum of 2 fold in RA compared to the general population, and increases with 
duration of the disease (Wolfe et al., 1994, Myllykangas-Luosuj~irvi et al., 1995, Naz, 
2007). As the disease develops, life expectancy of RA patients is reduced by 3-18 years, 
where patients with a more severe disease have an increased risk for earlier mortality 
(Reah, 1963, Reilly et al., 1990, Myllykangas-Luosuj~irvi et al., 1995). However, patients 
who respond to therapy have a better survival rate, and thus mortality rate is quite variable 
(Naz, 2007). 
 
RA patients are associated with an increased risk to CVD such as atherosclerosis, stroke, 
mycocardial infarctions (MI) and ischaemic heart disease (IHD) (Wolfe et al., 1994, 
Aviña-Zubieta et al., 2008, Gupta and Fomberstein, 2009). These types of diseases occur 
in approximately 50% of RA patients (Aviña-Zubieta et al., 2008). Other co-morbid 
diseases and disorders include hypertension, Sjogren’s syndrome, Felty’s syndrome, 
neuropathy, pericarditis, fibromyalgia, lymphadenopathy, non-Hodgkin’s lymphoma, 
pleural effusion, renal amyloidosis, diabetes, carpal tunnel, respiratory diseases such as 
lung cancer, fibrosis and pulmonary disease to name a few (de Groot, 2007, Naz, 2007). 
Co-morbidity is a common extra-articular aspect associated with RA and is a major 
contributor to mortality (Naz, 2007). 
 
The increased risk of mortality from co-morbid diseases may be explained by cigarette 
smoking, autoantibodies and the Human Leukocyte Antigen (HLA) genes, all of which 
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have been shown to be RA associated factors. Apart from a role in predisposing patients to 
RA disease, these factors could possibly render RA patients more susceptible to co-morbid 
diseases (Myllykangas-Luosuj~irvi et al., 1995, Mattey et al., 2007, Turesson et al., 2007). 
Another explanation for increased mortality rate could be due to the reduced functionality 
and mobility of the joints. Physical activity would be subsequently decreased, which may 
in turn contribute to higher CVD mortality due to the lack of fitness through 
cardiorespiratory exercise. 
 
Along with co-morbid diseases, RA patients can also experience flu like symptoms, such 
as fatigue, fever, anaemia, weight loss, morning joint stiffness, loss of appetite and a 
general feeling of unwell. These are all common systemic symptoms and can be quite 
pronounced, especially in people who have acute onset RA. 
 
1.1.8 Physiology of RA 
 
The synovial joint consists of a fibrous capsule surrounding two adjoining bones. The inner 
layer of the capsule is the synovial membrane, also known as the synovium (Figure 1.1.8a). 
Under normal healthy conditions, synovial like-fibroblasts and macrophage-like cells 
(synoviocyte A and B respectively) within the synovium produce and secrete hyalaronan 
(hyaluronic acid) and lubricin into the joint space (Bresnihan, 1999). These two 
constituents, along with trapped water, are the major components of the synovial fluid, 
which is responsible for the nourishment and lubrication of the articular cartilage and bone. 
This allows for fluidic movement, with the synovial membrane keeping the fluid contained 
within the joint space (Unsworth et al., 1971, Bresnihan, 1999). 
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Figure 1.1.8a: The joint and its structural components 
 
 
Reproduced from (Neumann, 2010) via http://ittcs.wordpress.com/2010/05/24/anatomy-and-physiology-
facet-joints-of-the-spine/, adapted by S. Judah 2014. 
 
 
In RA however, the synovial joint undergoes extensive degradation and damage due to 
excessive inflammation of the synovium (synovitis) and is used as a distinguishing factor 
of RA. This inflammation causes the joint capsule to swell (edema), due to an excess of 
synovial fluid (effusion) from the inflamed synovium (Figure 1.1.8b). Synovitis causes 
joint tenderness, swelling, and thus the pain felt by patients. In addition, inflammatory 
damage is not limited to just the joint, but also the surrounding tissue including the bursae, 
the tendon sheath and the ligaments. This subsequently weakens the ligaments ability to 
stretch, causing tendons to rupture and muscles to spasm and atrophy, leading to 
contracture (Unsworth et al., 1971, Bresnihan, 1999). 
 
Initially, synoviocytes A and B proliferate extensively (hyperplasia), increasing the 
thickness of the synovium from 2-3 cell layers up to 10 cell layers thick. In addition, the 
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number of blood vessels plus its permeability increase within the synovium, allowing an 
excess of fluid to enter the joint tissue resulting in swelling. In addition, an influx of 
leukocytes infiltrate the synovium which also secrete pro-inflammatory and degradative 
markers (eg. Matrix Metalloproteinases and degranulating neutrophilic enzymes), causing 
inflammation and destruction of the cartilage (Unsworth et al., 1971, Bresnihan, 1999). As 
the disease develops, the granuloma synovium becomes heavily inflamed, and makes this 
tissue protrude and extend out (the pannus) towards the cartilage and the bone surface 
(Figure 1.1.8b). The pannus adheres and infiltrates the articular cartilage surface, eroding it 
with leukocyte inflammatory mediators and numerous enzymes from osteoclasts, replacing 
it with soft fibrous connective tissue (Figure 1.1.8b). As the cartilage is degraded, the 
fibrous tissue left by the pannus is ossified by osteoblast cells which turn the tissue into 
bone. This ultimately fuses the two bones of the joint together, leading to crippling and 
immoveable affects. The destructive nature of the pannus is also involved in the 
destruction of the bone at the epiphysis corners, the ligaments, the joint capsule, the 
extracellular matrix (ECM), and the surrounding tissues. In addition, the excess synovial 
fluid creates a barrier for nutrients diffusing into the cartilage, which results in the 
starvation and necrotic death of the cartilage cells. The persistent inflammation and the 
resulting joint destruction cause joint swelling, tenderness and pain. This leads to the 
impairment of motility and functionality in varying degrees, as well as to deformity and 
disability (Unsworth et al., 1971, Bresnihan, 1999). Figure 1.1.8c demonstrates the 
progression of RA in an untreated patient over a period of 3 years, where it clearly depicts 
the thinning of the cartilage, fusion of the bones, and most dramatically, the erosion at the 
epiphysis corners of the bone (Figure 1.1.8c). 
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Figure 1.1.8b: Comparison of a normal joint and a joint affected by RA 
 
Reproduced from http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/default.asp. 
 
Figure 1.1.8c: Progression of joint damage in an RA patient over 3 years by radiographic 
imaging 
 
Reproduced from http://www.nras.org.uk/about_rheumatoid_arthritis/what_is_ra/what_is_ra.aspx. 
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1.1.9 Pathophysiology of RA 
 
Within a healthy individual there is a natural equilibrium which regulates the balance of 
the pro and anti-inflammatory response. The pathology of RA is due to an imbalance of 
this equilibrium with an excess of pro-inflammatory mediators, which is critical for the 
development, severity and progression of RA. There are various mediators involved in RA 
disease pathology including cytokines, chemokines, acute phase proteins including CRP, 
matrix metalloproteinases (MMPs), A Disintegrin And Metalloproteinases/ with 
Thrombospondin motifs (ADAM/Ts), degrading enzymes (collagenases, aggrecanases, 
cathepsin K, granulocyte enzymes) (Kojima and Ishiguro, 2012), prostaglandins, calcium 
binding protiens including calgranulin, T regulatory cell suppression, antibodies, serine 
proteases (neutrophil elastase), reactive oxygen species and numerous others that both 
directly and indirectly affect the destruction of the joint (Figure 1.1.9a) (Hutchinson et al., 
2002, Liao et al., 2004). However pro-inflammatory and immunomodulatory markers are 
the major mediators responsible for the pathogenesis of RA (Choy and Panat, 2001). RA 
pathophysiology is typically described as a T helper (Th) 1 type (CD4+ T cell) disease as a 
strong presence of Th1 type cytokines are found within the inflamed joint comparatively to 
other pro-inflammatory markers (Panayi et al., 1992, Fox, 1997, Miossec and van den 
Berg, 1997). Specifically, tumor necrosis factor-α (TNF-α), interleukin (IL) -1 and IL-6 are 
the most commonly known Th1 cytokines associated with RA and are key mediators in its 
pathology (Panayi et al., 1992, Fox, 1997, Choy and Panat, 2001). Although these 
cytokines are generally regarded as the main drivers in RA disease, there are numerous 
other inflammatory mediators at the joint site such as interferon (IFN)-γ, IL-12, IL-7, IL-8 
IL-17, IL-18, monocyte chemotactic protein (MCP) -1 and granulocyte macrophage-
colony stimulating factor (GM-CSF) to name a few, that are integral to the pathological 
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process. Not only are they conducive to directly inducing inflammation and joint 
degradation, but they also stimulate various cells within the joint to induce the expression 
of additional inflammatory markers (van Roon et al., 2003). This type of positive feedback 
loop creates and sustains the persistent inflammation found and characterised by this 
disease and hence termed as a chronic inflammatory disease. 
 
The pro-inflammatory response in the joint primarily arises due to the significant 
infiltration of leukocytes into the thickened synovium from the peripheral circulatory 
system, particularly macrophages and CD4+ T lymphocytes (Panayi et al., 1992, Fox, 
1997, Choy and Panat, 2001). These leukocytes migrate to the joint by passing through the 
blood vessels via adhesion molecules into the tissue, which are recruited in response to 
inflammatory chemoattractant stimuli from localized chemokine production from the joint 
(chemotaxis). The increased cellular infiltration of leukocytes, secreteing TNF-α and IL-1 
as well as other mediators promotes the induction of angiogenesis within the synovium and 
surrounding tissues. With the formation of new blood vessels, the number of immune 
effector cells migrating into the synovium is increased, including CD8+ cytotoxic T cells 
(Tc), granulocytes (neutrophils, basophils and eosinophils), mast cells, natural killer cells 
(NK), B cells and dendritic cells (DC) to the joint (Figure 1.1.9a). In addition, synovial 
macrophages and dendritic cells also function as APCs wtihin the joint, thereby 
contributing to further inflammation and establishing a localized immune response in the 
tissue. These various cells all contribute to disease pathology, increasing the swelling and 
the pain felt by patients as they secrete a vast spectrum of inflammatory mediators, 
degranulating enzymes, histamines and various other mediators such as prostaglandins and 
autoantibodies (Chaiamnuay and Louis Bridges Jr, 2005). This ultimately leads to the 
destruction of all the components within the joint (Choy and Panat, 2001). 
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Figure 1.1.9a: An overview of the main cells involved in RA disease 
 
Reproduced from www.bentham.org/.../afeltra/afeltra_.html adapted by S.Judah 2011. 
 
 
Although RA pathophysiology is predominately based upon the chronic stimulation of pro-
inflammatory mediators attacking the joint, non-immune cell types are also involved in RA 
disease. These include fibroblasts, chondrocytes, osteoclasts and osteoblasts. Resident 
fibroblasts stimulated by TNF-α and IL-1 from recruited T cells and macrophages, in turn 
secrete MMPs and various pro-inflammatory mediators which not only target the cartilage 
and bone for destruction, but recruit and promote additional leukocytes into the joint, such 
as neutrophils and monocytes. 
 
Chondrocytes reside in the cartilage and are responsible for maintaining the cartilaginous 
extracellular matrix (ECM) consisting of collagen and proteoglycans. With persistent 
stimulation and over expression of key pro-inflammatory mediators such as TNF-α and IL-
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1, chondrocytes alter to a pathological role secreting matrix degrading enzymes, such as 
MMP-1 and MMP-3. These ECM degrading enzymes target and attack the components of 
the cartilaginous matrix damaging the cartilage. The pro-inflammatory mediators secreted 
by T cells also stimulate and activate osteoclasts, which are responsible for bone 
resorption. Furthermore, TNF-α and IL-1 mediators simultaneously inhibit osteoblasts, 
which suppresses bone formation as type II collagen and proteoglycans are not synthesized 
(Figure 1.1.9b) (Goldring, 2003). The activation of osteoclasts and suppression of 
osteoblasts in concert with chronic inflammation and degrading enzymes therefore 
pernamently damage the bone, as well as inhibits the ability to repair the bone structure.
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Figure 1.1.9b: The general pathophysiological process of RA 
 
Reproduced from (Pope, 2002). 
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1.1.10 RA disease features 
 
RA is diagnosed and characterized by various disease features as classified by the 1987 
ACR revised criteria. These include early morning stiffness and the symmetrical arthritis 
of synovial joints, specifically the hands, bone erosion, nodules and rhematoid factor (RF). 
 
1.1.10.1. Synovial Joints 
 
Rheumatoid arthritis can gradually occur or manifest suddenly with a severe attack. In the 
early stages of disease, RA typically presents itself in the smaller peripheral synovial joints 
of the hands and feet. In particular, the distal and proximal interphalangeal (DIP and PIP 
respectively) and the metacarpophalangeal (MCP) joints of the fingers and the 
metatarsophalangeal (MTP) joints of the toes are primarily observed to be swollen and stiff 
(typically in the morning). It is unknown why in the initial symptomatic stages of the 
disease the smaller joints are affected first. However, they are not exclusively the only 
joints to show signs of early disease. 
 
As RA disease progresses in severity, the number of joints affected also increases as it is 
polyarticular, manifesting in the larger synovial joints such as the wrists, elbow, knees and 
ankles, along with the shoulders, neck, spine and jaw. It is not yet understood what governs 
the reason for disease development in these specific joints. The progression of the disease 
differs greatly for each patient, with the number and particular joints affected varying for 
each patient. Some patients only have acute short term symptoms, but for the majority of 
people, it is a progressive and painful disease for life, with flare exacerbations and 
remissions of joint swelling, stiffness and pain. Joint damage usually begins within the first 
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two years of the disease. As such, the first two years of the disease is classified as early 
RA, with particular emphasis on the first year of disease (Scott, 2007). 
 
Another clear indication of symptomatic disease of the joints is the erosion of the bone and 
cartilage. This is not always evident in recently diagnosed patients due to the lack of 
disease severity in the early stages where only 10-26% of RA patients develop erosions 
within 3 months from onset of the disease. Joint degradation has a very distinct 
morphology compared to a healthy joint and is assessed by radiographic techniques. In 
severe cases, the destruction of the joint can be so extensive that deformity and disability 
occur as a result, requiring the possibility of a joint replacement. Figure 1.1.10.1a 
illustrates the hands of an RA patient with severe deformity, while Figure 1.1.10.1b shows 
a radiographic comparison between a healthy individual hand and that of a RA patients’ 
hand, demonstrating that RA disease can affect the bone structure greatly. Eighty percent 
of these severe RA patients are disabled after 20 years of the disease. 
 
Although RA is a systemic disease, the characterization of disease severity is determined 
wholly upon the joint. This is based on the presentation of symptoms (joint pain, stiffness, 
tenderness and swelling), damage, physical function performing daily activities, deformity 
and disability. 
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Figure 1.1.10.1a: An RA patient with extrememly deformed hands. 
 
Reproduced from http://www.cedars-sinai.edu/5234.html. 
 
Figure 1.1.10.1b: Radiographic images of a healthy individual hand compared with a 
deformed hand of a RA patient. 
 
Reproduced from http://64.143.176.9/library/healthguide/en-us/support/topic.asp?hwid=zm6061 courtesy of 
Intermountain Medical Imaging, Boise, Idaho and courtesy of Paul Traughber, M.D., Boise, Idaho 
respectively. 
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1.1.10.2 Subcutaneous nodules 
 
Another feature of RA is the manifestation of extra-articular (“outside the joints”) features 
such as subcutaneous nodules (Turesson et al., 2003). These nodules are granuloma-like 
formations, ranging from a few millimetres to a few centimetres in diameter. This extra-
articular feature is a common characteristic of RA and is associated a severe erosive 
arthritis and mortality (Kaye et al., 1984). Nodules develop underneath the skin in the 
subcutaneous tissue overlying the bone (Figure 1.1.10.2). They are frequently observed at 
sites of mechanical pressure and stress, such as around the joints, as well as the hands, the 
back of the head, ears, heels, arms and legs (Ziff, 1990). Suppression of such stress may 
promote the disappearance of the nodule within a few days (Veys and De Keyser, 1993). 
Nodules can also develop in connective tissue of systemic organs, such as the valves of the 
heart, the meninges and the pleura. However this rarely occurs at these diverse sites except 
in patients with a very severe disease (Ziff, 1990). Five percent of patients develop nodules 
withing the 1st 2 years, which increases to 20-35% of patients with longer disease duration 
(Turesson et al., 2003). 
 
The development of nodules is unknown. However, it may come about through a piece of a 
bone that has become separated from the main bone fixture, which migrates and settles 
within the subcutaneous tissue (Ziff, 1990). Histologically, subcutaneous nodules have an 
appearance of a granuloma, which matures and consists of 3 distinct zones. These zones 
comprise of a central zone of necrotic tissue, a surrounding layer of palisading 
macrophages plus fibroblast mononuclear cells, and an outer layer of vascular connective 
tissue with infiltrating lymphocyte and plasma cells (Ziff, 1990, Baeten et al., 2004). The 
pathologic process of nodule formation is unknown, although it may be similar to joint 
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synovitis. This is due to the presence of various leukocytes and a Th1 pro-inflammatory 
cytokine profile (TNF-α, IFN-γ and IL-1β) which have been found within the nodule 
(Wikaningrum et al., 1998, Hessian et al., 2003). 
 
Figure 1.1.10.2: A subcutaneous nodule in an RA patient. 
 
Reproduced from (Hahn et al., 2005). 
 
 
 
1.1.10.3 Autoantibodies 
 
Another characteristic of RA is the development of autoantibodies. There are two 
commonly recognised autoantibodies present in RA disease: rheumatoid factor (RF) and 
anti-cyclic citrullinated protein (anti-CCP). The specific role for either autoantibody in RA 
pathology has not been determined. Although, they do contribute indirectly to RA disease 
pathology by tissue opsonisation, leukocyte mediated cytokine production, immune 
complex formation, apoptosis induction and initiating the complement system 
(Chaiamnuay and Louis Bridges Jr, 2005). 
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1.1.10.3.1 Rheumatoid Factor 
 
Rheumatoid factor (RF) is an autoantibody directed against the Fc region (the constant 
region) of immunoglobulins (Ig) to form immune complexes which contribute to disease. 
RF is important in RA pathology, as studies have found it to be independently associated 
with disease onset, severity, bone erosion, co-morbid diseases and increased mortality risk 
(Reilly et al., 1990, Myllykangas-Luosuj~irvi et al., 1995, Másdóttir et al., 2000, Wolfe, 
2000, Mattey et al., 2001b, Vencovsky´ et al., 2003, Greiner et al., 2005, Lindqvist et al., 
2005, Sihvonen et al., 2005, Mewar et al., 2006, Mattey et al., 2007, Turesson et al., 2007, 
Nielsen et al., 2012). High seropositive RF titres are also independently shown to be 
strongly associated with the presence of nodules which occur in approximately 20-30% of 
Caucasian RA patients. This would suggest that RF may be involved in the formation of 
subcutaneous nodules (Kaye et al., 1984, Mattey et al., 2002b). RF is thus used as a marker 
for disease severity, progression and outcome, and are additionally useful markers for 
prognosis since the majority of studies have shown elevated expression of RF are 
associated with a more destructive articular outcome (Vencovsky´ et al., 2003, Greiner et 
al., 2005, Lindqvist et al., 2005). 
 
RF is found to be present in approximately 60-90% of RA patients (van Gaalen et al., 
2005). RA patients are frequently seronegative within their first year of onset, but the 
frequency of seropositivity increases with disease duration, with 80% of patients 
developing RF over time. However there are a few RA patients that do not present with RF 
(10-40%). Rheumatoid factor is not restricted to RA, as it has been found to be present in 
other diseases such as Sjogren’s syndrome, systemic lupus erythematosus (SLE), and 
mixed connective tissue disease, as well as being present in 5-10% of normal healthy 
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individuals. RF has been shown to have approximately 60-70% sensitivity rate for RA 
disease (Nishimura et al., 2007), with a specificity rate of 70-80% but is still routinely used 
as an aid in the diagnosis and characterisation of RA (Westwood et al., 2006, Song and 
Kang, 2009). 
 
1.1.10.3.2 Anti-cyclic citrullinated protein 
 
Anti-cyclic citrullinated proteins (anti-CCP) are autoantibodies directed against cyclic 
peptides containing the amino acid citrulline. Citrulline is enzymatically converted in the 
post-translational modification of arginine residues in proteins by peptidylarginine 
deiminase (PAD) enzymes during inflammation and apoptosis (van Gaalen et al., 2005). 
Commercial assays for detecting antibodies to citrullinated proteins use a citrullinated 
peptide containing a dilsulphide bond which allows formation of a loop that transforms the 
synthetic peptide into a cyclic peptide (Figure 1.1.10.3.2) (Chaiamnuay and Louis Bridges 
Jr, 2005). 
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Figure 1.1.10.3.2: The generation process of anti-CCP autoantibodies. 
 
Reproduced from http://www.medscape.com/viewarticle/516643_2. 
 
 
The specific role of anti-CCP autoantibody in RA disease is unknown, although if the 
shape of the peptide is sufficiently altered, the crulline containing peptide could be seen as 
an antigen by the immune system thereby invoking an immune response. Studies have 
shown however that anti-CCP is independently associated with severity, bone erosion, co-
morbidity, nodules and increased mortality (Forslind et al., 2004, Greiner et al., 2005, 
Lindqvist et al., 2005, Sihvonen et al., 2005, van Gaalen et al., 2005, Avouac et al., 2006, 
Mewar et al., 2006, Turesson et al., 2007). This indicates that this autoantibody is 
important in the pathology of RA, and is used as a marker for disease severity, progression 
and outcome as well as a useful marker for prognosis (Vencovsky´ et al., 2003, Forslind et 
al., 2004, Avouac et al., 2006, Turesson et al., 2007, Valesini and Alessandri, 2009). Anti-
CCP is a very specific autoantibody to RA (88-96%), although rarely, it can be found in 
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other diseases such as psoriatic arthritis, SLE, Sjogren syndrome and scleroderma, as well 
as in healthy normal individuals, allowing for a sensitivity rate of 70-77% (Coenen et al., 
2007). Anti-CCP therefore has become a more reliable and effective tool for RA diagnosis, 
as it is more precise than RF but with similar accuracy (Greiner et al., 2005, van Gaalen et 
al., 2005, Nishimura et al., 2007). 
 
Since both autoantibodies are strongly associated with disease pathology (Mewar et al., 
2006, Agrawal et al., 2007), a combination of both anti-CCP and RF are found to be the 
most accurate prediction of severity and joint damage in RA patients (Vencovsky´ et al., 
2003, Forslind et al., 2004, Song and Kang, 2009). Both autoantibodies can also manifest 
in patients many years prior to the onset of RA, and before any joint symptoms are felt by 
the patient. Studies have revealed that this is associated with an increased risk for 
developing RA, as well as early disease onset (Rantapää-Dahlqvist et al., 2003, Vossenaar 
and van Venrooij, 2004, Niewold et al., 2007, Diaz et al., 2011, Nielsen et al., 2012). 
Despite the presence of both autoantibodies can occur before onset of RA, no evidence has 
been shown to suggest that they are the initial onset cause of disease, but rather as part of 
the pathological process. As no immediate effect is observed when autoantibodies develop, 
this suggests that additional aspects such as genetic and environmental factors are required 
for the onset of RA. As such, both these autoantibodies are considered as prognostic 
markers for RA development (Chaiamnuay and Louis Bridges Jr, 2005). 
 
Despite their strong association with disease pathology, these autoantibodies are not solely 
responsible for the pathological process of RA. As mentioned above, some RA patients are 
negative for the presence of either autoantibody, and in contrast, healthy individuals 
negative for RA can be positive for either autoantibody (<1%). This suggests that various 
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inflammatory mediators other than these autoantibodies are also driving and contributing 
to the disease pathological process. 
 
1.1.11 Other arthritides 
 
Many studies have investigated other autoimmune diseases as well as different arthritides 
in comparison with RA to determine differences and gain insights into the different 
processes between the different patholgies. In the present study, comparisons were made 
between RA patients and patients with two other types of inflammatory arthritis (psoriatic 
arthritis, reactive arthritis) and a “non-inflammatory” arthritis; osteoarthritis. These three 
different forms of arthritis’ are generally considered to have a less severe disease 
pathology outcome compared to that of RA. A brief description of each these arthritides is 
provided below. 
  
1.1.11.1 Reactive arthritis 
 
Reactive arthritis is an asymmetrical inflammatory oligoarthritic disease that arises in 
response to an infection in a distant part of the patients’ body. The infection triggers an 
immune response against the infection as well as subsequently against the joints, gradually 
developing 1-4/6 weeks after the initial infection (Kim et al., 2009, Kwiatkowska and 
Filipowicz Sosnowska, 2009). It is unclear why these “reactive” symptoms develop in 
areas of the body that were not infected by the foreign antigen, though a number of 
possible explanations have been suggested. It is postulated that the immune system hyper-
responds to the initial infection, which creates an abundance of the inflammatory response, 
resulting in the destruction of surrounding tissues, thereby inducing autoimmunity (Hill 
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Gaston and Lillicrap, 2003). Studies have found that joint culture results are negative in the 
majority of patients, making it unlikely that a viable infection can exist within the joint 
space. However non-viable fragments of bacterial antigens such as nucleic acids and 
proteins have been identified in the synovium, which may cause the immune response, and 
so trigger the onset of disease (Pacheco-Tena et al., 2001, Singh et al., 2007b). These 
infection fragments created through the destruction of the antigen could circulate in the 
bloodstream and migrate, and subsequently deposit in the joint, creating a persistent 
presence of foreign material within the joint, triggering the onset of disease and the 
inflammatory cascade. A third possibility is the presence of an arithrogenic type peptide 
sequence within the foreign antigen protein structure. In such a situation, the immune 
system would recognize and target the arthritogenic peptide within the joint, as well as the 
invading antigen (Hill Gaston and Lillicrap, 2003). 
 
The invading organism responsible for onset of ReA can occur at any site in the host, but is 
usually present in the gut or urethra. Infections that are in the gut could be responsible for 
the onset of ReA include shigella, salmonella, streptococcus, campylobacter and yersinia 
(Ugrinovic et al., 1997). Additionally, Chlamydia, neisseria gonorrhoeae, HIV and viral 
infections that cause sore throat, coughs and skin rashes can sometimes be the antigenic 
trigger to disease. It is very difficult in determining what the initial infection is, as it is 
usually treated and cured before the symptoms of reactive arthritis develop and are 
observed. However, arthritic symptoms can sometimes appear before the initial infection is 
resolved (Hill Gaston and Lillicrap, 2003). 
 
Reactive arthritis is also known as Reiter’s syndrome, as it was first discovered by the 
German doctor, Dr Reiter. It is a systemic extra-articular disease, with three common 
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symptoms- urethritis, conjunctivitis and uveitis. Patients can also express additional 
symptoms including skin rashes, mucocutaneous lesions, circinate balantis, keratoderma 
blennorrhagica (Figure 1.1.11.1), mouth ulcers, gastrointestinal and genitourinary 
problems, fever, weight loss, nail changes similar to psoriasis, nodules primarily on the 
soles of their feet, tiredness, and in rare instances heart and kidney problems. Certain 
features of reactive arthritis resemble rheumatoid arthritis, with inflammatory swelling and 
pain affecting the lower and peripheral joints. These include joints such as the knee, 
ankles, toes and the hands, wrists and feet, but also can affect the spine, making it 
additionally a spondylarthropathic type condition. Joint arthritis develops very quickly 
(typically within a day), though in some cases it develops gradually. Like RA, synovitis 
affects the surrounding tissue such as the tendons (tendonitis) and ligaments, which 
become inflamed and swollen with enthesitis and dactylitis common features of ReA. 
Diagnosis of the disease is determined by the presence of these clinical measures for more 
than one month, plus microbial culture tests to determine presence of infection (Hill 
Gaston and Lillicrap, 2003, Kim et al., 2009, Kwiatkowska and Filipowicz Sosnowska, 
2009). 
 
Reactive arthritis, unlike RA which is a chronic disease, is usually self-limiting. Once 
arthritis develops, it will run its full course, ranging from a few weeks to years. Most 
patients experience symptoms lasting 2-6 months, and these then dissipate without leaving 
any long-term problems termed as acute ReA. Patients with ReA lasting longer than 6 
months are termed as chronic, and are likely to have bone erosion and disability as a result, 
as well as manifestation of extra-articular features. Chronic ReA is observed in 
approximately 4-19% of patients. ReA disease duration varies between patients, possibly 
due to the genetic disposition of the individual, as well as the type of triggering pathogen 
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within the host (Hill Gaston and Lillicrap, 2003, Kim et al., 2009, Kwiatkowska and 
Filipowicz Sosnowska, 2009). 
 
ReA is typically observed in 4% of the population. It can occur at any age but is mostly 
seen between the ages of 20-40 (Kvien et al., 1994). In contrast to RA, ReA is more 
common in males than in females (3:1), and has a more severe pathology in males (Bas et 
al., 2001). The disease affects individuals worldwide but is more prevalent in Caucasian 
individuals due to its strong association with the presence of the HLA-B27 molecule which 
is predominantly found in white populations. Studies have shown that about 70% of ReA 
patients are positive for HLA-B27 and are more likely to have severe and prolonged 
episodes of ReA (Kim et al., 2009, Kwiatkowska and Filipowicz Sosnowska, 2009). 
 
There is no cure for reactive arthritis, as in the majority of cases the disease will disappear 
in 3-4 months. Antibiotics are only prescribed to eliminate the initial bacterial infection 
that triggered the disease. There are treatments that relieve disease symptoms, including 
the use of analgesics and non-steroidal anti-inflammatory drugs which reduce 
inflammation and pain. Patients with severe ReA can be prescribed immunosupproesive 
drugs (methotrexate and sulphalzaxzine), corticosteroids or biologic therapy if they cannot 
be controlled by other drugs (Hill Gaston and Lillicrap, 2003, Kim et al., 2009, 
Kwiatkowska and Filipowicz Sosnowska, 2009). 
 
A number of patients (15-50%) after recovery have symptoms that can re-emerge months 
or even years after the first onset. This may be due to a spontaneous flare-up or a reaction 
as a result of a new infection, as the patient is more susceptible to repeated infections. 
Repeated attacks over many years are common and can develop into a chronic condition 
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that ultimately leads to joint erosion, disability and systemic extra-articular manifestations 
(Hill Gaston and Lillicrap, 2003, Kim et al., 2009, Kwiatkowska and Filipowicz 
Sosnowska, 2009). 
 
Figure 1.1.11.1: Pustules on the feet of a Reactive arthritis patient. 
 
Reproduced from http://archive.student.bmj.com/issues/00/03/education/70.php 
 
 
1.1.11.2 Psoriatic arthritis 
 
Psoriatic arthritis (PsA) is a systemic autoimmune inflammatory type arthritis which 
commonly affects the joints of the hands and feet causing swelling, stiffness and pain. This 
disease can also affect the larger joints of the body including the wrists, knees, elbows, 
shoulders, hips and at times the spine (spondyloarthropathic). Psoriatic arthritis typically 
presents as a mild asymmetrical oligoarticular disease, however with time it often 
progresses and develops to a symmetrical polyarticular pattern. This disease is said to 
resemble RA symptomatically although the majority of patients experience a milder form 
of severity than RA patients (McGonagle et al., 2011, Mease, 2011). 
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Other symptoms experienced by patients with PsA are general tiredness, swelling of the 
hands, feet and digits (dactylitis), along with the muscle, entheses (enthesitis) and tendons 
(tendonitis), further limiting movement (Carneiro et al., 2011). Patients also experience 
shortening of the digit due to bone lysis, bone fusion and digit telescoping where the bone 
overlaps another. As a result of disease progression, 20% of these patients will develop a 
severe disease outcome with increasing inflammation, pain, joint destruction and disability. 
Psoriatic arthritis patients who initially present polyarticular disease, have a higher risk for 
disease progressing into a severe phenotype with joint deformity, plus an increased 
mortality rate due to the development of co-morbid diseases (Gladman et al., 2005). 
 
This disease not only affects the joints, but a skin rash of raised red skin with scales or 
plaques also develop in parallel (Figure 1.1.11.2a). This rash is similar to patients with 
psoriasis (PS) alone. Approximately 10-30% of PS patients develop PsA due to the 
persistence of the pro-inflammatory response. Usually, the more severe presentation of 
skin rash, the greater the likelihood that PsA develops, which occurs approximately 10 
years after the first signs of psoriasis. There is a subset of patients, where the arthritic 
symptoms develop prior to the presence of the skin rash. Psoriatic arthritis is typically 
described as a RF sero-negative arthritic disease. However RF has been detected in 
approximately 13% of patients with PsA. Unlike RA, the presence of extra-articular 
manifestations such as nodules are not present in PsA (Mease, 2011). Other manifestations 
of the disease include nail pitting, which are round lesions on the surface of the nail plate 
and occur in 80% of PsA patients (Figure 1.1.11.2b). Onycholysis can occur in extreme 
severe cases, which is the complete loss of the nail itself. 
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Psoriatic arthritis disease can manifest at any age, although it does tend to develop between 
the ages of 30-50 years old. The prevalence of the disease is estimated to be between 2-3% 
of the general population, and 7% of the total arthritic population. Furthermore, people 
who have psoriasis have a higher rate of arthritis than the general population. Disimillar to 
RA, both males and females are equally susceptible to the disease, although females tend 
to have a worse PsA outcome compared to males (Gladman et al., 1987, Gladman et al., 
2005). 
 
The exact cause of PsA is unclear, though a number of associations with particular genes 
have been identified. These include the HLA- class 1 type MHC molecules, including 
those of the B and C classes, as well as IL-23R and IL-12B SNPs (Rahman and Elder, 
2005, Liu et al., 2008). Unfortunately, both psoriatic arthritis and psoriasis are life-long 
conditions, with no cure as yet. The treatment of the disease is similar to that of RA where 
NSAIDs and DMARDs are used, and if necessary biologic therapy (Gottlieb et al., 2008). 
Remission of the PsA disease can occur, though this tends to be observed in male patients 
with a low number of inflamed joints. Additionally, flare-ups of the disease can occur at 
any time point after the initial treatment. Complete remission of the disease is rare (6% of 
patients), and a majority of patients are on some type of permanent drug therapy to manage 
the disease. 
 
 
 
 
 
 
 36 
Figure 1.1.11.2a: Skin psoriasis rash.        Figure 1.1.11.2b: Nail pitting. 
  
Figure 1.1.11.2a reproduced from (Goedkoop et al., 2004). 
Figure 1.1.112b reproduced from http://www.psoriasis-tablets.com/psoriasis_skin.html 
 
 
1.1.11.3 Osteoarthritis 
 
Osteoarthritis (OA) is a non-inflammatory disease that involves degradation of the joint. It 
is the most frequent type of arthritis in the UK, affecting approximately 8.5 million people, 
and more prevalent in females than in males (Brandt et al., 2009). 
 
This degenerative arthritis typically affects joints which are load bearing and under the 
most mechanical activity such as the knees, hips, spine and the small joints of the hands 
and feet. These joints are the most motile and therefore more prone to be affected, although 
any joint can be afflicted by the disease. The disease involves degradation of the joint 
where the cartilage thins down until the bone ends are exposed for erosion. OA is 
considered to be a non-inflammatory disease especially when compared to RA, although 
mild inflammation of the joint does occur. This arises due to the break down products of 
the cartilage which are deposited into the synovial space. Synoviocytes within the synovial 
membrane increase and consequently attempt to remove the break down products. Some 
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patients experience a synovial effusion of the joint due to the amount of fluid that builds up 
in the joint space. As the disease progresses, the joint space between the bones narrows, 
due to thickening and creation of new bone to compensate for the lack of protection from 
the worn down cartilage. This leads to bone contact and locking with creation of a fused 
joint, where the ends rub together causing friction and further bone damage (Kean et al., 
2004, Dieppe and Lohmander, 2005, Abramson and Attur, 2009, Brandt et al., 2009). 
 
A distinguishing feature of OA is the formation of osteophytes which develops around the 
edges of the joint as an attempt to repair disease damage unlike in RA. This type of bone 
outgrowth however can be quite debilitating for articular movement and create another 
friction point which can cause pain to the patient. During the progression of OA, bone 
nodes which are hard bony enlargements, develop particularly on the DIP and PIP joints. 
Nodes, although not directly painful to the patients, do significantly limit the movement of 
the peripheral joints (Figure 1.1.11.3a). OA at the toes leads to the development of bunions 
(Kean et al., 2004, Dieppe and Lohmander, 2005, Abramson and Attur, 2009, Brandt et al., 
2009). As a result of decreased movement, muscles, tendons and ligaments begin to 
atrophy and relax. 
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Figure 1.1.11.3a: Presentation of OA in the hands. 
 
Reproduced from http://www.hopkins-arthritis.org/arthritis-info/osteoarthritis/clinical_4.html 
 
 
Patients with OA experience joint pain, tenderness and stiffness but not typically swelling 
as a non-inflammatory type arthritis. Symptoms can differ greatly between patients ranging 
from mild to severe, with the number of joints and the amount of damage. In addition, OA 
patients feel worse through the day due to use of their joints, while RA patients often feel 
better after motility. Unlike RA which progressively worsens in severity, OA plateaus over 
time but patients experience persistent stiffness and pain. In some individuals, symptoms 
are alleviated as the body repairs itself, while in others the damage is too severe for joint 
repair- such patients will always experience stiffness and pain (Kean et al., 2004, 
Abramson and Attur, 2009, Brandt et al., 2009). 
 
Most cases of OA have no known cause and are referred to as primary OA, which is 
characterized as chronic and degenerative. Primary OA is associated with aging due to the 
“wear and tear” process, and is most prevalent in individuals over 50 years old. OA 
develops gradually over many years as the protein content (collagen) within the cartilage 
decreases over time, and thus is susceptible to degradation. The ‘wear and tear’ action is 
not the direct cause of the condition, as some elderly people do not suffer from OA (Radin 
 39 
et al., 1972). Other factors such as infection, injury, hereditary factors, pathological and 
congenital disorders, obesity, developmental causes plus metabolic and mechanical 
stresses are considered to be causes of secondary OA. Mechanical stress is the most 
common cause of osteoarthritis. This includes bone misalignment, injury, obesity, loss of 
supporting joint muscle strength, and peripheral nerve impairment that lead to movements 
that overstress the joints (Kean et al., 2004, Valdes and Spector, 2008, Brandt et al., 2009). 
Regardless of the cause of OA, the resulting pathology is the same in primary and 
secondary OA. A sub-set of primary OA is termed erosive OA (EOA) which has an 
aggressive pro-inflammatory response compared to normal OA, and results in high bone 
erosion of the DIP joints. This condition though is not a common form of OA (Belhorn and 
Hess, 1993). 
 
Figure 1.1.11.3b: Differences between the various joint states. 
 
 
There is currently no cure for OA. The symptoms are managed through the use of 
analgesics, to reduce the amount of pain and inflammation. Modifying lifestyle aspects, 
such as losing weight and physical therapy also help, as it alleviates the pressure on the 
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joint and keeps it motile. NSAIDs are prescribed if conventional pain relief is not 
sufficient. A number of other treatments such as glucocorticoids and antibodies are also 
available for moderate to severe patients. In severe OA patients, joint replacement surgery 
or resurfacing can be undertaken if previous treatments were ineffective (Dieppe and 
Lohmander, 2005, Abramson and Attur, 2009, Brandt et al., 2009). 
 
The table below (Table 1.1.11) summarizes the major similarities and differences between 
the different arthritides. 
 
Table 1.1.11: Comparison of arthritides 
  OA PsA ReA RA 
Cause/origin 
natural joint 
degradation, "wear and 
tear" 
autoimmune 
A cross-
reaction in 
response to 
infection 
autoimmune 
Disease pattern 
• oligo and polyarthritic 
• peripheral & large 
joints 
• load bearing & high 
mechanical activity 
joints 
• asymmetrical 
• oligoarthritic 
progressing to 
polyarthritic 
• peripheral & 
large joints 
• asymmetrical 
progressing to 
symmetrical 
• oligoarthritic 
• peripheral, 
large & lower 
joints 
• asymmetrical 
• polyarthritic 
• peripheral, large  
& lower joints 
• symmetrical 
Disease span 
chronic & progressive 
(gradual), which 
plateaus over time 
chronic & 
progressive 
acute & self 
limiting 
chronic &  
progressive 
Disease features 
• finger bone nodes & 
osteophytes (bone 
spurs) 
• skin rash with 
raised scale 
plaques 
• finger digit 
shortening 
• nail pitting 
• feet & palm 
pustules/nodul
es, skin rashes 
& lesions 
• nail pitting 
• urethritis, 
conjunctivitis 
& uveitis 
•HLA-B27 
positive (70%) 
• subcutaneous 
nodules 
Autoantibodies RF seronegative 
typically RF 
seronegative 
(87%) 
RF 
seronegative 
typically anti-CCP 
 & RF seropositive  
(60-90%) 
Age range 50+ 30-50 20-40 40-50 
male:female 
ratio 
1:2 1:1 3:1 1:3 
Prevalence 3.8% 2-3% 4% 1% 
OA=Osteoarthritis, PsA=Psoriatic arthritis, ReA=Reactive arthritis, RA=Rheumatoid arthritis. 
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1.1.12 RA Treatment 
 
Complete and permanent remission of RA disease is very rare, with the majority of 
patients suffering from the disease until mortality, which is often premature. Patients can 
experience periods of regression, followed by flare-ups which are exacerbated symptoms. 
As such, the disease is managed by reducing inflammation and the destructive activity of 
RA with the use of various chemical agents. Drugs for the treatment of RA can be classed 
into two categories: non-steroidal anti-inflammatory (NSAID) and disease modifying anti-
rheumatic drugs (DMARD) (Green, 2001). 
 
1.1.12.1 NSAID treatment 
 
NSAIDs have 2 major actions which include an analgesic which reduces the pain felt by 
the patient as well as acting an anti-inflammatory agent which reduces stiffness and 
swelling. This occurs through the inhibition of cyclooxygenase (COX) type enzymes 
which subsequently reduce prostaglandin levels from damaged tissue and thus decreases 
the level of inflammation and symptoms felt by the patient (Vane, 1996). There are various 
NSAIDs used to treat RA patients (asprin, ibuprofen, celecoxib, diclofenac, diflunisal, 
etodolac etc.) as not all NSAIDs are effective for each patient. However, they all have 
similar anti-inflammatory and analgesic effects (Majithia and Geraci, 2007). As every 
individual is different, their response to NSAID treatment will also differ between them. 
NSAIDs do not actually effect the pathophysiology of RA, but aid more in the 
management of its symptoms. NSAIDs therefore are commonly used in conjunction with 
more potent RA drugs such as disease modifying anti-rheumatic drugs (DMARDs) and 
biologics that help slow disease development and progression. 
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NSAIDs vary in strength and thus the level of COX enzyme inhibition and ultimately 
expression of prostaglandins. Prostaglandin not only stimulates inflammation but also aids 
in the protection of the stomach lining and kidneys. High strength NSAIDs therefore can 
inhibit prostaglandin synthesis excessively which can cause negative side effects termed as 
adverse drug reactions (ADR), which are undesired secondary responses of the intended 
drug effect. Other ADRs include stomach pain, skin rash, constipation, diarrhoea, 
dyspepsia, drowsiness, nausea, anaemia, dizziness, leg swelling, headaches, ear ringing, 
skin bruising (Giercksky et al., 1989, Bjarnason et al., 1993, Rainsford, 1999). NSAIDs 
can also have toxic effects which are any outcomes that are harmful to the body generally 
resulting from high doses of the drug. Toxic effects of NSAIDs include anaphylaxis, 
abnormal liver enzyme levels, increased heart attack and stroke risk, increased blood 
pressure, kidney (fluid retention) and liver damage. NSAID toxicity can also induce 
stomach ulcers and gastrointestinal bleeding and therefore a strong stomach acid blocker is 
also prescribed to prevent stomach problems. Due to the number of ADRs and toxicity, 
NSAIDs should be prescribed with caution to patients if they have kidney or liver disease, 
heart failure, high blood pressure, diabetes, asthma or ulcers. As a consequence the COX-2 
inhibitor NSAIDs (eg. Celecoxib and etoricoxib) were developed. These function in a 
similar way to the original NSAIDs but were believed to have reduced ADRs. However, 
numerous ADRs similar to those of the original NSAIDs, have been reported (Giercksky et 
al., 1989, Bjarnason et al., 1993, Rainsford, 1999). Corticosteroids are prescribed to RA 
patients when traditional NSAIDs fail (Süleyman et al., 2007). Corticosteroids reduce pain, 
stiffness and swelling in RA patients. This drug is used on a short term basis as long term 
use of the drug creates ADRs such as weight gain, acne, excess hair growth, menstrual 
irregularities, insomnia, skin bruising, muscle weakness and skin thinning. This treatment 
can cause ulcers, stomach bleeding, osteoporosis, cataracts, glaucoma, diabetes, fluid 
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retension, infection susceptibility, hypertension, capillary fragility as well as making 
existing conditions such as diabetes and glaucoma worse (Süleyman et al., 2007). 
 
1.1.12.2 DMARD treatment 
 
In patients where NSAIDs are not effective, DMARDs are used instead. DMARDs alter 
the disease course as they slow down the progression and improve long term outcome as 
well as relieve symptoms like inflammation, stiffness and swelling. They do not however 
reverse the damage already presented (Nandi et al., 2008). DMARDs work by dampening 
down the functional activity of immune cells. This includes reducing the production of 
inflammatory molecules, as well as cell division rate by inhibiting enzymes responsible for 
producing DNA and RNA. There are numerous DMARDs currently used with varying 
modes of action and efficacy in patients. They are slow acting with a delay of 3-6 months 
before a response is observed (Capell et al., 2007). Early administration of DMARDs is 
therefore more effective for RA patients to limit the progression and damage of the disease 
(Emery, 1995). However, this is not always implemented, as patients must meet certain 
criteria to move onto DMARDs (Nell et al., 2004). The most commonly prescribed 
DMARDs are Methotrexate (MTX), leflunomide, hydroxychloroquine and sulphasalazine. 
In particular, MTX is the preferred drug of choice, especially when active RA has been 
diagnosed. However it does not work in every patient so a trial and error based method of 
DMARD treatment is undergone until the most suitable drug is determined. DMARDs lose 
their effectiveness over time (2-5 years) as patients develop resistance to them but are most 
likely to be discontinued in patients first due to the high level of toxicity (Alarcóan et al., 
1989, Pincus et al., 2004, Donahue et al., 2008). DMARDs are usually well tolerated, 
though there are a few ADRs as a cause of their action. These include nausea, vomiting, 
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headaches, dizziness, abdominal pain, mouth ulcers, diarrhoea, hair loss or thinning, skin 
rashes (Pincus et al., 2004, Donahue et al., 2008). In addition, DMARDs have toxic effects 
and cause liver and kidney damage, decreased WBC count, susceptibility to infections (due 
to alteration of the immune system from DMARDs), high blood pressure, pancreas gland 
inflammation, lung disease and increases the risk of birth defects (Donahue et al., 2008). 
Combinations of DMARDs are often used together but at lower doses, which allows the 
toxicity and ADRs to be kept at a reduced level and provide increased efficacy in patients 
who do not respond to just one DMARD (Capell et al., 2007, Majithia and Geraci, 2007). 
Additionally, NSAIDs can also be used in conjunction with DMARD therapy to target both 
aspects of RA disease. 
 
1.1.12.3 Biologic therapy 
 
With an increased understanding of pathology in the joint, drug development has shifted 
away from chemical agents and directed to the development of biological agents. Increased 
knowledge of cells and molecules that have significant roles in RA have been used as 
specific targets for therapeutic intervention. Biologic therapy is a new form of treatment 
for RA which targets specific molecules, both soluble and cell-bound and competitively 
binds to them. This alters their functional ability either by inhibiting them or acting as 
decoys by binding to cell receptors thereby activating cell processes. There are now a few 
biologic therapies available with varying modes and sites of action: either cytokine or cell 
mediated. Table 1.1.12.3 summarizes these biologic therapies. 
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Table 1.1.12.3: Summary of Biologic drugs currently available. 
Drug Primary action Structure Administration 
Half 
Life 
Infliximab 
TNF-α antagonist, 
activate complement & 
destroy TNF-α 
expressing cells 
Chimeric anti-TNF 
monoclonal antibody 
Intravenous (IV) 
infusion 
9 days 
Etanercept 
TNF-α & β 
(lymphotoxin) 
antagonist 
Recombinant 
heterodimeric TNF 
receptor II fusion 
protein 
Subcutaneous 
injection 
4 days 
Adilumimab 
TNF-α antagonist, 
activate complememt 
& destroy TNF-α 
expressing cells 
Chimeric anti-TNF 
monoclonal antibody 
Subcutaneous 
injection. Self 
administered 
2 weeks 
Certolizumab TNF-α antagonist 
Chimeric anti-TNF-α 
monoclonal antibody 
Subcutaneous 
injection 
2 weeks 
Anakinra 
IL-1 Receptor 
antagonist (Ra) 
Recombinant non-
glycosylated human 
IL-1ra 
Subcutaneous 
injection 
4-6 
hours 
Rituximab 
Binds to B cell CD20 
inducing down-
regulation of B cell 
receptor, sheds CD23 
IgE receptor, increases 
HLA II & adhesion 
molecules plus induce 
B cell destruction  
Chimeric murine anti-
CD20 monoclonal 
antibody 
Intravenous 
infusion 
1-16 
days 
Abatacept 
Binds to B7, CD80/86 
on APC inhibiting 
CD28 T cell co-
stimulation of naïve T 
cell 
Cytotoxic T 
lymphocyte-associated 
antigen 4-Ig 
(CTLA4Ig) fusion 
protein. 
Intravenous 
infusion 
13 days 
Tocilizumab/MRA 
IL-6 Receptor 
antagonist 
Anti-IL-6 receptor 
monoclonal antibody 
Intravenous 
injection 
- 
 
Biologic therapy supersedes conventional therapy of DMARDs, although a third of 
patients do not respond to this type of therapy. Clinical studies where patients do respond 
to therapy, have shown it to be effacious with complete and sustained suppression of 
inflammation (Majithia and Geraci, 2007). However, only a 50% reduction in symptoms is 
observed, with patients still functionally disabled. This type of therapy must be continuous 
as relapses can occur if treatment is ceased, although most patients will stop responding to 
treatment eventually. Interestingly, response to biologic therapy decreases if patients had 
previous similar biologic treatment in the past limiting its efficacy. Biologic therapy is well 
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tolerated but can induce side effects including nausea, abdominal pain, fever, malaise, 
headaches, rashes at injection site, vomiting, diarrhoea and respiratory and urinary tract 
infection. It also has toxic effects, liver disease, malignancies, high blood pressure, serious 
susceptibility to infections (tuberculosis etc), convulsion, anaphylaxis, blood cell damage, 
with larger doses increasing the risks of side effects. As it is still a relatively new type of 
treatment the long term side effects are unknown (Majithia and Geraci, 2007). Despite 
these limitations, biologic therapy is still a very useful treatment strategy and further 
development and understanding in this area will ultimately lead to better responses in 
patients. Due to the relative new advancement of biologic therapy, it is a very expensive 
treatment and patients must fulfil specific criteria including failure on MTX and another 
DMARD before being prescribed biologic therapy. Even though studies indicate that early 
referral and early treatment in patients have improved outcomes, diagnosis and 
presentation usually take longer and early treatment is usually too late (Song and Kang, 
2009). 
 
Combination of all 3 drug categories provides the best approach for patients against RA 
disease as it would reduce inflammation and symptoms, slow disease progression and limit 
immune activity. Combination therapy is also useful for limiting ADRs and toxicity since 
using a combination approach allows lower doses of drugs to be administered. Biologic 
therapy in conjunction with DMARDs and NSAIDs therefore has the best potential to 
dramatically reduce RA activity and severity. A study showed where a combination of 
anti-TNF-α biologic therapy and DMARDs improved outcome in RA patients more than 
just a single treatment therapy (Hyrich et al., 2006). As each individual patient is different 
and experience RA differently, it takes time to determine the best combination of drugs by 
trial and error process. 
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1.2.1 RA genetics 
 
There have been a number of genes that have been identified with RA disease. These 
include the Human Leukocyte Antigen (HLA), protein tyrosine phosphatase non-receptor 
22 (PTN22) and the glutathione S-transferase theta/Mu (GST T/M1) gene. The following 
sections details the genes associated with RA that are involved in its onset, development, 
severity, progression and outcome. 
  
1.2.1.1 Identification of the genetic influence 
 
Identification of a genetic component in RA aetiology was determined through inheritance 
studies. In a number of families, the prevalence of RA was higher compared to the general 
population. Additionally, first- and second-degree relatives also had an higher incidence of 
RA than normal healthy individuals, indicating family history as a risk factor (Grant et al., 
2001). From twin studies the concordance for RA showed increased rates in monozygotic 
twins comparatively to dizygotic twins (Aho et al., 1986, Silman et al., 1993). As the 
concordance rate is not fully complete between twins, it indicates that RA aetiology is not 
solely genetic, and an interaction with environmental factors must occur. From these 
studies, the genetic component was calculated to be approximately responsible for 60% of 
RA susceptibility and an integral part for RA onset (Macgregor et al., 2000). 
 
As RA is driven by an excessive pro-inflammatory response, analyses of genes coding for 
proteins that are involved in the immune response and its regulation are of high importance 
for identifying genetic aetiological and pathological factors. The HLA has been thoroughly 
investigated in RA, as this genetic locus has over 200 genes coding for proteins involved in 
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the function of the immune system (Aguado et al., 1999). As a result, it has been 
determined that the HLA is a major factor in RA in both its susceptibility, onset, 
development, severity, progression and outcome and was calculated to contribute 37% to 
the disease (Deighton et al., 1989). 
 
1.2.1.2 Association of the HLA genes with RA 
 
The HLA also known as the Major Histocompatability Complex (MHC) in all mammals 
are cell surface antigen presenting proteins. They are expressed on antigen presenting cells 
(APC) primarily on macrophages and dendritic cells which present antigenic peptides to T 
helper (Th) cells to activate the adaptive immune response and aid in the innate immune 
response. The genetic HLA locus is highly polymorphic with over 6000 HLA alleles 
identified, the majority of which are contained within HLA class I subtypes (HLA-A to –
G, excluding HLA-D). The remaining polymorphic variability are contained in the class II 
subtypes (HLA-DM, -DN, -DO, -DP, -DQ and -DR) (IMGT/HLA-Database, 2011). A 
number of these subtypes have been found to be associated with RA susceptibility as well 
as its onset, development, progression, severity and outcome, specifically the –DR subtype 
(Reveille, 1998). In particular, specific alleles pertaining to the first beta chain gene (B1) 
out of four isoforms of the class II -DR subtype (HLA-DRB1) have been shown to be the 
most associated with RA disease. This gene is encoded at several loci positions for 
different subtypes of the beta 1 chain: HLA-DR1 to HLA-DR17. In particular, alleles of 
the DR1 and especially those of the DR4 subtypes, give the greatest susceptibility for RA 
as well as its severity (Jaraquemada et al., 1986). 
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The most consistent and strongest HLA-DRB1 RA association are the alleles of the shared 
epitope (SE) (Gregersen et al., 1987). The shared epitope is a highly conserved sequence 
of 5 amino acids in the 3rd hypervariable region in certain HLA-DRB1 subtypes and 
represents codons 70-74 of the HLA-DRB1 molecule. Over 15 RA DRB1 alleles posses 
the SE, encoding the amino acids QKRAA, QRRAA and the rare RRRAA sequence, 
where the amino acids specifically differ at position 70-71 in the molecule (Jameson, 
1998). Some SE alleles are greater risk factors than others, eight of which are shown to be 
associated with RA: HLA-DRB1*0101 and *0102 of the DR1 subtype, *0401, *0404, 
*0405 and *0408 of the DR4 subtype, *1001 of the DR10 subtype and *1402 of the DR6 
subtype. Studies have shown that SE alleles are associated more with severity and disease 
progression than with RA onset (Weyand et al., 1992). Despite this, the SE is still a leading 
risk factor in the development for RA disease, as a strong positive association was 
observed with patients positive for SE and the risk of RA development (Criswell et al., 
2006). 
 
Many studies have demonstrated various HLA-DRB1 associations with numerous RA 
features and disease measures. However, those of the DR4 subtype and of the SEs in 
particular have been the most consistent association (Deighton et al., 1989). Patients 
carrying the homozygous SE HLA-DRB1*0401 genotype were shown to be independently 
associated with the presence of subcutaneous nodules (Mattey et al., 2002b). Other studies 
have shown that patients carrying alleles of the shared epitope to be associated with anti-
CCP positivity and concentration, rapid disease progression, worse outcome including the 
presence of erosions as well as early mortality, especially from co-morbid diseases 
independent of RF (Mattey et al., 2001b, Irigoyen et al., 2005, Klareskog et al., 2006, 
Mattey et al., 2007, Farragher et al., 2008, Kapitány et al., 2008, Morgan et al., 2009, 
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Rojas-Villarragaa et al., 2009, Uçar et al., 2011). Rheumatoid factor has had conflicting 
studies, debating its association with HLA-DRB1 genes. A number of studies have shown 
no significant association with this particular disease feature, while other studies have 
demonstrated a positive association (Weyand and Goronzy, 1997, Van Jaarsveld et al., 
1998, Mattey et al., 2002a, Irigoyen et al., 2005, Morgan et al., 2009, Uçar et al., 2011). 
Additionally, it has been suggested that the SE may have non-antigen specific roles in RA. 
It can activate production of nitric oxide (NO), a known vasodilator and reactive oxygen 
species, in increased amounts from B cells and synovial fibroblasts by acting as a 
signalling ligand to the NO-mediated pro-oxidative pathway, and so contribute to RA 
pathogenesis, as well as enhancing inflammation (Ling et al., 2006). 
 
The presence of these particular SE alleles either singularly or in combination, on one or 
both chromosomes respectively, is independently associated with varying degrees of 
progression, severity and early mortality as well as susceptibility and so can be used as a 
possible prognostic factor (Weyand et al., 1992, Mattey et al., 2007, Farragher et al., 
2008). For example, an individual with a homozygous DR4 genotype SE like *0401 and 
*0404 has considerably more RA severity than someone with a homozygous DR1 
genotype, a heterozygous SE or with only one SE such as a *0101, however this 
mechanism is still not understood (Weyand et al., 1992, Wordsworth et al., 1992, Mattey 
et al., 2007). It is thought that the allelic variants are thought to have different peptide 
binding specificity clefts due to the differing amino acids and so form different antigen 
binding pocket specificities to other HLA-DRB1 molecules. This may allow the 
presentation of arithrogenic peptides to occur and consequently initiate the immune 
response. 
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While HLA-DR4 and DR1 show positive association with RA susceptibility, progression 
and severity, the HLA has also been shown to display negative associations to disease 
development and thus are considered to be protective against RA disease. These alleles are 
of the subtypes DR2, DR3, DR5, DR7 and DR8 and are also observed to be less in 
frequency compared to controls (Young et al., 1984, Larsen et al., 1989, del Rincón and 
Escalante, 1999). In particular, it was shown that alleles encoding the amino acid sequence 
DERRA in the SE region, are protective against RA development (Wagner et al., 2003). 
The amino acid sequence of the SE is not the only factor to determine association with RA 
susceptibility. Alleles that encode an aspartic acid residue at position 70 within the β1 
domain protect against RA development (Mattey et al., 2001a). 
 
1.2.1.3 Association of HLA genes with RA prevalence 
 
HLA genetic studies have identified that particular SEs are a major genetic risk factor in 
different ethnic populations. Specific RA alleles are observed more prevalently in certain 
ethnic populations and thus a greater risk than others, with some patients suffering more 
severe forms of RA within the ethnicities (Ferucci et al., 2004). The HLA-DR4 subtype 
gene, alleles DRB1*0401 and *0404 are more prevalent in North American and Western 
European Caucasian populations compared to other ethnic populations (50% and 30% 
respectively) (Silman and Pearson, 2002). High frequencies of HLA-DRB1*1402 were 
observed in American Indians and Alaskan natives (Ferucci et al., 2004). 
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1.2.1.4 Linkage disequilibrium and HLA haplotypes 
 
The contribution of the HLA genes to the development of RA is complicated, as a number 
of genes appear to be “linked” with close or distant genes on the same 6th chromosome. 
Certain alleles have been shown to be commonly observed in conjunction with several 
other alleles from different loci and are inherited together in a block on the same 
chromosome (haplotypes). A number of haplotypes are more frequently observed than a 
random haplotype formation and are said to be in linkage disequilibrium. In addition, the 
two HLA homologous chromosomes are inherited polygenically, meaning that an 
individual will carry and co-dominantly express a heterozygous or a very rare homozygous 
HLA genotype, due to the variability of inheritance (Jirholt et al., 2001). 
 
It has been estimated that ~40% of the HLA genes have a role in the immune system, and 
the others are still of unknown function (Aguado et al., 1999). The carriage of specific 
HLA-DRB1 genes are not the only susceptibility factor for RA, as 10-15% of RA patients 
do not carry any of the specific RA HLA-DRB1 molecules. This was observed in a study 
where the majority of African-American RA patients did not express the SE (McDaniel et 
al., 1995). A study of Greek patients also demonstrated that just over half of patients (57%) 
lacked the HLA-DRB motif (Boki et al., 1992). In particular populations, patients can be 
independent of the presence and dose effect of the SE to the predisposition and severity of 
RA development (McDaniel et al., 1995, González et al., 1997). These studies suggest that 
other immune related gene (a heterogeneous immunogenicity), are involved in disease 
susceptibility within these patients. Conversely there are many individuals that carry the 
RA associated HLA-DRB1 molecules who do not present RA disease, indicating that these 
HLA genes are not the only driving factor for disease development (O’Dell et al., 1998). 
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1.2.1.5 Other RA genetic influences 
 
While the HLA is the primary genetic locus associated with RA development accounting 
for approximately 30-50% of the disease genetic contribution, there are polymorphisms 
outside the HLA region that are also associated with RA disease both with susceptibility 
and severity (Table 1.2.1.5), although, none have shown as strong and consistent 
association as the HLA. Other gene polymorphisms have been identified through the use of 
gene association studies and genome wide association studies (GWAS) (Barton and Ollier, 
2002, Lettre and Rioux, 2008). These type of investigations have brought the total number 
of confirmed RA risk loci to 31 among individuals of European ancestry (Stahl et al., 
2010). Patients expressing a number of risk factor alleles including those of the SE 
therefore may have an increased risk of early onset, disease severity and earlier mortality 
(Lee et al., 2005, Karlson et al., 2008, Orozco et al., 2008).  
 
RA is a polygenic and genetically heterogeneous disease. Thus, a number of different 
genes predispose to RA, which may differ from one patient to another. Furthermore, 
certain combinations of genetic polymorphisms can increase the risk of RA onset (Chen et 
al., 2002). Due to the gentic background of RA involving multiple genes, allelic 
polymorphisms can only partially explain the variable course of RA (Jawaheer and 
Gregersen, 2002). The contribution of genes to RA disease can therefore be used as 
prognostic factor for severity and outcome in patients. 
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Table 1.2.1.5: A selection of identified polymorphic genes that influence RA susceptibility 
and severity 
Polymorphism Gene 
GWAS/Gene Association study 
sources 
Autoimmune regulator (AIRE) (Terao et al., 2011) 
Protein tyrosine phosphatase non-receptor 22 (PTPN22) 
(Begovich et al., 2004, Plenge et 
al., 2005) 
N-acetyltransferase 2 (NAT2) (Tanaka et al., 2002) 
TNF receptor-associated factor 1 (TRAF1) 
(Plenge et al., 2007, Toms et al., 
2011) 
Complement Component 5 (C5) 
(Plenge et al., 2007, Toms et al., 
2011) 
Signal Transducer and Activator of Transcription 4 (STAT4) 
(Sugino et al., 2010, Kunz and 
Ibrahim, 2011, Toms et al., 2011), 
Methylenetetrahydrofolate reductase (MTHFR) (Naoko et al., 2007) 
Serum amyloid A1 (SAA1) gene promoter (Naoko et al., 2007) 
Manganese Superoxide Dismutase (MnSOD) (Mattey et al., 2000) 
Peptidyl-arginine deiminase I4 (PADI4) 
(Suzuki et al., 2003, Sugino et al., 
2010) 
Solute carrier family 22 member 2 (SLC22A2) 
(Tokuhiro et al., 2003, Sugino et 
al., 2010) 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) 
(Gregersen et al., 2009, Sugino et 
al., 2010) 
Cluster Determinant 40 (CD40) 
(Raychaudhuri et al., 2008, Kunz 
and Ibrahim, 2011) 
Protamine 1 (PRM1) (Kunz and Ibrahim, 2011) 
Tumor necrosis factor alpha-induced protein 3 (TNF-ΑIP3) 
(Julià et al., 2008, Kunz and 
Ibrahim, 2011) 
Krueppel-like factor 12 (KLF12) (Julià et al., 2008) 
IL-6 Signal Transducer (IL-6 ST) (Stahl et al., 2010) 
Sprouty-related, EVH1 domain-containing protein 2 (SPRED2) (Stahl et al., 2010) 
Recombining binding protein suppressor of hairless (RBPJ) (Stahl et al., 2010) 
Interferon regulatory factor 5 (IRF5) (Stahl et al., 2010) 
PX domain containing serine/threonine kinase (PXK) (Stahl et al., 2010)  
V-rel reticuloendotheliosis viral oncogene (REL) (Gregersen et al., 2009) 
Protein kinase C theta type (PRKCQ) (Gregersen et al., 2009) 
B lymphoid tyrosine kinase (BLK) (Gregersen et al., 2009) 
AF4/FMR2 family member 3 (AFF3) (Stahl et al., 2010) 
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1.3.1 Cigarette smoking 
 
Cigarette smoking is widely accepted to be hazardous to health in humans due to the 
numerous chemical toxins secreted through tobacco inhalation and second-hand smoke 
(Solomon et al., 1999). There are over 4000 identified chemicals contained in cigarettes, 
with 50 of the components being carcinogenic in nature and include benzene, cadmium, 
lead, acetone and arsenic (Harder, 2002). It is commonly known that cigarette smoking 
contributes to the development of many diseases including cancer, COPD, asthma, crohn’s 
disease and numerous others (Madretsma et al., 1996b), as well as to be involved in RA 
(Solomon et al., 1999). A study on RA monozygotic and dizygotic twins discordant for 
cigarette smoking, identified a significant association between patients who had ever 
smoked and RA disease (Silman et al., 1996). This indicates that cigarette smoking 
regardless of genes is in an important factor in the development of RA. 
 
1.3.1.1 Association between cigarette smoking and RA susceptibility 
 
A number of studies demonstrated cigarette smoking to be associated with RA disease, 
being more common in smokers both past and current than in non-smokers (Hazes et al., 
1990, Heliovaara et al., 1993, Silman et al., 1996, Symmons et al., 1997, Uhlig et al., 
1999, Hutchinson et al., 2001, Costenbader et al., 2006, Criswell et al., 2006). This 
association between smoking exposure and increased risk of RA was also observed in a 
study performed by Criswell et al, 2006, in patients independent of genetic factors of the 
SE and null GSTM1 gene where patients are unable to detoxify cigarette compounds 
(Criswell et al., 2006). In addition, the effect of smoking increased the risk of RA 
development and was found to be much stronger in individuals positive for RF than RF 
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negative (Costenbader et al., 2006). As such, smoking is considered a major risk factor for 
RA disease susceptibility. However, the mechanism of how cigarette smoking influences 
susceptibility is still unclear, although there are a number of mechanisms that have been 
suggested. One such mechanism is that smoking may modify potential autoantigens such 
as citrullinated proteins, that are then recognized by T cells (particularly via the HLA-
DRB1 molecule on APCs) (Klareskog et al., 2006). Another mechanism is the delivery of 
autoantigens to the HLA by cigarette smoke. A third mechanism is that cigarette smoke 
substances may act as an adjuvant, and subsequently trigger the pro-inflammatory immune 
response. Cigarette smoking is also considered as an immunosuppressant as it affects the 
function and numbers of inflammatory cells including T cell unresponsiveness and anergy, 
as well as other tissues, such as the epithelium in blood and respiratory vessels (Geng et 
al., 1996, Sopori and Kozak, 1998, McCue et al., 2000, Singh et al., 2000, Mehta et al., 
2008). This could allow the presentation of arithrogenic peptides, and initiate the immune 
response rather than enable immunotolerance of the molecule. 
 
1.3.1.2 Association between cigarette smoking and RA severity 
 
Numerous studies have revealed smoking to be associated with increased disease severity 
and progression (Heliovaara et al., 1993, Saag et al., 1997, Másdóttir et al., 2000, Wolfe, 
2000, Mattey et al., 2002c). The mechanisms of how smoking influences disease 
progression and severity is still not fully understood. However, the various toxic 
compounds present in cigarette smoke have been implicated in the process. This may 
partly explain modulate and alter immune cell function and quantities in RA smokers 
(Ginns et al., 1982, Hughes et al., 1985, Tollerud et al., 1989, Adams et al., 1997, Mehta et 
al., 2008). Consequently, such alterations therefore may effect which mediators are 
 57 
secreted and their level of expression (Ginns et al., 1982, Hughes et al., 1985, Tollerud et 
al., 1989), as smoking is known to induce apoptosis and angiogenesis via the the 
endothelial nicotinic acetylcholine receptor, collagen synthesis and cytokine production 
(Ginns et al., 1982, Hughes et al., 1985, Tollerud et al., 1989, Tappia et al., 1995, 
Madretsma et al., 1996a, Nakamuraa et al., 1998, Anderson et al., 1999, Sher et al., 1999, 
Singh et al., 2000, Knuutinen et al., 2002, Lei et al., 2002, Barua et al., 2003, Nordskog et 
al., 2003, Cozen et al., 2004, Raitio et al., 2005, Glossop et al., 2006, Karimi et al., 2006, 
Cooke, 2007, Harel-Meir et al., 2007, Cooke and Ghebremariam, 2008, Shizu et al., 2008, 
Egleton et al., 2009, Valavanidis et al., 2009). 
 
As cigarette smoke is a foreign agent within the host, it may be able to act as an adjuvant 
and induce an immune response against it. RA patients who had a history of smoking were 
observed to have more active and severe disease compared to non-smokers (Söderlin et al., 
2011). In contrast another study did not demonstrate any association with disease severity 
variables (ESR, pain, joint counts or functional ability) and smoking (Wolfe, 2000). 
Furthermore, one study revealed that RA patients showed no significant difference in 
disease activity scores (DAS 28) between current smokers and non-smokers with past 
smokers in either RF positive or negative patients (Westhoff et al., 2008). This suggests 
that cigarette smoking may not contribute to alterations in disease activity measures, but 
does play a role in disease severity. Additionally, the effects of smoking have been shown 
to be independently associated with co-morbidity and mortality in RA patients (Reilly et 
al., 1990, Wolfe et al., 1994, Myllykangas-Luosuj~irvi et al., 1995, Turesson et al., 2003, 
Wolfe et al., 2003, Sihvonen et al., 2005, Mattey et al., 2007).  
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1.3.1.3 Association between cigarette smoking and RA features 
 
As cigarette smoking is associated with the severity and progression of RA, it is therefore 
not surprising that several studies have shown it to be significantly associated with various 
features of RA. This includes the manifestation of subcutaneous nodules which has been 
shown to be independently linked with smoking in RA patients (Másdóttir et al., 2000, 
Mattey et al., 2002b). In addition, patients with a history of smoking were associated with 
increased joint damage and bone erosions, independently of RF (Wolfe, 2000). Another 
study revealed that female patients who had ever smoked (past and current), as well as past 
and current smokers individually, was associated with worse radiographic outcome and 
HAQ score than RA patients who had never smoked, but this may be influenced by the 
GSTM1 null gene and RF presence in smokers (Mattey et al., 2002c). However, there are a 
number of studies that do not reveal an association between smoking and joint damage. A 
study by Finckh et al, 2007 showed that radiographic damage progressed at a similar rate 
in current smokers and non-smokers (Finckh et al., 2007), which is similar to another study 
that showed no differences in radiographic damage between current smokers and never 
smokers along with past smokers, in either RF positive or negative patients (Westhoff et 
al., 2008). 
 
1.3.1.4 Association between cigarette smoking and autoantibodies 
 
Numerous studies have reported the independent association of smoking and the presence 
of RF and anti-CCP autoantibodies in RA patients (Mattey et al., 2002a, Morgan et al., 
2009). A Finnish study in RA, revealed that men who smoke were more likely to be RF 
seropositive than non-smokers (Heliovaara et al., 1993). Another study demonstrated that 
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patients with any smoking history had an increased risk for RF seropositivity in both 
genders, although this was only shown in heavy smokers (Stolt et al., 2003). Although the 
presence of RF can be observed in RA non-smokers, RF production is found to be at 
higher titres in the serum of smokers compared to non-smokers, with current smokers 
significantly more RF positive than past or never smokers (Wolfe, 2000, Mattey et al., 
2002a, Mattey et al., 2002c, Westhoff et al., 2008). Cigarette smoke may modify B cell 
function and give rise to RF. The mechanism is still unclear but may invovled the CD91 
scavenger pathway (Jónsson et al., 1998, Newkirk et al., 2012). 
 
1.3.1.5 Association between cigarette smoking duration and frequency and RA 
 
Not only is the status of cigarette smoking in patients (never, past and current) important in 
RA but also the duration and frequency (quantity per day) of smoking over the years (pack 
year history). The risk for the development of RA was found to be significantly elevated in 
patients who smoked >10 pack years and increased significantly with the increased number 
of pack years (Costenbader et al., 2006). In addition, this study also demonstrated that 
increased risk of RA disease remained elevated in past smokers until 20 years or more after 
patient cessation (Costenbader et al., 2006). A study in post-menopausal women showed 
that both the duration and frequency of smoking were associated with the development of 
RA. This was still found to be significant when adjusted for age, menopausal age, oral 
contraceptive use and hormone replacement therapy (Criswell et al., 2002). Another study 
demonstrated an increasing association between increased pack years and the development 
of RA. This particular study also showed that heavy smoking (41-50 pack years) was 
strongly associated with RA development (Hutchinson et al., 2001). 
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Various investigations have demonstrated that the more an individual smokes, the more 
severe the disease in RA patients, thereby indicating a dose-dependent response. This has 
been shown in autoantibody positive patients, where a dose-dependent effect was shown 
between increased frequency of smoking and the occurrence of anti-CCP autoantibodies 
(Klareskog et al., 2006). A study by Masdottir et al, 2000 revealed that heavy smoking RA 
patients who smoked more than 20 cigarette packs a year showed an association with the 
presence of rheumatoid nodules, more radiological damage as well as worse functional 
ability (a higher HAQ and lower grip strength severity score). 
 
In addition, a positive correlation was observed between smoking quantity and the level of 
RF as well as its positivity (Másdóttir et al., 2000, Morgan et al., 2009). Another study by 
Saag et al. also demonstrated similar results where pack years were significantly associated 
with RF seropositivity, radiographic erosions and nodules in a dose-dependent manner 
(Saag et al., 1997). Furthermore, patients who smoked more than 25 pack years were over 
3 times more likely to be seropositive and over 2 times more likely to have the presence of 
erosions than patients who had never smoked. However analysis revealed that smoking 
was associated with less severe radiographic disease rather than worse radiographic scores 
than patients who have never smoked (Saag et al., 1997). It was also found that the number 
of years smoked was associated with the presence and level of RF as well as the formation 
of nodules, radiographic progression and pulmonary disease, with the latter 3 effects 
shown to be independent of RF (Wolfe, 2000). Interestingly, this particular study 
demonstrated an association between overall disease severity and smoking, but not with 
disease process activity measures (ESR, pain, joint count, global severity or functional 
ability) (Wolfe, 2000). Interestingly, while RA patients with any smoking history were 
associated with an increased risk for RF in both genders, this was only observed in subjects 
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who had smoked more than 20 years and evident with a moderate frequency of smoking 
(6-9 cigarettes per day). The risk also increased in a dose-dependent fashion, with the 
cumulative addition of smoking. In addition, this risk for seropositivity remained for up to 
10-19 years after smoking cessation (Stolt et al., 2003). In contrast, a particular study of 
RA non-smokers and those who smoked less than 20 pack years were twice as likely to 
reach ACR improvement compared to RA patients who smoked >20 pack years (Westhoff 
et al., 2008). These type of studies illustrate that the pack year history is related to various 
aspects of RA disease, including its development, progression and outcome as well as 
development for co-morbid diseases. 
 
Although the majority of studies illustrate an association with RA disease and increased 
number of pack years, a study performed by Finckh et al, suggested that cigarette smoking 
does not accelerate progression of RA disease, as an inverse dose-dependent response was 
observed. RA patients who smoked more than one pack a day (heavy smokers) progressed 
significantly less than either moderate smokers and non-smokers as well as demonstrating 
better functional scores, suggesting that smoking does not accelerate disease progression 
and have protective properties (Finckh et al., 2007). 
 
As smoking has been found to be predominantly associated with RA development, severity 
and progression, further studies are required to determine if there is a direct relationship, 
and what mechanisms may be involved, such as the alteration of various factors such as the 
production and secretion of inflammatory mediators, proteins, anti-oxidants as well as 
interactions with various genes. 
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1.3.2 A gene-environment interaction 
 
Both smoking and genes have been shown to strongly influence RA disease, a combination 
of these factors specifically a gene-environment interaction is thought to be involved in the 
susceptibility, development, progression and outcome of RA. 
 
1.3.2.1 A gene-environment interaction for RA susceptibility 
 
The combination of gene and environmental factors has been found to be responsible for 
the onset of RA disease. This has been demonstrated in several studies where the HLA-
DRB1 gene (shared epitope alleles in particular), and cigarette smoking is associated with 
RA susceptibility (Klareskog et al., 2006, Morgan et al., 2009). The combination of these 
two factors may trigger immune reactions which are involved in the development of RA 
(Gorman, 2006, Källberga et al., 2007). A study with a population of older Caucasian 
women, found that those who smoked and carried a SE allele had a significant risk of 
developing RA (Criswell et al., 2006). 
 
Other genes with cigarette smoking have also been demonstrated to be associated with 
disease susceptibility. A significant risk of RA development was found in patients who 
smoked and had the GSTM1 null genotype (Criswell et al., 2006). One study demonstrated 
a combination of a 2 gene-environment interaction and RA, where risk substantially 
increased with the combination of the PTPN22 gene (another gene highly associated with 
RA susceptibility), the HLA-DRB1 SE and cigarette smoking to the development of RA 
(Morgan et al., 2009). This illustrates that a combination of multiple genes and an 
environmental factor further increases the risk of RA disease. 
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1.3.2.2 A gene-environment interaction for RA severity and progression 
 
A gene-environment interaction has also been demonstrated to be associated not only with 
susceptibility to RA, but also with severity and progression of disease. A major interaction 
between cigarette smoking and the HLA-DR genes was evident for anti-CCP positive RA 
compared to negative anti-CCP RA patients. Furthermore, patients with a smoking history 
and the presence of SEs on both chromosomes, increased the risk 21 fold for RA positive 
anti-CCP compared to non-smokers without the presence of SE genes (Klareskog et al., 
2006). 
 
In addition, a gene-environment interaction of patients carrying double SE genes and 
cigarette smoking combined with anti-CCP autoantibodies was shown to be associated 
with a greater risk of mortality from CVD (Farragher et al., 2008). This type of 
combination of various factors can indicate a worse type of RA, as it is linked with co-
morbidity. 
 
In some studies the GSTM1 genotype and cigarette smoking has been shown to be 
associated with increased RA severity, while in others no interaction was found (Mattey et 
al., 2002c, Bohanec Grabar et al., 2009). A study in 2002, performed by Mattey et al. 
demonstrated the effects of smoking on radiographic damage in RA could be modulated by 
the GSTM1 polymorphism. Patients who were GSTM1-null and smoked, had worse 
disease outcome than non-smokers. While in contrast, patients who had a functional 
GSTM1 and smoked, had less severe radiographic outcome than null GSTM1 patients. 
Interestingly, this study found that smoking was associated with RF production in patients 
carrying the GSTM1 null allele only (Mattey et al., 2002c). RF is closely associated to 
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smoking, therefore true correlation between GSTM1 and smoking is difficult to determine. 
As this study found that GSTM1 null associated with RF, it can be partly explained by the 
relationship between GSTM1 and RF in production in smokers. 
 
Another study investigating the GSTT1 genotype revealed an interaction with the 
polymorphisms of this gene and cigarette smoking. In a group of RA smokers, patients 
carrying the homozygous deletion of GSTT1 (GSTT1 null) had over an 8 fold higher risk 
for developing high disease activity scores (DAS 28) than patients carrying the functional 
GSTT1 genotype (Bohanec Grabar et al., 2009). Therefore those RA patients that carry 
GSTT1 have less severity then those who do not carry this gene. 
 
Rheumatoid factor has been shown to be independently associated with both cigarette 
smoking and HLA-DRB SE polymorphisms, but adjusting for previous or current smokers, 
the significance was reduced or lost respectively (Mattey et al., 2002a). Particularly 
patients that carried the *0401 SE and smoked, increased the likelihood of RF production 
(Mattey et al., 2002a). This suggests that RF synthesis occurs through a different 
mechanism in smokers compared with non-smokers who carry the SE allele. A study by 
Padyukov et al, showed nearly a three fold increased risk for RF positive RA in the 
presence of SE alleles in non-smokers, and over a two fold increased risk for RF positive 
RA in current smokers without carriage of SE genes (Padyukov et al., 2004). The 
combination of current smoking and the carriage of a SE showed a seven fold increased 
risk for RF positive RA. In addition, smokers carrying SE alleles on both chromosomes 
displayed nearly a sixteen fold increased risk for RF positive RA. This study illustrates 
significant interaction between smoking and the SE genes, where the additional presence 
of SE genes increases the likelihood of RF positive RA (Padyukov et al., 2004). 
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There are studies however that demonstrated no association between smoking and the 
PTPN22 gene. One study found no association in patients carrying the PTPN22 gene and 
smoking for the development of anti-CCP (Källberga et al., 2007). Another study which 
investigated the combination of PTPN22 and smoking found that it did not affect the risk 
of mortality (Farragher et al., 2008). 
 
Although a gene and environment interaction influences RA disease in both its 
development and severity, the relative contribution of genetic and environmental influence 
upon the development of RA and its severity differs between individual patients. 
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1.4 Biomarkers 
 
Biomarkers typically refer to biological molecules that are used as measurements to reveal 
indications of a biological state or condition. Biological molecules particularly those 
involved in biochemical pathways or physiological processes (eg. proteins, hormones, 
enzymes, growth factors, steroids, metabolites, cytokines etc.), are termed as mediators and 
are used to assess normal and pathogenic activity. 
 
A number of factors are able to influence mediator expression including environmental 
toxins (pollution and smoking), drugs (medicinal and recreational) as well as induction of 
the immune response though diseases and infections (bacteria and viruses). Such 
alterations to mediator expression generate downstream effects through the complex 
cellular-mediator network by intracellular signalling which subsequently changes the 
mediator environment. RA is thought to arise through the dysfunction of the immune 
system, where immune regulation is lost and leads to an inbalance of excess production of 
inflammatory and modulatory response mediators (markers of immune dysfunction). 
Measurement of these biomarkers is therefore crucial to assess immune activity and 
determine what pathological processes are occurring in RA disease. 
 
Mediators are classically measured in the blood but also other bodily fluids, such as the 
synovial fluid, tissue, urine and saliva, by the use of protein based assay systems like the 
enzyme linked immuno-sorbent assay (ELISA), liquid chromatography, flow cytometry, 
protein microarray, mass spectrometry and the multiplex suspension array system. 
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There are a number of qualities that make an ideal biomarker, such as a long half-life, 
easily and safely measured, non-invasive, reproducible, economical as well as being 
proportionately representative of the investigating outcome. In addition, any potential 
biomarker needs to be able to identify the investigating outcome accurately. This is 
achieved by evaluating its validity (test accuracy), measuring its level of sensitivity and 
specificity. Sensitivity relates to its ability to correctly identify an individual of the 
particular outcome, whereas specificity relates to its ability to correctly identify an 
individual that is free of the investigating outcome. Therefore, it needs to be sensitive 
enough to include anyone presenting with the outcome in any displayed fashion, but 
specific enough to not incorporate anyone displaying outcomes of a similar but different 
nature. Furthermore, potential biomarkers are evaluated in terms of their reliability of 
identified individuals actually having the investigated outcome (result accuracy). This is 
achieved by measuring its positive and negative predictive value (PPV and NPV 
respectively). PPV relates to how many outcome identified individuals actually have the 
outcome, whereas NPV relates to how many outcome-free identified individuals are 
actually free of the outcome. Both these performance evaluations are calculated by 
equations using true positive, true negative, false positive and false negative values (Parikh 
et al., 2008). 
 
With the advancement of technology, an increasing number of studies have been able to 
investigate multiple biological mediators in parallel in RA patients. This allows a much 
more extensive and comprehensive analysis of the mediators responsible and its 
interactions involved in RA disease rather than singular mediators, which can give insights 
into the RA altered environment and help elucidate the comprehensive cellular-mediator 
network in RA. In addition, sets of mediators termed as profiles or signatures can also be 
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identified and illustrate relationships to specific disease measure indices. These can 
become specific biomarkers used to assess the level of disease activity and severity in RA, 
and can provide greater accuracy (sensitivity and specificity) rather than singular 
biomarkers. One clinical biomarker profile has been recently characterized and validated is 
the multi-biomarker disease activity (MBDA) (Cavet et al., 2010, Centola et al., 2013). 
This new assessment measure is a composite of 12 mediators (EGF, VEGF-A, leptin, IL-6, 
serum amyloid A (SAA), CRP, VCAM-1, MMP-1, MMP-3, TNF-RI, human cartilage 
glycoprotein 39 (YKL-40) and resistin) and evaluated through a specifically designed 
algorithm (Centola et al., 2013). This novel assessment measure complements current RA 
disease activity measures (Bakker et al., 2012, Curtis et al., 2012, Eastman et al., 2012, 
Hirata et al., 2013). It should be noted that this measure of disease activity was not used in 
this project, as the MBDA incorporates mediators which were not investigated at the time 
of this study. 
 
Biomarker profiling investigations can also give insights into the heterogeneity of RA and 
aid in the characterization of phenotypes and classification of sub-types. Biomarker 
profiling can also elucidate the extent of immune activity occurring in RA as well as 
provide useful indications into its disease pathological process (onset, development, 
progression and outcome), which ultimately can assist in RA diagnosis as well as identify 
stages of disease. Identification of biomarker profiles can eventually become useful clinical 
markers in the management of RA to improve patient care and outcome as well as 
becoming potential new targets for therapeutic intervention. In addition, biomarkers also 
have the potential to become a valuable clinical prognostic tool for diagnosing disease 
early as well as predicting its activity, severity, outcome, re-occurrence potential and the 
response individuals may expect to treatment intervention for newly developed arthritic 
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patients. This allows for more appropriate management and treatment early in the course of 
the disease which may limit the level of destruction of RA and possibly drive it to a state of 
remission.  
 
With further understanding of the various mediators involved in RA and its complex 
network of interactions, this can give insights into the immune dysfunction and pathology 
of RA. Ultimately this can help elucidate the mechanisms and molecular pathways 
involved in RA disease, which may provide potential novel targets for therapeutic 
intervention. This could eventually develop into targeted personalized medicine based on 
the unique biomarker profile presentation of the patient. Biomarker drug therapy could 
become specific to the individual and be selected to enable the best type of response based 
on the presentation of the individuals’ unique biomarker profile, rather than employing 
general drug treatments which require multiple administrations. Ultimately, research into 
mediators may lead to prognostic biomarkers that could indicate disease risk and 
susceptibility in undiagnosed asymptomatic individuals, and therefore prevention of the 
disease before onset and symptoms of the disease could be halted before they even 
develop. Thus, early therapeutic intervention as well as more specifically targeted drug 
development will ensue. 
 
Biomarker profiles that are specific for disease pathologies and their symptoms would 
provide many advantages to pharmaceutical companies, as it could be determined with 
high likelihood what drug treatments would be successful. In addition, which patients 
would best respond to the treatment due to their biomarker profile, as well as have clues 
into the potential side effects of the drug. This would ultimately significantly reduce the 
cost of developing effective drugs, clinical trials, insurers and hospitals. 
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Initially, understanding of the relationship between biomarkers and RA disease activity and 
severity is required first to fully optimize their potential in both the research and clinical 
setting. This would provide the first steps to creating biomarker diagnostic and therapeutic 
applications. There have been a number of studies which have investigated multiple 
mediators (>5 mediators) in RA patients to identify profile signatures specific to RA 
disease, as well as relationships to disease activity and severity measures. 
 
1.4.1 Biomarker profiling RA disease activity and severity 
 
A number of studies have demonstrated a particular type of biomarker profile of various 
interleukins and other notable mediators to be linked with RA autoantibodies. In particular, 
several studies have shown that IL-1β, IL-4, IL-10, IL-12, TNF-α and GM-CSF in 
particular, specifically distinguished RA patients positive for RF and/or anti-CCP 
autoantibodies (Hitchon et al., 2004, Alex et al., 2007, Hueber et al., 2007, Jørgensen et 
al., 2008, Kokkonen et al., 2010, Meyer et al., 2010, Chandra et al., 2011, Hodkinson et 
al., 2011). This type of biomarker profile and autoantibody expression was also illustrated 
in pre-disease onset patients, where autoantibodies have been found prior to disease 
development (Jørgensen et al., 2008, Deane et al., 2010, Kokkonen et al., 2010). 
Interestingly, inflammatory regulators sTNF-R1 (Jørgensen et al., 2008) and IL-1ra 
(Jørgensen et al., 2008, Kokkonen et al., 2010) were also found in patients with high 
autoantibody expression prior to their disease onset (Jørgensen et al., 2008, Kokkonen et 
al., 2010). However one study revealed a completely contrasting biomarker profile with 
autoantibody expression. From a set of 163 immune related mediators which included 
various interleukins and cytokines, a unique profile of high M-CSF, TNFRSF9, myeloid 
progenitor inhibitory factor-1/macrophage inflammatory protein (MPIF-1/MIP-3), TGF-α 
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and B lymphocyte chemoattractant (BLC) expression correlated with RF expression in RA 
patients (Rioja et al., 2008). This type of profile of various interleukins and other notable 
mediators therefore could predict a more severe phenotype as autoantibodies have been 
associated with worse disease and poorer outcome. 
 
Acute phase proteins (CRP and SAA) and the ESR are common markers of peripheral 
inflammation, where a number of studies revealed IL-6, MIP-1α, M-CSF, TNFRSF9, 
MPIF-1/MIP-3, TGF-α and BLC in particular to be linked with these inflammatory 
processes (Hueber et al., 2007, Rioja et al., 2008, Meyer et al., 2010). This type of profile 
therefore would be a good indicator of systemic active disease in RA. 
 
Disease activity composites are useful indicators of general disease activity and severity 
status in RA patients. Many mediators including interleukins, growth factors, RA 
commonly regarded mediators, chemokines and TNF receptors from a number of studies 
have been shown to be associated with assorted disease activity composites such as the 
DAS28, active-quiescent index and the simplified disease activity index (SDAI) 
(Paramalingam et al., 2007, Rioja et al., 2008, Meyer et al., 2010, Hodkinson et al., 2011). 
However, IFN-γ, VEGF, TGF-α, MPIF-1/MIP-3, M-CSF and TNFRSF9 were shown in 
particular to be predominantly linked with disease activity composites, and thus could be a 
profile for worse disease activity (Paramalingam et al., 2007, Rioja et al., 2008, Meyer et 
al., 2010, Hodkinson et al., 2011). 
 
A range of mediators have been identified with bone erosions in RA patients, including 
elevated expression of IL-1α, IL-2 (Fong et al., 1994), MMP-1, MMP-3, MMP-8, MMP-9 
and TIMP-1 (Yoshihara et al., 2000), and decreased IL-4, IL-18 (Uppal et al., 2008). 
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Interestingly RA patients positive for nodules, expressed a profile of elevated IL-2,  IL-7, 
IL-12, VEGF and IFN-γ also presented with larger amounts of bone damage compared to 
nodule negative RA patients (Hodkinson et al., 2011). Another study demonstrated 30 
mediators incorporating serum proteins (CRP, α2-plasmin inhibitor, glutathione 
transferase), metabolic enzymes (triosephospate isomerise, G3PDH), calcium binding 
S100 proteins (S100A4, A8, A9, A11, A12, S100P), matrix-degrading cysteine proteinase 
cathepsin B and its inhibitor cystatin B, cellular signalling proteins (14-3-3 protein, 
RhoGD12) and various other less characterized proteins to be more abundant in erosive 
positive RA patients with low kininogen, apolipoprotein C-II and vitamin K-dependent 
protein C expression in addition (Liao et al., 2004). This diverse range of mediators 
identified from these various studies could be a marker for a more destructive disease 
outcome, although further investigation should be undertaken to better characterize 
mediators involved in joint damage. Biomarker profiling studies have also identified a 
possible prognostic profile for bone erosion, where increased IL-6 (Knudsen et al., 2008), 
MMP-8, MMP-9 (Yoshihara et al., 2000), GRO- α and RANTES (Boiardi et al., 1999) as 
well as decreased eotaxin (Syversen et al., 2008) in early RA patients have been shown to 
be associated with increased radiographic progression. 
 
Other joint specific indices have also been identified with specific mediator profiles, where 
one study demonstrated high IL-6, M-CSF, TNFRSF9, MPIF-1/MIP-3 and TGF-α 
correlated with the 68 swollen joint score (Rioja et al., 2008). Similarly this profile with 
the addition of BLC also correlated with the tender joint score (Rioja et al., 2008). 
Interestingly another study in seropositive RA patients, revealed IL-4 was correlated with a 
smaller number of joint involvements (3-6 joints), illustrating that this anti-inflammatory 
cytokine is linked with less joint activity (Uppal et al., 2008). 
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1.4.2 Biomarker profiling for RA disease subtypes 
 
As RA is a heterogenic disease, a number of studies have used grouping methods in an 
attempt to characterize biological subtypes of the disease. Characterizing RA disease will 
not only be useful in elucidating the diverse pathological pathways of RA, but also may be 
important in clinical use as they may have also differential responses to therapy. 
 
Two studies were able to identify patient clusters based on their relative mediator 
expression level (ie. low, moderate, high etc. mediator expression) (Alex et al., 2007, 
Hueber et al., 2007). In particular, relative expression of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-
7, IL-8, IL-10, IL-12p40/70, IL-13, TNF-α, MIP-1α and GM-CSF were shown to 
correspond to the level of disease activity of their respective cluster, where autoantibodies, 
ESR, CRP and the HAQ were either relatively low, moderate or high to their respective 
patient cluster (Alex et al., 2007, Hueber et al., 2007). This indicates that these patients 
had a relatively homogenous disease type that varied in phenotype severity rather than in 
functional disease subtypes. 
 
Another study identified 2 clusters within early RA patients where a profile of IL-4, IL-12, 
IL-13 and TNF-α was shown to significantly distinguish between the 2 clusters. 
Furthermore, the relatively higher expression cluster had low expression of IL-2, IL-5, IL-
10 and IL-12 but high IL-4, IL-6, IFN-γ and GM-CSF levels comparatively to the lower 
expression cluster, and interestingly demonstrated significantly higher autoantibody 
presence (Hitchon et al., 2004). However, these 2 clusters displayed similar scores of CRP, 
ESR, HAQ, VAS and swollen joint counts suggesting that this patient cluster could be an 
autoantibody specific subtype. 
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Furthermore, one study revealed a subset of seronegative patients at early RA disease with 
elevated IL-1α, IL-1β, IL-6, IL-12 p40 and p70 subunits, IL-15, IL-17, eotaxin, FGF-β, IP-
10, MCP-1, TNF and GM-CSF, which were more reflective of a seropositive RA disease. 
This could illustrate a subtype of RA more clinically and immunologically aggressive than 
previously assumed, although it should be noted that RF may not yet have developed in 
these early RA seronegative patients (Chandra et al., 2011). 
 
1.4.3 Biomarker profiling pre-development and onset of RA disease 
 
A few studies have identified specific profiles which were characterized in RA patients 
before their onset and diagnosis of disease (pre-RA undifferentiated arthritis), where IL-10, 
IL-13, TNF-α, FGF-β and IP-10 were found to be predominantly linked with pre-RA 
patients compared to healthy individuals or established RA patients (Raza et al., 2005, 
Jørgensen et al., 2008, Deane et al., 2010, Kokkonen et al., 2010). This suggests that these 
are important mediators involved in the initial development of RA and could be a 
prognostic indicator for individuals who may potentially develop disease pathology. 
Specific mediators of this profile were also shown to be elevated in pre-RA patients who 
were closer to their time of diagnosis and increased as time of diagnosis approached, and 
were also predictive of decreased time to diagnosis (Deane et al., 2010). A distinct profile 
of elevated IL-1α, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-12p70, sTNF-RI and RII plus 
low TGF-β expression was found however to be associated with RA disease onset 
(Jørgensen et al., 2008, de Paz et al., 2010), whereas another study distinguished pre-RA 
developed patients from RA onset patients with a profile of IL-4, IL-6, IL-17, G-CSF, 
VEGF, PDGF-ββ, MIP-1β and MIG (Kokkonen et al., 2010). It should be noted that 
classification of pre-RA patients is dependant on how quickly rheumatologists are able to 
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diagnose undifferentiated arthritides, as patients could be characterized with unclassified 
polyarthritis for years rather than recognising that they were actually in the early stages of 
RA. Interestingly, patients with raised IL-4 and IL-18 in PBMC both correlated with an 
earlier age disease onset in seropositive patients and IL-8 correlated with established RA 
disease (Uppal et al., 2008). These studies give insights into the development and 
progression process in the different stages of RA. 
 
1.4.4 Biomarker profiling RA in comparison with other disease pathologies 
 
Various studies have investigated multiple mediators in RA patients compared with 
healthy individuals to further understand the pathology of RA. Studies revealed 
predominantly IL-4, IL-6, IL-10, TNF-α and MCP-1 that distinguished RA patients against 
from those without disease (Butrimiene et al., 2004, Hitchon et al., 2004, Stabler et al., 
2004, Havemose-Poulsen et al., 2005, Alex et al., 2007, Hueber et al., 2007, 
Paramalingam et al., 2007, Jørgensen et al., 2008, Knudsen et al., 2008, Rioja et al., 2008, 
de Paz et al., 2010, Kokkonen et al., 2010, Meyer et al., 2010). Interestingly, a number of 
studies revealed IL-10 to be either elevated (Butrimiene et al., 2004, Hitchon et al., 2004, 
Stabler et al., 2004, Havemose-Poulsen et al., 2005, Jørgensen et al., 2008, Kokkonen et 
al., 2010, Meyer et al., 2010), or decreased in comparison with healthy people (de Paz et 
al., 2010). This contributes further to the well known pleiotropic roles of IL-10 with both 
pro- and anti-inflammatory effects, as well as further illustrating the heterogeneous 
developmental pathways of RA. In addition, metastasin (S100A4); a calcium binding 
protein involved in regulation of cellular processes including cell cycle, has been shown to 
be reduced in RA patients compared to healthy individuals (Liao et al., 2004). 
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Multi-biomarker profiling has also been performed in other arthritides for comparison with 
RA to identify profiles that distinguish between the different arthritides. This type of 
profiling will not only be useful in aiding differential diagnosis, but may also help in 
potentially being able to direct aggressive destructive articular diseases like RA to milder 
arthropathic forms. 
 
Reactive arthritis is a self-limiting arthritis and so has been compared with RA to identify 
ways able to restrict the chronicity of RA. There have only been a few multi-mediator 
profiling studies between these arthritides, each revealing a different profile that 
distinguished RA from ReA. One such study demonstrated a profile of high IL-4, IL-8, IL-
10 and sTNFR-II along with a low expression of IFN-γ in RA patients compared to 
patients with ReA (Ribbens et al., 2000). Another study revealed a profile of significantly 
lower IL-6, IL-17, TGF-β and IFN-γ expression in patients with RA compared to patients 
with ReA disease (Singh et al., 2007a). One study also illustrated elevated levels of IL-10 
in RA patients, but interestingly within acute ReA patients in comparison to chronic ReA 
patients, revealing the diversity of this cytokine as mentioned previously (Butrimiene et 
al., 2004). This particular study also demonstrated RA patients had higher expression of 
the pro-inflammatory cytokine TNF-α than in both acute and chronic ReA patients 
(Butrimiene et al., 2004). 
 
Distinct profiles were also found in a few studies distinguishing RA from psoriatic arthritis 
(PsA), where IL-1β, IL-8, IL-10, TNF-α, TNF-β (lymphotoxin) were shown to be highly 
expressed in RA patients with low IL-4 compared to those with PsA (Partsch et al., 1997, 
Partsch et al., 1998). Another study demonstrated elevated IL-1α, IL-12p40, IL-13, TNF-α, 
IP-10, eotaxin and MCP-1 with low IL-8 in early RA patients against PsA patients (Hueber 
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et al., 2007). Whereas a study in the synovial fluid of early RA patients demonstrated a 
profile of IL-2, IL-4, IL-13, IL-15, FGF-β and EGF that differentiated RA from early PsA 
patients (Raza et al., 2005). Interestingly this profile also discriminated RA from both 
crystal- and non-crystal related resolving arthritis (Raza et al., 2005). 
 
Chondrocalcinosis also known as pseudogout is a crystal oligarticular arthritis through the 
deposition of calcium pyrophosphate (CPP) in the synovial joints. It is an inflammatory 
arthritis, typically afflicting the larger joints of the body including the wrist, elbow, ankle 
and knees with pain. One study identified IL-8, IL-10 and sTNFR-II to be largely 
expressed in RA disease compared with acute crystal arthritis (Ribbens et al., 2000). 
 
Systemic lupus erythematosus (SLE) although an autoimmune disease that targets nuclear 
material and thus affects any part of the body, commonly afflicts the joints in patients due 
to the excessive accumulation of auto-antibody complexes. A sera profile of 12 mediators; 
IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-12p40, TNF-α, GM-CSF and MCP-1 
were found to be specific to RA compared with SLE (Szodoray et al., 2004, Alex et al., 
2007). This type of profiling can give insights into RA pathology as SLE is also an 
autoimmune disease and includes auto-antibody complexes like RA, but is a less 
destructive and disabling disease of the joints than RA. 
 
Another autoimmune disease; relapsing polychondritis (RP), is a chronic reoccurring 
inflammatory disorder of the cartilage. It inflames and destroys cartilage particularly in the 
ear, nose, windpipe, spine and any other place with cartilage. It also affects predominantly 
joints of the hands, feet, knees, ankles, wrists plus elbows and therefore sometimes is 
misdiagnosed as RA especially in the early stages of disease. Despite that RP and RA are 
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both autoimmune diseases that target the cartilage, a study illustrated the 2 disease states 
are distinctly different as IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IFN-γ, TNF-α, 
G-CSF, GM-CSF and MCP-1 were found to be higher in RA than in RP patients while IL-
8, IL-13, and MIP-1β were shown to be significantly lower in RA patients (Stabler et al., 
2004). These differences in mediator expression may in part explain why RP is a 
seronegative, non-deforming and non-bone destructive polyarthalgia comparatively to RA. 
 
Osteoarthritis has been commonly compared with RA as it is regarded as a non-
inflammatory arthritis. Studies have shown that a profile of IL-1β, IL-4, IL-6, IL-8, IL-10, 
TNF-α and IFN-γ in particular discriminated RA disease from OA (Schlaak et al., 1996, 
Partsch et al., 1997, Partsch et al., 1998, van den Ham et al., 2009, Moura et al., 2010). 
Furthermore, extracellular matrix degrading enzymes were also shown to differentiate 
between the arthritides, where particularly MMP-1, -2, -3, -8 and -9 were elevated in RA 
patient synovial fluid compared to OA patients (Yoshihara et al., 2000, Tchetverikov et al., 
2004). 
 
These studies illustrate the diverse process pathways between the different pathologies and 
demonstrate biomarker profiles that may be able to distinguish RA from different 
arthritides. 
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1.4.5 RA biomarker profiling between the peripheral circulation and the synovial 
joint 
 
Multi-biomarker profiling studies have been predominantly performed in either the 
peripheral circulation or the synovial joint with the former particularly investigated due to 
the ease of procuring samples. However the peripheral circulation may not reflect the same 
level of immune activity as within the joint, the main site of inflammation. There are a 
limited number of biomarker profiling studies that have investigated differences between 
the peripheral circulation and the active joint. Commonly associated RA pro-inflammatory 
cytokines IL-6, TNF-α and IFN-γ have been shown to be abundantly expressed in the 
synovial fluid compared to the plasma in RA patients (Steiner et al., 1999), as well as 
extracellular matrix degrading enzymes MMP’s -1, -2, -3, -8 plus TIMP-1 (Tchetverikov et 
al., 2004). Another study revealed a profile of just under 30 other inflammatory mediators 
of various interleukins (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-15, 
IL-17, IL-18), chemokines (IL-8, MCP-1, MIP-1α, MIP-4, eotaxin, TARC, MIG, IP-10, 
CCL22) and other mediators (TNF-α, IFN-γ, OPG, MIF, OSM, sRANKL, sCD54, 
sCD106) that were elevated in the synovial fluid which was not reflected in the plasma 
(van den Ham et al., 2009). This raised mediator pattern was similarly shown with IL-6, 
IL-8, IL-10, IL-23, OPG, APRIL (A Proliferation Inducing Ligand) and BAFF (B cell 
activating factor) which were distinctly elevated in the joint of RA patients compared with 
the sera (Moura et al., 2010). Although in contrast, TGF-β an anti-inflammatory cytokine 
was shown to be higher in the sera than in the active joint (Moura et al., 2010). These 
studies illustrate that the mediator environment is uniquely diverse between these 2 sites 
and that the joint has specific mediators in comparison to the periphery which can reflect 
their respective site. 
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In contrast, similar profile patterns have also been identified between the peripheral 
circulation and the synovial joint where IL-1α, IL-2 (Fong et al., 1994) and calcium 
binding proteins calgranulin A, B and C (Liao et al., 2004) were shown to be elevated in 
both the active joint and the peripheral circulation of erosive RA patients in comparison to 
non-erosive RA patients. These studies suggest not only a more destructive outcome of RA 
disease in both the periphery and the active joint, but also a relationship between the 2 sites 
as indicated by the strong correlation found in MMP-8 and MMP-9 expression between the 
serum and synovial fluid of RA patients (Tchetverikov et al., 2004). Similarities between 
the 2 environments are not unexpected since the synovial joint recruits inflammatory cells 
and mediators from the peripheral circulation to promote disease activity within the active 
joint. However calcium binding proteins S100A4, A11 and S100P were found to be highly 
expressed in the synovial fluid of erosive RA patients but were not reflected in the sera 
compared to non-erosive patients (Liao et al., 2004). This suggests that this joint biomarker 
profile specifically relates to bone erosion and joint damage. 
 
Additional comparative investigation in RA patients is warranted to identify specific 
peripheral or joint originating profiles which contribute to RA activity and severity 
respectively. It should be noted, that the majority of these studies were performed with 
serum/plasma and synovial fluid samples procured at different time points as synovial 
effusions do not always coincide with time of blood attainment. Therefore further profiling 
investigations using paired RA samples would be useful for accurately comparing between 
the 2 environments. 
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1.4.6 Cigarette smoking and biomarker profiling 
 
Cigarette smoking exacerbates all aspects of RA pathology (onset, development, activity, 
progression, severity, outcome), by influencing the production and secretion of mediators. 
However there is a paucity of multi-biomarker profiling studies in RA smokers with the 
exception of one study which demonstrated TNF-α to be higher in RA patients with a 
smoking history compared to those who never smoked, and correspondingly increased with 
duration of smoking as well as quantity of cigarettes smoked (Glossop et al., 2006). 
 
A few studies however have investigated the influence of cigarette smoke upon mediators 
in healthy individuals, which can provide insights into how smoking may effect immune 
function and give indications in relation to RA disease. Past studies have demonstrated a 
number of mediators (IL-1α, IL-1β, IL-5, IL-6, IL-8, IL-13 and TNF-α) to be raised with 
cigarette smoke (Tappia et al., 1995, Wang et al., 2000, Lei et al., 2002, Cozen et al., 
2004, Karimi et al., 2006, Shizu et al., 2008). MMPs (MMP-2, -8, -9) have also been 
shown to be raised in individuals who smoke compared to non-smokers suggesting that 
smoking can also effect extracellular matrix degradation and turnover (Nakamuraa et al., 
1998, Knuutinen et al., 2002, Raitio et al., 2005). The actual mechanism of how cigarette 
smoke can alter mediator expression is unknown, although it is a foreign toxic compound 
and therefore has the ability to induce an inflammatory immune response. Cigarette smoke 
has also demonstrated downstream effects as cigarette smoke condensate (CSC) was 
shown to augment the effects of TNF-α to induce interleukins IL-1α, IL-1β, IL-6 and IL-8 
(Shizu et al., 2008). Such modulations to mediator expression can also affect the mediator 
environment which consequently can contribute to disease pathologies. 
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The mechanism of how cigarette smoke modulates mediator expression seems to reflect a 
dose-dependent response. Healthy heavy smokers (>20 cigarettes/day) were shown to 
express IL-5 and IL-13 significantly higher than that of light smokers (<20 cigarettes/day) 
or non-smokers (Cozen et al., 2004). Levels of TNF were also found to be increased in 
both smokers and non-smokers PBMC alike after incubation with nicotine at incremental 
concentrations (Lei et al., 2002). Furthermore, cigarette smoke has been shown to alter 
mediator expression in a time-dependent manner, where individuals who had smoked for 
more than 20 years, expressed higher MMP-9 compared to those who smoked for less than 
20 years (Nakamuraa et al., 1998). Therefore individuals who smoke both heavily and for 
multiple years are likely to have a very altered mediator environment as shown in a CSC 
treated synovial fibroblast cell line, where protein levels of IL-1α, IL-1β, IL-6, IL-8 were 
up-regulated in both a time- and dose-dependent manner (Shizu et al., 2008). This dual 
relationship was similarly observed in a study with RA patients, where increased TNF-α 
expression corresponded with increased smoking quantities and length of time (Glossop et 
al., 2006). Therefore cessation of cigarette smoking is also likely to alter mediator 
expression and environment as shown in healthy individuals who had ceased smoking for 
more than 6 months, had significantly lower levels of MMP-9 than current smoking 
individuals (Nakamuraa et al., 1998), illustrating the quick-turn around effects of stopping 
this mediator influencing stimulus. 
 
Cigarette smoke has also been shown to inhibit mediator expression, such as smokers were 
found to have decreased expression of IL-2, IL-10, IFN-γ , human beta defensin-2 (hBD2) 
and TIMP-1 (cell proliferator with anti-apoptotic abilities as well as MMP inhibitor) 
compared to healthy non-smoking individuals (Madretsma et al., 1996a, Madretsma et al., 
1996b, Ouyang et al., 2000, Lee et al., 2007, Choi et al., 2008), as well as in a dose-
 83 
dependent manner (Madretsma et al., 1996a, Choi et al., 2008). This suggests that cigarette 
smoke may have pleiotropic effects with inhibitory activities also which could suppress 
immune and downstream responses (Lee et al., 2007). This immunosuppressive activity 
could account for the increased susceptibility of microbial infections in individuals linked 
with cigarette smoking (Sopori et al., 1998, Raza et al., 1999, Choi et al., 2008), as well as 
the contribution of a worse pathophysiology in diseases, including RA. Although this is not 
the case for all pathologies as cigarette smoking seems to have a beneficial effect in 
individuals with ulcerative colitis (UC), a colon autoimmune disease, which could be 
brought about by the immunosuppressive properties of cigarettes (Madretsma et al., 1996a, 
Madretsma et al., 1996b). Although another suggested theory is hydrogen cyanide within 
cigarette smoke reacts with hydrogen sulphide from the UC gut flora to produce non-toxic 
isothiocynate thereby inhibiting sulphides from disrupting the colon-mucosa balance 
(Levine et al., 1998). 
 
In contrast, other studies have demonstrated an opposing expression of specific 
aforementioned mediators including IL-1β, IL-8 and particularly TNF-α to be inhibited in 
the presence of cigarette smoke (Madretsma et al., 1996a, Ouyang et al., 2000, Lei et al., 
2002, Lee et al., 2007). This could be due to the paradoxical ability that has been observed 
with cigarette smoking, of being able to both promote and inhibit mediator expression, 
where one study demonstrated raised TNF expression in individuals which corresponded to 
incrementing concentrations of nicotine, until TNF expression was inhibited (Lei et al., 
2002), this suggests a possible immunoregulatory threshold limit within individuals. 
 
Interestingly, some mediators such as IL-2, IL-4, IFN-γ, TNF-α and MMP-1 have shown 
no differences in expression levels with or without the presence of cigarette smoke in 
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healthy individuals (Knuutinen et al., 2002, Cozen et al., 2004). This could be attributed to 
the suggestion that cigarette smoke appears to modulate mediator expression within certain 
specific cells, as demonstrated in a study with RA patients where TNF-α from 
lymphocytes, not monocytes, were significantly higher in patients who had ever smoked in 
their lifetime than those who had never smoked (Glossop et al., 2006). This is similarly 
demonstrated with specific mediators from certain types of cells in other studies 
(Knuutinen et al., 2002, Cozen et al., 2004), including IL-8 which was highly secreted 
from both monocytes and macrophages in comparison to other peripheral blood 
mononuclear cells (PBMC) (neutrophils and lymphocytes) upon cigarette smoke 
stimulation (Karimi et al., 2006). Therefore comprehensive biomarker profiling in RA 
smokers is necessary to elucidate what mediators are modulated by cigarette smoke and 
how this influences RA disease. 
 
1.4.7 RA drug treatment and biomarker profiling 
 
Therapeutic drug agents intervene in the disease process and progression of RA, making it 
difficult to identify the true mediator environment in RA and what immune activity 
processes are actually occurring. This is particularly true of DMARDs compared to 
biologics, as they are in greater use and are administered at an earlier stage of RA, which 
would influence the development of disease. Multi-biomarker profiling in RA patients 
receiving treatment allows for the identification of profiles specific to therapy responsive 
patients. RA disease therapy like biologics not only affects the specifically targeted 
mediator but also consequently generates downstream effects, which ultimately influences 
the mediator environment. One such example is the restoration of T regulatory cellular 
function after anti-TNF-α treatment, and its subsequent inhibition of cytokine production 
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and suppression of T helper cells (Ehrenstein et al., 2004). This type of biomarker profiling 
can help better understand the mediator-cellular network involved in RA as well as gain 
insights into the pathways involved in disease pathology. 
 
Various studies have demonstrated a range of mediators have their expression altered in 
response to infliximab, etanercept or adalimumab RA anti-TNF-α treatment, including 
decreased OPG, sRANKL (Ziolkowska et al., 2002), BLC (CXCL13), MIP-3/MPIF-1, 
TFG-α (Rioja et al., 2008), IL-7 (van Roon et al., 2007), IL-6 and IL-13 but increased M-
CSF (Tokayer et al., 2002), sIL-2R (Amital et al., 2007), MCP-1, EGF (Fabre et al., 2008) 
and interestingly TNF-α, despite responding to treatment (Amital et al., 2007). Another 
study which investigated a combination of 3 RA geographical independent cohorts also 
demonstrated TNF-α as well as IL-15 to be significantly elevated (Hueber et al., 2009). 
Rituximab, a B cell antagonist biologic drug treatment also demonstrated changes in 
mediator expression in responsive RA patients, where IL-6 was revealed to be decreased 
but MCP-1 and EGF were elevated (Fabre et al., 2009). This differential mediator 
expression further reveals the discrete downstream pathways of the cellular-mediator 
network in RA as well its variable heterogeneity. Patients are distinct individuals and so 
respond uniquely, which may explain why a third of patients do not respond to biologic 
treatment (refractive patients). 
 
As the mediator environment is consequently altered in RA responsive patients, the level 
of disease activity and inflammation also changes, and severity and joint damage alter as a 
result. A number of studies have illustrated that the level of inflammation and 
autoantibodies were decreased after the administration of biologic therapies (Alessandri et 
al., 2004, Ehrenstein et al., 2004, Rioja et al., 2008, Sennels et al., 2008, Fabre et al., 
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2009). A profile of reduced IL-6 and IL-13 but increased M-CSF was shown to have a 
clinical improvement in RA patients (Tokayer et al., 2002), while a decrease in IL-7 
correlated with a decrease of ESR and DAS (van Roon et al., 2007). Another study 
revealed a profile of IL-6, BLC, MIP-3 (CCL23) and M-CSF positively correlated with the 
DAS28 score in anti-TNF-α treated patients (Rioja et al., 2008). 
 
DMARDs suppress the immune system to inhibit leukocyte functional activity, although 
the exact mechanism is still unknown, so the expression of mediators changes as a result. 
A large range of mediators have been found to be altered after DMARD treatment in RA 
patients including reduction in various interleukins, ECM related mediators, adhesion 
molecules, cartilage glycoproteins, chemokines and growth factors (Barrera et al., 1994, 
Boiardi et al., 1999, Kraan et al., 2000, Alex et al., 2007, Knudsen et al., 2008, van Roon 
et al., 2008, Maillefert et al., 2010), plus the upregulation of soluble TNF receptors 
(Barrera et al., 1994). A profile of IL-1β, IL-6, TNF-α, and MCP-1 in particular were 
downregulated after treatment with DMARD therapy. Mediator expression after DMARD 
treatment also seem to reflect a dose-dependent relationship where one study revealed 
reduced levels of interleukins, cytokines, chemokines and growth factors which 
corresponded to incremented methotrexate (MTX) concentrations (Alex et al., 2007) 
Furthermore,  one study demonstrated IL-1β was no longer reduced after long term 
treatment of MTX (Barrera et al., 1994). This could be because chronic stimulation leads 
to RA patients developing a resistance to DMARD efficacy leading to a loss of effect on 
mediator expression (Donahue et al., 2008). 
 
As DMARDs are able to effect the mediator environment this ultimately influences the 
level of disease activity and severity in RA, where peripheral inflammation (ESR, CRP) 
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and joint disease activity (SWJ, TJ) have been shown to be reduced (Knudsen et al., 2008, 
van Roon et al., 2008). A few studies have identified specific profiles with clinical 
improvement where decreased IL-2, IL-4, IL-6, IL-8, IL-13, IL-17, TNF-α, G-CSF, GM-
CSF and MCP-1 was shown to correlate with a reduction in both the HAQ and the DAS 28 
score (Alex et al., 2007). Another study singularly demonstrated a decrease of IL-7, an 
important mediator in T-cell activity to correlate with ESR, swollen joint and tender joint 
count reduction (van Roon et al., 2008) while a reduction of GRO-α and RANTES has 
been shown to halt the progression of joint erosion (Boiardi et al., 1999). As each RA 
patient is a unique individual, DMARD suppression is not always complete and thus the 
alleviation of symptoms felt by patients can differ considerably between them. 
 
Multi-biomarker profiling also can be useful in identifying patients who are more likely to 
respond to RA treatments and thus a better use of resources as well as earlier 
administration and more appropriate treatment to the specific patient. This was 
demonstrated in a study where a prognostic profile of IL-1α, IL-1β, IL-6, IL-12-p40 and 
p70, IL-15, GM-CSF, FGF-β, MCP-1, eotaxin, TNF-α and IP-10 as well as a number of 
autoantigens predicted a positive response to etanercept (Hueber et al., 2009). 
 
The efficacy of RA treatments can also be influenced by various factors like toxins, 
physiological factors such as stress as well as cigarette smoking. RA smokers have a 
poorer outcome despite responding to anti-TNF-α therapy (Hyrich et al., 2006), and 
smokers generally feel worse and have a higher need for increased DMARDs to control 
disease activity. This may reflect alterations in pharmacokinectics (Westhoff et al., 2008). 
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Overall these profiling studies illustrate the wide range and the complex network of 
mediators involved in RA, although further investigation is needed to fully elucidate the 
mediators specifically connected to RA and their role in the disease process. A number of 
these studies investigated a restricted set and limited number of mediators (due to the 
expensive nature of multi-mediator profiling in terms of both cost and mediator target 
availability) which limits profiling analysis as well as not being able to give a complete 
reflection of the broad range and extensive network of mediators in RA disease. 
Furthermore a few studies were performed with PBMC, specific cells of tissues which do 
not accurately reflect the various cells and tissues involved in RA. Appropriate samples 
such as the synovial fluid and sera or plasma should be used alternatively as they better 
encompass the extensive mediators involved in RA.
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2.1 Aims 
 
The main aim of this research is to investigate the relationship between markers of immune 
dysfunction and the disease process in RA, as well as their relationship to disease severity 
and therapeutic response. Research in this area is important for further understanding the 
pathological process and the molecular pathways involved in the development of RA, and 
to identify potential molecular targets for therapeutic intervention. Such information could 
help in the development of new strategies for manipulation of immune function in patients 
with RA, and provide alternative therapies to those currently available. 
 
2.2 Objectives 
 
Three patient cohorts were investigated in this study; an early RA cohort with 5 year 
follow-up data, RA patients with paired serum and synovial fluid and a cohort which 
allowed comparison between patients with RA with other arthritic pathologies. These are 
summarized in further detail below. 
 
2.2.1 Early and established RA 
 
The purpose of this research is to investigate markers of immune dysfunction which 
contribute to RA disease development and severity. RA has a variable developmental 
course, which results in a wide variety of outcomes, ranging from mild disease, with 
limited bone damage to severe RA including disability, deformity and premature death. 
The measurement of biomarkers in serum from patients with early RA could provide 
valuable clues to the pathways by which RA develops. This investigation will also 
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determine whether specific measures of disease activity and severity are associated with 
particular markers of immune dysfunction, both in early and established RA. This is only 
possible because of the unique patient database available which contains an extensive and 
comprehensive range of data at baseline and 5 year follow-up. It includes a broad set of 
demographic and lifestyle factors as well as clinical data on disease activity and severity 
which will allow detailed analysis of the various factors associated with specific disease 
characteristics, disease progression and disease outcome. 
 
The availability of serum samples at baseline and after 5 year follow-up in RA patients is a 
unique resource which will allow investigation of changes in biomarkers and their 
relationship to changes in disease activity and severity during the progression of RA. This 
contrasts with most previous studies which have examined biomarkers at only one time 
point and have not investigated such a wide range of markers as this study. Another 
objective is to identify prognostic biomarkers which are predictive of disease outcome in 
established RA, which could provide clues to the pathways in RA development. Clinically, 
the use of biomarkers may have a significant impact on the ability to predict disease 
outcome and the type of response to treatment that might be expected. This may in turn 
make it possible to determine what type of treatment to use in the early stages of the 
disease to achieve a better response. 
 
Smoking has repeatedly been shown to be significantly involved in the onset and 
development of RA as well as being strongly associated with worse disease progression 
and severity. While it is unlikely that smoking is the only environmental factor involved in 
the development of RA, it may provide important clues as to how changes in immune 
regulation lead to disease development. Therefore, a secondary objective of this 
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investigation is to determine whether cigarette smoking in RA patients is associated with 
any biomarkers which may be related to alterations in immune regulation. Such 
investigations can elucidate the role of cigarette smoking in RA as well as help understand 
the mechanisms involved in the effects of smoking in RA. 
 
2.2.2 Paired RA sera and synovial fluid 
 
Investigation into the relationship between paired serum and synovial fluid biomarkers is 
another objective of this study. The availability of paired serum and synovial fluid samples 
from the same patient, alongside extensive clinical information, is another novel feature of 
this study. No previous studies have reported on analysis of multiple biomarkers in such 
paired samples. Such investigations are important since the peripheral circulation may not 
necessarily reflect the same level of immune activity as within the joint, the main site of 
inflammation. Comparison of markers between the 2 sites may provide unique insights into 
immune activity in the different environments within RA and provide further clues into the 
pathological process. In addition, investigation of biomarkers can determine whether there 
are specific markers which results in the destruction of the joint. As the active joint recruits 
biomarkers from the peripheral circulation, this can elucidate the relative contribution of 
markers from the different environments involved in joint damage. 
 
Additionally, investigation into the relationship between cigarette smoking and biomarkers 
in both the joint and the peripheral circulatory system will also be undertaken. This will 
determine whether cigarette smoking is associated with any effects on immune activity in 
the joint and how this compares with any effects it has upon immune activity in the 
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peripheral circulatory system. Such information would be important in helping to 
understand the mechanisms involved in the effects of smoking in RA. 
 
2.2.3 RA and other arthritic diseases 
 
Another objective of this study is to investigate the expression of biomarkers in sera from 
other arthritic diseases and to compare this with their expression in RA. These other 
arthritides include 2 inflammatory diseases: reactive arthritis and psoriatic arthritis, along 
with a non-inflammatory disease: osteoarthritis. Comparisons between the different 
arthritides may indicate whether there are particular markers which may explain the 
different pathologies of these arthritides. Such information may be useful in diagnosis, 
where a particular profile of markers could be indicative of the type of arthritis, and may 
provide clues to the different routes involved in development of inflammatory arthritis 
compared with less/non-inflammatory types of arthritis. In addition, investigation of the 
relationship of biomarkers with disease activity and severity in the different arthritides may 
determine whether any markers could explain the more destructive and damaging 
outcomes of RA compared to other arthritides.
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3.1 Patients 
 
All the patients used in this study were selected from a patient population database that had 
been previously generated at the Staffordshire Rheumatology Centre at the Haywood 
Hospital. 
 
3.1.1 Patient cohorts 
 
All the patients used in this study were selected from a patient population database that had 
been previously generated at the Staffordshire Rheumatology Centre at the Haywood 
Hospital. Three major patient cohorts were studied in total: early RA patients with a 5 year 
follow up, RA patients with paired serum and synovial fluid, and patients with different 
types of early arthritic diseases: osteoarthritis (OA), psoriatic arthritis (PsA) and reactive 
arthritis (ReA). The latter cohort was used as comparative groups with early RA. 
 
3.1.1.1 Selection criteria and consent 
 
Diagnosis of RA was based on the 1987 American College of Rheumatology (ACR) 
revised criteria (Arnett, et al., 1988). Patients with early stage RA characterized by a 
disease duration of < 2 years at time of first admittance to the clinic (baseline) were 
included in the study. These patients were then invited back to the centre after 5 years for a 
follow up. This gave a unique database that charted the progress of RA patients through 
using numerous parameters. 
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The selection criteria for the paired serum and synovial fluid RA cohort was based on 
patients having available both serum and synovial effusion sample obtained at the same 
time point. The disease duration for the procurement of the paired samples were not 
limited to a specific time frame.  
 
The third cohort included a selection of patients with other arthritic diseases for 
comparative investigations with baseline RA. Patients with confirmed OA, PsA and ReA 
were selected for study as representative of other types of non-inflammatory (OA) or 
inflammatory arthritis (PsA, ReA). 
 
All the patients included in this project were confirmed to have ReA, OA, PsA or RA by a 
consultant rheumatologist at the centre. All the patients in this study had previously given 
written informed consent for their data and samples to be used for research purposes. This 
study was also approved by the Medical Ethics Committee of the North Staffordshire 
Hospital Trust. 
 
3.1.1.2 Population cohorts’ major characteristics and features 
 
The patient database contained comprehensive data for every individual. This included 
information on a broad set of demographic and lifestyle factors such as age, gender, 
cigarette smoking as well as data on disease measures and features. The major 
characteristics for each cohort are illustrated in Table 3.1.1.2 below to demonstrate the 
extensive range of the data. Although the database encompasses a large amount of data, not 
all the information on the patients were complete as some were either unavailable or 
recorded. In addition, some patients were either lost or their patient sample was no longer 
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available at time of 5 year follow-up and thus could not be investigated. Thus an indication 
of the number of patients which were available for each analysis will be mentioned. 
 
Table 3.1.1.2: The major characteristics and features for each of the 3 patient cohorts 
  Cohort 1 Cohort 2 Cohort 3 
Characteristic and 
Lifestlye Information 
RA Baseline 
5 year 
Follow-up 
Paired RA OA PsA ReA 
Number of patients 86 77 52 20 34 26 
Male/Female (No.) 39/47 34/43 24/28 9/11 17/17 18/8 
Age, mean +SD, years 
(total n) 
53 +13.10 
(85) 
52 +13.0 
(77) 
57.0 +16.0 
(52) 
61.0 
+10.6 
(20) 
41.3 
+14.2 
(34) 
34.4 
+13.0 
(25) 
Disease duration, mean 
+SD, years (total n) 
0.58 +0.38 
(86) 
5.54 +0.30 
(77) 
6.6 +9.0 
(52) 
1.1 
+1.0 
(20) 
1.7 
+1.9 
(33) 
0.32 
+0.53 
(26) 
RF positive % (total n) 52.3% (86) 52% (77) 43.2% (44)    
Anti-CCP positive % 
(total n) 
72.1% (86) 72.7% (77) 67.3% (52)    
Nodule positive % (total 
n) 
3.5% (85) 2.63% (76) 9.8% (51)    
Synovial effusion % (total 
n) 
18.6% (86) 100% (52)    
Erosions % (total n) 65.8% (76) 75.7% (37)    
Ever Smoked positive % 
(total n) 
68.6% (86) 66% (77) 60% (40) 
70.6% 
(17) 
53.3% 
(30) 
52.2% 
(23) 
Smoke status i.e. non-
smoker: past smoker: 
current smoker counts 
(total n) 
27:35:24 
(86) 
26:34:17 
(77) 
16:10:14 
(40) 
5:6:6 
(17) 
14:7:9 
(30) 
11:3:9 
(23) 
DMARD treatment % 
(total n) 
14% (86) 91% (76) 45% (51)  
9% 
(32) 
 
 
3.1.2 Smoking history and classification 
 
Cigarette smoking has been repeatedly shown to be important in the development and 
severity of RA as discussed earlier in the section 1.3. Therefore each patient had their 
smoking history recorded when attending the clinic and used in analyses in this study 
(Appendix figure 3.1.2 for patient smoking questionnaire). Patients were asked if they had 
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smoked at any time in their lives (ever smoked) as well as their current smoking status; if 
they were a current smoker (having smoked > 1 year), a past smoker (cessation > 6 
months) or a never smoker. These patient numbers are included in the Table 3.1.2 above. 
In addition, the quantity, frequency and duration of cigarettes smoked was also recorded. 
This allowed the determination of the intensity patients smoked and is described as patient 
smoking pack year history. This was calculated by the formula below, where a cigarette 
pack has 20 cigarettes in each pack, therefore 1 pack year=20 cigarettes per day for a year. 
 
Number of cigarettes per day smoked x Number of years smoked 
Number of cigarettes in a pack 
 
 
3.1.3 RA measures of disease 
 
Assessment and monitoring of RA is integral to determine the activity and severity of the 
disease in patients. There are numerous assessment measures for RA such as Simplified 
Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Global Arthritis 
Score (GAS), Rheumatoid Arthritis Articular Damage (RAAD) etc. However the patient 
database already held a large set of clinical and laboratory assessment measures for disease 
activity and severity for each patient. These various disease measures encompass markers 
of inflammation, pain, function and joint damage parameters, which illustrate the process 
and outcome of RA disease (Table 3.1.3). The following section details an explanation of 
each disease measure used and its implementation in RA monitoring and assessment. 
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Table 3.1.3: Clinical and laboratory measures of disease activity and severity parameters 
Disease Processes (Disease Activity) Disease Outcomes (Disease Severity) 
Inflammation Pain Damage Function 
CRP VAS Bone Erosion HAQ 
ESR TJ OSRA-D EMS 
SJ RI Larsen Hand Score Grip strength 
WBC    
CGDA    
DAS44CRP    
DAS44ESR    
OSRA-A    
SI    
PIPS    
Platelets    
Anaemia    
Rheumatoid Factor    
Anti-CCP    
Synovial effusion    
CRP (C-reactive protein), ESR (erythrocyte sedimentation rate), DAS (Disease Activity Score), SJ (Swollen 
joints), TJ (Tender joints), RI (Ritchie Index), SI (Stoke Index), OSRA-A/D (Overall Status in RA-
Activity/Damage), CGDA (Clinician’s Global Disease Activity), VAS (Visual Analogue Score), PIPS 
(Proximal Interphalangeal Score), HAQ (Health Assessment Questionnaire), EMS (Early Morning Stiffness). 
 
 
3.1.3.1 Markers of Inflammation 
 
The erythocyte (red blood cell) sedimentation rate (ESR) is a common haematology test. It 
is the measurement rate of red blood cells sedimenting in a period of one hour (mm/h). The 
ESR is dependent on a balance between pro-sedimentation factors particularly fibrinogen 
versus anti-sedimentation factors mainly erythrocyte negative charge. In an inflammatory 
process, high levels of fibrinogen produced from the liver causes red blood cells to stick to 
 100 
one another and form stacks which sediment faster. Thus ESR rate is a useful tool in the 
monitoring of disease activity and thus commonly used as a marker of inflammation. 
 
Another commonly used marker of the inflammatory process is C reactive protein (CRP). 
This protein is rapidly synthesized in the liver in response to inflammation after the onset 
of either trauma (injury and burns), infection, diseases or tissue necrosis. It is part of the 
acute phase response which is an early defence system in innate immunity as it enhances 
phagocytosis and activates the complement system. This acute phase protein is measured 
by testing the blood and is highly expressed in individuals depending on the type of 
infection, disease or trauma. A level of more than 10mg/L is considered abnormal and 
indicates inflammation. This protein therefore is useful in monitoring disease activity as it 
better reflects short-term changes and.more sensitive than the ESR as it is less susceptible 
to disturbing factors. 
 
The platelet count is another marker of the inflammatory process where the number of 
platelets in the patient's blood are counted and used to indicate the level of inflammation, 
as excess amounts of platelets are rapidly sent to sites of inflammation and aid in the 
secretion of inflammatory cytokines by interacting with leukocytes which can reflect 
disease activity of a few weeks. The normal of platelets in the blood is between 150,000-
400,000 platelets per microlitre (mcL), and above this is considered abnormal and an 
indication of inflammation. Similar to that of platelet count is the white blood cell count, 
another measure of inflammation, where approximately 4,000-11,000 cells per cubic 
millimetre of blood is the normal range whereas anything above this is considered 
leukocytosis and an indication of an immune response. 
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Anaemia which is a reduction in the number of erythrocytes or a deficiency of 
haemoglobin (Hb): the iron-containing oxygen-transport metalloprotein in the blood, and is 
also used as an inflammatory marker. There are several types of anaemia each with a 
different cause, although one type of anaemia is present in chronic illnesses due to 
persistent infection, constant immune activation or malignancy which is known as anaemia 
of chronic disease (ACD) (Beutler, 2003, Weiss and Goodnough, 2005). This condition 
may be largely due to the increased production of hepcidin: a master regulator of iron 
metabolism (Nemeth and Ganz, 2006). Hepcidin is synthesized in the liver as a response to 
inflammatory cytokines which in turn prevents the release of iron from iron stores (Beutler, 
2003, Nemeth and Ganz, 2006). Inflammatory cytokines also decrease the release of iron 
directly as well as shorten the survival of circulating erythrocytes and decrease the 
production of red blood cells in the bone marrow (Beutler, 2003, Means Jr, 2004). As such, 
anaemia is therefore a good marker for inflammation in chronic diseases such as RA, 
where Hb levels lower than 13.3 in males and lower than 12 in females is characterized as 
anaemic. 
 
The 44 swollen joint count is a clinical measure of inflammation used in assessing RA 
activity and severity. It is a quantitative assessment of the joint, where the number of 
swollen joints incorporating also soft tissue joint margin swelling, synovial effusion, joint 
fluctuation and joint swelling are counted in a set of 44 joints. These joints include those of 
the hands, wrists, ankles, feet, elbows, knees, shoulders and collar bone (Figure 3.1.3.1). It 
should be noted that there is also a 28 swollen joint count, although this clinical measure 
does not include the joints of the collar bone, feet, ankles which are affected in RA and 
thus the original measure of 44 joints was used in this study. 
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Figure 3.1.3.1 Diagram of the 44 joints counted for joint swelling 
 
Reproduced from (Fleischmann, 2006). 
 
The Clinician’s/Physician’s Global Disease Activity (C/PGDA) score is a measurement of 
overall activity and severity of RA disease as judged by the clinician or physician. This 
incorporates patient physical examination and laboratory results, such as swollen joints, 
functionality, ESR, CRP, autoantibodies etc and rated by a qualified evaluator by marking 
vertically on a 10cm line according to a set visual analog scale: left end of line = no 
evidence of disease activity, midpoint of line = moderate disease activity and right end of 
line = extremely active/severe disease activity. In addition global disease activity is also 
rated on a 5-point Likert scale: 0 = none, 1 = mild activity, 2 = moderate activity, 3 = severe 
activity, 4 = extremely severe activity. Although this RA assessment measure is somewhat 
biased, it is performed by qualified skilled professionals and is an established measure in 
assessing RA disease. 
 
The Proximal Interphalangeal Synovitis (PIPS) score is an assessment of the synovial 
thickening of the proximal interphalangeal joints which are between the proximal (first) 
and intermediate (second) phalanges (0=nil, 1=possible, 2=definite, 3=gross). Due to the 
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measurement of synovial thickening it therefore is used as an indicator of inflammation 
and used in the assessment of RA. 
 
The Overall Status of Rheumatoid Arthrits (OSRA) is a summary measure based on patient 
history and physical examination. The OSRA questionnaire incorporates 4 components: 
demographic information, the OSRA-disease activity (OSRA-A), the OSRA-damage 
(OSRA-D) and a treatment category (Harrison et al., 2007). In this study the OSRA-A and 
OSRA-D scores were used independently of the complete OSRA. The OSRA-A score was 
developed to represent the potentially reversible aspects of RA whereas the OSRA-D score 
aimed to capture the irreversible impact of the disease. The OSRA-A and OSRA-D scores 
both are based on 5 different components of activity (well being, pain, EMS, active joints 
(swollen and tender), extra-articular disease) and damage (function, social life, number of 
destroyed or replaced large joints, small joint damage, organ impairement) respectively. 
Both these measures require a clinician to assess the patient mobility and disability as well 
as to complete a questionnaire on the patients’ functional ability. Below are the 5 varying 
components of the OSRA-A and OSRA-D to determine overall activity and overall 
damage of patients. These measures provide a good overall summary of the disease activity 
and damage and thus are broad markers of inflammation and damage respectively. These 
scores are widely established in clinics and were used in this study as well. 
 
Some disease measures used in this study are composites of other formulated disease 
measures. The Disease Activity Score (DAS) is one of such composite disease measures 
and is calculated through the use of 4 parameters. This incorporates the number of swollen 
joints out of a set of 44, the Ritchie Index and either the ESR or CRP to allow the 
formulation of the DAS44ESR or DAS44CRP respectively. The mathematical formulas 
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below show how they are calculated and where the higher the DAS score the worse disease 
activity of RA. 
 
(0.54 x √Ritchie Index) + (0.065 x 44 swollen joint count) + (0.33 x Ln/Log natural ESR) 
+ 0.224 = DAS44ESR 
(0.54 x √Ritchie Index) + (0.065 x 44 swollen joint count) + (0.17 x Ln/Log natural 
(CRP+1)) + 0.65 = DAS44CRP 
 
There are a number of validated formulas for the DAS score which also incorporate the 
VAS for pain, general health, tender joint score etc to accommodate what data is available 
at the time. As this is a composite measure, therefore this gives an overall assessment of 
RA disease as it uses multiple measures and thus is a good indicator of activity and 
severity (van der Heijde et al., 1993, Fransen et al., 2003, Anderson et al., 2011). 
 
Another composite measure is the Stoke Index which is a Staffordshire validated measure. 
It is a global measure of RA disease activity and comprises of a complex hierarchical 
formula involving the PIPS, ESR, EMS, CRP and the Ritchie Index. It is an algorithm 
developed into a flow diagram to classify patients into 1 of 17 ranked classes of RA 
activity (Davis et al., 1990). This measure is therefore another useful inflammatory marker 
and was used in the study. 
 
Disease measures which are composited from independent inflammatory measures are 
overall global assessors of the disease process and thus can be separated into phenotypes of 
severity. The Stoke Index is divided into 4 phenotype categories based on patient scores. 
These phenotype categories are: minimal (0-3), mild (4-7), moderate (8-11) and severe 
(12-17). The DAS44ESR and DAS44CRP can also be categorized into severity 
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phenotypes. These phenotypes are separated by patient scores into: low (<2.4), moderate 
(>2.4-3.7) and high (>3.7). In addition, a score of <1.6 in either the DAS44ESR or 
DAS44CRP in patients are characterized as remission, although this is used when disease 
is an established stage (reproduced from http://www.das-score.nl/downloads.html). 
 
Another marker for inflammation is the manifestation of a synovial effusion where an 
excess of synovial fluid in the joint arises due to inflammation and is demonstrated by 
swelling of the joint capsule and must be drained. 
 
Autoantibodies RF and anti-CCP are also used as markers of inflammation, and are 
described in section 1.1.10.3.1 Seropositivity of RF is considered to be levels above 
60IU/mL, while levels above 5 units/mL is considered positive for anti-CCP. 
 
3.1.3.2 Markers of Pain 
 
There are three measures of pain in the patient database and used in this study, one of 
which is the visual analogue scale (VAS) for pain. This measurement of pain is subjective 
as it based on the patient, and involves the patient marking on a 10cm horizontal line 
similar to that of the CGDA according to a set visual analog scale: left end of line = no 
pain felt, midpoint of line = moderate pain felt and right end of line = severe pain felt. 
Although this is a biased measure of the disease process, and each individual patient has a 
different resistance threshold, only the subject can indicate if the joint is painful or not, and 
thus is a realistic indicator of pain and therefore included in this study. 
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The number of tender joints is also a measure of pain and is the total count of the same set 
of 44 joints as detailed in the swollen joint counts. It is assessed by the clinician by 
applying pressure to the joint or with movement and determining if the patient is in pain, 
and as such is a good marker for the amount of pain felt. 
 
Another measure of pain is the Ritchie Articular Index (RAI). It is based on the sum of 
applying pressure to 26 joints (shoulders, elbows, wrists, MCP, PIP, hips, knees, ankles, 
talocalcaneal, midtarsal, metatarsals, temporomandibular, cervical spine, sternoclavicular 
and acromioclavicular) and is graded on a 0-3 scale of pain intensity: 0= no tenderness, 1 = 
pain felt, 2 = pain felt and expressed wincing, 3 = pain felt, expressed wincing and 
withdrew (Ritchie et al., 1968). RAI is a more detailed assessment of pain as it measures 
the intensity of pain. This score therefore is a reliable indicator of pain and is not biased on 
subject perception, and as such is used in this study. 
 
3.1.3.3 Markers of Damage 
 
A strong marker for joint damage is the presence of any bone erosion in joints. This is 
determined by a radiologist through radiograph examination of the joints. As such this 
marker is very useful in the assessment of damage and outcome in RA. It should be noted 
that erosive data in most patient cases was not collected at baseline or at 5 year follow-up 
but recorded at any time point and is indicative of an erosive disease. 
 
The Larsen score is also a marker for damage, where the joints of the hands, wrists and feet 
are examined and graded on a scale of increasing damage where the total is used to asses 
full extent of the patients’ bone damage (Larsen et al., 1977). The scoring method is a 
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combination of bone erosion presence, soft tissue swelling, cartilage thinning and 
narrowing of the joint space and is determined by a radiologist. 
  
The OSRA-D is used as a marker for damage and one parameter of the OSRA, and has 
been previously discussed. 
 
3.1.3.4 Markers of Function 
 
The Health Assessment Questionnaire (HAQ) is a patient questionnaire to clinically 
measure health-related quality of life for RA patients. It assesses the mobility and 
functional status of patients in daily activities such as walking, grooming etc. It is scored 
by a clinician and graded on an increasing scale of 0-3 of worse mobility (Appendix figure 
3.1.3.4 for HAQ questionnaire). The HAQ has become an established clinical assessment 
for health outcome and thus included in this study. 
The Early Morning Stiffness (EMS) disease measure is a marker of function. Joints are 
commonly stiff, sore and painful after inactivity for a long period of time or a nights sleep 
in RA patients. After moving a while, the joints “loosen up” as they are move around and 
are used. In RA, the lubrication of the cartilage with joint fluid is inadequate during rest 
periods as there is less cartilage, less fluid and cartilage is poorer in quality and thus feels 
stiff. EMS is difficult to quantify, where the length of time (minutes) until joints are 
moveable is recorded. EMS is one of the parameters for the ACR classification of RA, and 
thus also used in this study. 
Grip strength is a test to measure the maximum isometric strength of the hand. A 
sphygmomanometer cuff inflated to 30mmHg (millimetre of mercury) is used, where the 
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patient squeezes the apparatus and the pressure achieved is recorded. This disease measure 
is therefore a good indicator of functional ability in patients and thus used as a marker of 
function and mobility outcome. 
 
These measures of disease described above are all valid indicators of RA activity and 
severity and were all included in the study to assess the overall process and outcome of 
RA, not just particular aspects of the disease. In addition, many patients have exceptions to 
the expected standard, where some patients have swollen joints, but little pain, whereas 
others may have considerable pain but few swollen joints. Therefore using multiple 
measures of disease for assessing the RA process and outcome encompasses the extensive 
range of severity and activity of RA rather than relying on one clinical measure to indicate 
the activity and severity of RA disease. 
 
3.1.4 Patient drug therapy regimes 
 
Regardless of the type of disease, most patients were receiving various anti-inflammatory 
and/or anti-rheumatic therapy drugs, either singularly or in combination. The drugs 
administered to the patients included analgesics, NSAIDS, DMARDs and steroids. None of 
the patients in this study were receiving biologic therapy. Table 3.1.4 below describes the 
percentage of patients on the various drug therapy regimes in each patient cohort at both 
baseline and at 5 year follow up. Approximately half of the RA, PsA and ReA patients 
were receiving NSAIDs at baseline. The figure lowers for patients with OA (35%), 
although more of these patients were taking analgesics (40%). The paired RA cohort had a 
large number of patients receiving both NSAIDs and DMARD therapy. This can be 
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explained by the longer disease duration for this group. Unsurprisingly, for patients with 
RA or PSA, the percentage receiving DMARDs had greatly increased at 5 years follow up.  
It is should be noted that it is unknown at what time point patients were started on 
analgesics or NSAIDs since General Practitioners could have prescribed treatment before 
attendance at the clinic. Patient drug therapy may also have changed during the 5 years 
prior to follow up data collection. However no data was available for the time points when 
any therapy changes occurred. 
 
Table 3.1.4: The percentage of patients on DMARD treatment at baseline and 5 year 
follow-up 
 Cohort 1 Cohort 2 Cohort 3 
Patient Groups Baseline RA Five year follow-up RA Paired RA OA PsA ReA 
DMARD positive 
% (total n) 
14% (86) 91% (76) 45% (51) 0% (20) 9% (32) 0% (26) 
 
 
3.2 Methodology 
 
The measurement of numerous mediators was investigated in the serum and synovial fluid 
by use of ELISAs (Enzyme Linked Immunosorbance Assay) and multiplex bead assays. 
The following sections describe the methodological protocols performed for investigation 
into mediator quantification in the various cohorts. 
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3.2.1 Patient sample collection 
 
Patient sample collection was performed by a qualified nurse practitioner at the clinic both 
at baseline and at subsequent 5 year follow up. These patient samples of synovial fluid and 
blood for serum isolation were used to perform the number of investigations discussed in 
this project. 
 
3.2.1.1 Blood collection and serum isolation 
 
Blood was collected by drawing 22mls of peripheral blood from patients from either arm. 
This was achieved by tying a tourniquet around the patients’ upper arm to increase the 
blood pressure in the veins of the arm. The skin over the blood vessel, usually the median 
cubital vein on the inside of the elbow is cleaned with antiseptic. A sterile needle is then 
inserted into the vein while the opposite end of the needle is inserted into a sterile 
vacutainer subsequently drawing up blood. All blood samples were processed within 1 
hour of collection and stored in a -80°C freezer. The standard procedure for isolating 
serum from whole blood samples was performed by a clinical technician within 1 hour of 
blood collection. Serum was removed from whole blood by allowing the sample to clot for 
30 minutes at room temperature. This sample was then spun in a 5°C centrifuge for 15 
minutes at 4000rpm. The serum at the top of the vacutainer was then drawn off by a glass 
pasteur pipette and into a sterile microcentrifuge tube to be stored in a -80°C freezer until 
use for either ELISA or multiplex assays. 
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3.2.1.2 Synovial fluid extraction 
 
Synovial fluid is extracted from patients by arthrocentesis, which involves a practitioner 
inserting a needle into the affected inflamed joint. A syringe is then attached to draw up the 
synovial fluid. A local anaesthetic is administered before the needle and syringe are 
applied. Synovial fluid samples are also stored in the -80°C freezer until use in ELISA and 
multiplex assays. Synovial fluid after extraction from the joint did not require any 
additional preparation for mediator investigation. 
 
3.2.2 Biomarkers investigated and their quantification 
 
Forty one different mediators in total were investigated in this study. Osteoprotegerin 
(OPG), osteopontin (OPN), Dkk-1 and endostatin were measured by the use of ELISAs. 
The remaining 37 mediators were investigated by using 3 types of multiplex systems: a 27-
plex from Bio-Rad, a MMP-plex and a TIMP-plex both from R&D Systems. The Luminex 
system is designed to facilitate measurement of different assay plates from different 
manufacturers. The 3 multiplex systems are each able to detect a specific set of mediators. 
The specific set of mediators for each system is listed in Table 3.2.2. 
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Table 3.2.2: A list of mediators investigated 
27-plex Multiplex 
 (Bio-Rad) 
MMP Multiplex 
(R&D Systems) 
TIMP Multiplex 
(R&D Systems) 
Duo Set/Quantikine* 
ELISA (R&D Systems) 
IL-1β G-CSF MMP-1 TIMP-1 OPG 
IL-1ra GM-CSF MMP-2 TIMP-2 OPN 
IL-2 IFN-γ MMP-3 TIMP-3 Dkk-1 
IL-4 PDGF-bb MMP-8 TIMP-4 Endostatin* 
IL-5 TNF-α MMP-9   
IL-6 VEGF MMP-12   
IL-7 IL-8    
IL-9 Eotaxin    
IL-10 IP-10    
IL-12p70 MCP-1    
IL-13 MIP-1α    
IL-15 MIP-1β    
IL-17 RANTES    
FGF-β     
 
 
3.2.2.1.1 Sandwich based Enzyme Linked Immunosorbance Assay (ELISA) 
 
Following serum isolation from blood and collection of synovial fluid, quantification of 
specific mediators in both the serum and synovial fluid samples were performed through 
the use of the sandwich Enzyme Linked Immunosorbance Assay (ELISA) system. The 
basic principle of the sandwich ELISA procedure is based on a two antibody immunoassay 
system. This involves the molecule of interest bound between the capture antibody and the 
detection antibody, hence its given name “sandwich”. The capture antibody is permanently 
attached to the well plate. The target molecule binds to the specific capture antibody and 
the specific detection antibody in turn binds to the target molecule. A third enzyme 
conjugated antibody is designed to bind to the constant region of the detection antibody. 
Enzymes commonly linked to these antibodies are alkaline phosphatase or horseradish 
peroxidise (HRP). An alternative to using an enzyme conjugated third antibody is to use a 
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Streptavidin-HRP conjugate which will bind to a biotinylated detection antibody. With the 
addition of Tetramethylbenzidine (TMB) substrate the HRP enzyme is catalyzed which 
leads to a change in colour. The absorbency of the plate wells as measured by the optical 
density determines the presence and quantity of the target molecule. The figure below 
(Figure 3.2.2.1.1) shows simply the procedure of the most common sandwich ELISA 
process. 
 
Figure 3.2.1.1: The mechanism of a common-sandwich ELISA system 
 
Reproduced from http://www.synchronium.net/wpcontent/uploads/2009/09/sandwich_elisa.jpg. 
 
 
The above procedure is one of the most common methods of sandwich ELISAs. However 
there are other sandwich ELISA methods, that use different enzymes instead of horseradish 
peroxidise (HRP) for colour development. There are also sandwich ELISAs that 
completely bypass the use of a third antibody or a streptavidin protein. In these cases the 
colour changing enzyme is conjugated instead to the detection antibody directly. This was 
the case with endostatin assay, where a specific Quantikine ELISA kit was purchased from 
R&D Systems which utilized this method. This specific protocol is discussed in detail in 
section 3.2.2.1.3. 
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The investigation into OPG, OPN and Dkk-1 were performed by the classic sandwich 
ELISA methodology. These ELISAs were performed using ELISA Duoset kits (R&D 
Systems) according to the manufacturer’s instructions. The section below (section 
3.2.2.1.2) describes in depth the protocol used for these investigations. 
 
3.2.2.1.2 Duoset ELISA methodology 
 
The levels OPG, OPN, and Dkk-1 as well as IL-17 and FGF-β were quantified by the 
ELISA Duoset Development Kits (R&D Systems). These kits contained 1 vial each of 
specific capture and detection antibodies, 2 vials of the standard and a vial of Streptavidin-
HRP. All the reagents were brought to room temperature and mixed thoroughly prior to 
experimental use. 
 
The capture antibody and biotinylated detection antibody were reconstituted from powder 
to the desired concentration and then diluted to the working concentration with filtered 
phosphate buffered saline (PBS) (Sigma) and 1X reagent diluent (R&D Systems) 
respectively. The ELISA plate consists of 96 wells which were pre-coated with the specific 
working concentration of the capture antibody the previous day and incubated at room 
temperature over night to allow adherence to the plate. The following day, the plate was 
then aspirated and washed 3 times with 0.05% Tween 20 (R&D Systems) in PBS wash 
buffer. The wells were then blocked with either 300µl of 1X reagent diluent (DY995-R&D 
systems) or 1% Bovine serum albumin (BSA) (Sigma) for 1 hour at room temperature to 
prevent non-specific antibody cross-reactive binding. Patient samples, either serum or 
synovial fluid were diluted with 1X reagent diluent at the desired dilution with an addition 
of 3ug/ml Heteroblock (Omega) final concentration for 1 hour at room temperature. The 
 115 
mediator standard was reconstituted to the required concentration and subsequently used to 
prepare a 7 point standard curve using 2 fold serial dilutions in 1X reagent diluent.  
 
The ELISA plate was aspirated and washed three times with wash buffer. Next, 100µl of 
both the prepared standards in duplicate and samples, as well as a blank control were added 
into their respective wells. These samples were incubated for two hours at room 
temperature to allow binding to the capture antibody. The plate was washed three times to 
remove unbound samples. A 100µl of biotinylated detection antibody was added to each 
well and further incubated for 2 hours at room temperature. After the removal of the 
detection antibody, Streptavidin-HRP was diluted 1:200 in 1X reagent diluent and a 100µl 
was added into each of the wells. The ELISA plate was then placed away from direct light 
and incubated for 20 minutes at room temperature. The wash process was repeated and a 
100µl of substrate solution consisting of a 1:1 mixture of colour Reagent A (H2O2) (R&D 
Systems) and Reagent B (Tetramethylbenzidine) (R&D Systems) was subsequently added 
to the wells. This mixture was left to incubate at room temperature for 20 minutes avoiding 
direct light to allow blue colour development. Lastly 50µl of “stop solution” (2N H2SO4), 
stored at 4°C was added to the wells containing the substrate solution to stop colour 
development. This was observed by the blue colour changing into yellow.  
 
The plate was read immediately on a microplate reader (Titertek) with 2 filters, one at 
450nm the other at 575nm. The use of dual filters allow for wavelength correction for any 
optical imperfections in the plate which can alter the results. The optical density (OD) was 
then read and a standard curve and quantification of the mediator level was automatically 
generated from the Titertek software and recorded. 
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3.2.2.1.3 Quantikine ELISA methodology for the measurement of Endostatin 
 
This kit contained a microplate pre-coated with a monoclonal antibody specific to 
endostatin. The plate was pre-wetted with 100µl of assay diluent to each well. Patient 
samples were diluted with 1X calibrator diluent at the desired dilution along with an 
addition of 3ug/ml Heteroblock (Omega) final concentration for 1 hour at room 
temperature. The endostatin standard was reconstituted to the required concentration and 
subsequently used to prepare a 7 point standard curve using 2 fold serial dilutions in 1X 
calibrator diluent. Fifty microlitres of prepared standards, blank control and samples were 
added to the wells. The plate was then incubated for 2 hours at room temperature on a 
horizontal orbital microplate shaker at 500rpm to allow binding of endostatin. The plate 
was then washed and aspirated 4 times using the supplied wash buffer. The addition of 
200µl of endostatin conjugate, a horseradish peroxidase enzyme-linked monoclonal 
endostatin specific mouse antibody was added. This was incubated again at room 
temperature for two hours on the orbital shaker to allow the specific binding. The wash 
procedure was performed again to remove any unbound antibody-enzyme-reagent. Then 
200µl of substrate solution (1:1 mixture of Colour Reagent A and B) was pipetted into each 
well and incubated for 30 minutes at room temperature avoiding direct light. During this 
incubation a blue colour develops in proportion to the amount of endostatin bound in the 
initial step of the assay. The colour development is subsequently stopped with 50µl of stop 
solution (2N sulphuric acid). The colour intensity or absorbance was determined by 
measuring optical density (OD). This was achieved by the use of a microplate reader 
(Titertek) set at 450nm and then at read again at 575nm for wavelength correction. The 
Titertek programme automatically generated the standard curve and endostatin 
concentration results which were subsequently recorded. 
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3.2.2.2 The Multiplex bead based X-multianalyte profiling (-MAP) principle 
 
A sophisticated piece of technology called the Luminex (Bio-PlexTM 200 X-map 
suspension array System, Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire, United 
Kingdom) is used to measure numerous analytes in parallel. The multiplex system has the 
ability to measure up to 100 analytes in a single assay. The Multiplex is based on a 2 way 
system incorporating the sandwich ELISA method and the fluorescence activated cell 
sorting principle (FACS) Flow Cytometry principle. The microparticle beads contain 2 
fluorescent dyes in variable intensities to create a distinct bead set for each analyte. 
Molecules bind to the specific antibodies attached to the bead surface which are then 
subsequently tagged by fluorescent labelled reporter protein. The beads are passed 
individually through a two laser column in the Luminex machine, and their fluorescent 
biochemical reactions are measured and reported. The red laser reads the beads’ unique 2 
dye fluorescent emission to determine its unique analyte bead identity. The green laser then 
measures the reporter label to determine fluorescence quantity. The fluorescence activity 
within a sample is directly related to the concentration of the specific analyte in the sample. 
The diagram below (Figure 3.2.2.2) shows in brief the process that occurs within the 
Luminex machine. 
 
Figure 3.2.2.2: The bead reading system of the Luminex machine 
 
1. Microsphere bound with analyte molecule captured between immunoglobulin probes and fluorescently labelled 
reporter tags. 
2. Microparticle beads within a fluidic stream pass through the red and green lasers. 
3. Molecular tags & microsphere are both excited & the fluorescent intensity is identified & measured. 
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This rapid method for mediator level quantification was performed on numerous mediators 
on both serum and synovial fluid samples. All the multiplex assays were performed 
according to the specific manufacturers kits’ instructions. Although each multiplex assay 
system varies in its reagent concentrations, the principle of the assay between the systems 
are the same and are described below. 
 
The filter microplate was first pre-wetted with 100µl either wash buffer or assay buffer 
depending on the protocol. This buffer was then removed completely through the filter 
attached at the bottom of the plate by a vacuum manifold system (5 Hg). Analyte specific 
antibodies are pre-coated onto the microparticle beads. This is done by the manufacturer, 
as each bead has a unique identification which is determined by the 2 colour dye of the 
bead. The beads are diluted to the required concentration depending on the particular 
multiplex assay and 50µl was pipetted into each the wells. Next 50µl of prepared samples, 
a blank control and a 7 point standard was then added to the respective wells. This was 
then incubated at room temperature on a horizontal orbital plate shaker at 500rpm for two 
hours. This allowed the mediators in the samples and standards to bind to the specific 
analyte antibody coated microparticle beads. Un-bound standards and samples were 
removed by washing 3 times with 100µl of wash buffer using the vacuum manifold 
between each step. The biotinylated detection antibodies specific to the analytes of interest 
was diluted to the desired concentration and either 25µl or 50µl was pipetted into each well 
depending on the particular assay. This was then incubated on the horizontal orbital plate 
shaker for 30 minutes or 1 hour at room temperature, depending on the multiplex assay. 
The wash step procedure was performed again after the removal of the detection 
antibodies. Next, 50µl of Streptavidin-Phycoerythrin (PE) was added and incubated for 
either 30/20/10 minutes depending on the specific protocol at room temperature on the 
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orbital shaker out of direct light. The plate was washed a final three times through the 
vacuum manifold and given a final incubation on the orbital plate shaker, covered from the 
light for two minutes in assay buffer to resuspend the microparticle beads. 
 
The Bio-Plex 200 equipment was calibrated to each of the specific multiplex assay 
protocols and the plate was immediately read in the Bio-Plex 200 after bead resuspension 
to determine the phycoerythrin fluorescence levels. The fluorescence level is directly 
proportional to the amount of specific analyte. Therefore analyte concentration levels are 
quantified by fluorescence level. The quantification of each of the specific analytes in the 
multiplex was automatically generated by the Luminex software including their relative 
standard curves. The software also allowed the ability to remove outlier standard results to 
create an optimal standard curve and the mediator quantitative levels were then recorded. 
 
With the range of mediators investigated, a number of different dilution factors were 
required for serum and synovial fluid sample preparation. The 27-plex multiplex required a 
1:4 dilution of both serum and synovial fluid samples as stated by the protocol. MMP-1, -
2,-3,-8 and -12 were all performed with serum samples at a 1:10 dilution, while synovial 
fluid used a 1:1000 dilution factor. Serum samples for MMP-9 investigation required a 
dilution of 1:100. A 1:10,000 dilution was required for MMP-3 investigation into synovial 
fluid samples, while a 1:50 dilution was used for both serum and synovial fluid 
investigating TIMPs. 
 
The ELISA assays for endostatin and OPN were performed using a 1:50 dilution for serum 
samples. Synovial fluid for measurement of OPN was diluted to 1:400 or 1:800 if the 
sample was above the recordable threshold at 1:50 dilution. Serum samples were diluted to 
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a 1:10 dilution in Dkk-1 ELISAs and synovial fluid at 1:5. OPG ELISAs required serum 
samples to be diluted 1:10 and a dilution factor of 1:50 for synovial fluid. FGF-β and IL-17 
ELISAs were predominantly performed with serums at a 1:5 dilution factor. However a 
number of samples were above the recordable threshold and therefore had to be repeated at 
a higher dilutions ranging from 1:10, 1:20 and 1:40. 
 
Investigation of endostatin was performed on a total of 81 patients from the baseline RA 
cohort. A total of 86 baseline RA patients were assayed by a polystyrene bead based 27-
plex multiplex assay while the paired RA cohort was assayed with a magnetic bead based 
27-plex multiplex kit. All other mediator assays were performed on all patients available. 
 
Both ELISAs and multiplex assays were performed with patient samples in duplicate in 
majority of the assays. However some samples were performed in singlets due to limited 
well space. 
 
The possibility of cross-reactive interference from competitive Rheumatoid Factor (RF) 
autoantibody was considered in these assays since both the ELISA and multiplex bead 
arrays are based on antibody binding systems. In order to block cross-linking by RF, 
patient samples in sample diluent were pre-incubated with a compound called Heteroblock 
(Omega Biologicals Incorporated, Bozeman, Montana, USA) at a final concentration of 
3µg/ml for 1 hour prior to addition to the plate wells. 
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3.2.3 Statistical software and data analysis 
 
All data was analysed using Number Cruncher Statistical Software package for Windows 
(NCSS 2000, NCSS Statistical Software, Kaysville, Utah, USA). A probability value of 
<0.05 was used to determine significance level. Various techniques from NCSS including 
multivariate variable selection, discriminant stepwise-selection and regression, multiple 
regression, forward logistic regression, one way analysis of variance (ANOVA), Two-
sample and paired T-tests, principal component analysis (PCA), correlation matrices, Chi-
square, odds ratio and receiver operating characteristic (ROC) analysis were used. Results 
were also adjusted for confounding variables such as disease duration, smoking, 
autoantibody presence and DMARD treatment where appropriate. Furthermore, parametric 
and non-parametric analyses were used depending on the distribution of the data when 
appropriate. Analysis of normal distribution incorporated 7 tests (Shapiro-Wilk W, 
Anderson-Darling, Martinez-Iglewicz, Kolmogrov-Smirnov, D’ Agostion -skewness, -
Kurtosis and -Omnibus test) as well as a frequency distribution histogram and normal 
probability plot to determine normality. In addition, the Variance Ratio and the Modified 
Levene equal variance test were also used when appropriate for determining equal or 
unequal variance. 
 
Testing against a variable (dependent) repeatedly (multiple comparison testing) increases 
the likelihood of identifying a significant result purely by chance when there actually is 
none (type 1 error) with each additional comparison, ie. false positive rate. Adjustment for 
this type of error in one-way ANOVA where comparison is with 3 or more groups was the 
regular z-value test of the Kruskal-Wallis multiple comparison analysis for non-parametric 
data, whereas Scheffes’s multiple comparison test was used for normally distributed data. 
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Other multiple comparison analyses may be considered significant after the Bonferroni 
adjustment for multiple testing e.g. with a p-value <0.01 for up to 5 comparison tests, 
<0.005 for up to 10 comparisons and <0.0001 for up to 50 comparisons. Setting a stricter 
p-value threshold reduces the risk of type 1 errors, however increases the risk of type 2 
errors, that is failing to identify a significant result when there actually is one ie. false 
negative rate. Consequently, as the risk of type 2 errors rise, statistical power in turn 
decreases as it is 1 minus type 2 error probability. Adjustment for multiple comparisons in 
other analyses were generally not undertaken as they were largely exploratory in nature. 
Statistical power is the probability of identifying a significant result when there actually is 
one ie. detecting true significance. Typical power values are set to 80%, which means an 
80% chance (eg. 8 out of 10 times) or greater of finding a significant result when there is 
one. With a reduction in the power of the analysis, the conclusion of a result as statistically 
significant becomes more difficult, regardless of whether it’s true or false. An increase of 
the p-value or the number of samples can increase the power of a test. Without knowing 
the likely effect size and nature of response for each biomarker in these studies it was 
difficult to pre-determine the sample size necessary to achieve power of 80% or more. 
Many of the analyses were largely exploratory in nature, although the numbers used were 
consistent with published studies of a similar type. The results of the current study may be 
used to better inform future studies in their design and estimation of sample sizes to 
achieve sufficient power. 
 
3.2.3.1 Principal Component Analysis biomarker profiling 
 
PCA reduces the dimensionality of a large number of variables to a smaller set of 
independent components based on their data correlation pattern and the maximum number 
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of iterations. These component group profiles then can also be investigated for their 
association with disease measures and features with the various techniques mentioned 
above. 
 
PCA, although exceptionally useful in reducing the number of variables, is still limited by 
the number of variables it can include in respect to the number of patient samples. As such, 
PCA was initially performed on all the mediators collectively and subsequently particular 
mediators were selected to be included in the final PCA analysis based on their maximum 
variability score. 
 
3.2.3.2 Genesis hierarchical clustering biomarker profiling 
 
Genesis 1.7.2 software (Institute for Genomics and Bioinformatics, Graz University of 
Technology, Alexander Sturn) was used to generate heat maps of multiple continuous 
variable measurements for each patient in a single display. This allows for visual 
representation of the mediator levels in patients as well as illustrating all the disease 
measure variables.  
 
The Genesis programme uses a two-way hierarchical clustering method which enables 
groups of variables with similar expression levels to be clustered together, as well as 
grouping together patient samples with similar expression patterns. This can then create 
phenotype profiles which can be included in statistical analyses. 
 
The range of results obtained from the multiplex and ELISA assays were extremely wide 
between the various mediators. As a consequence, using the in-house function of the 
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software Log2 transformation of the raw results was performed, and then subsequently 
normalized to get bring the values within range of one another. A Heat Map utilizes a 
colour key which displays a gradual scale of intensity (-2.0 to +2.0 score) to reflect the 
levels below and above the standard deviation. The increasing intensities of yellow and 
orange are associated with highest expression levels of mediators, while increasing 
intensity of blue is associated with lower levels of mediators relative to the mean. Missing 
or unrecorded values, or those below the limit of detection are indicated by the grey boxes. 
Dendrogram branch lengths and distances between nodes illustrate the extent of 
similarities. 
 
Hierarchical clustering and Principal Component Analysis were both used in this study to 
profile mediators. Hierarchical clustering, although not a statistical tool, does generate an 
overall image which provides information on mediator levels in different groups of 
patients, and how these may relate to disease phenotype. PCA profiling in contrast, is a 
statistical tool that identifies the most important mediators and determines distinct profiles. 
Using both hierarchical clustering analysis and principal component analysis in this study 
maximizes the ability to identify prominent mediators which would theoretically be good 
targets for disease intervention. This type of analysis help to elucidate which mediators are 
more likely to be associated with greater disease activity and severity, as well as 
contributing insights into the biological mechanisms. 
 
A summary explaining all the statistical analyses utilized and the rationale of why they 
were used for each cohort section is presented in a flow chart (Appendix figure 3.2.3).
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CHAPTER 4 
RESULTS AND DISCUSSION 
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4.1 BIO 
MARKER PROFILING IN EARLY AND ESTABLISHED RA 
 
Patients with early and established RA were investigated to determine whether any specific 
biomarker profiles may explain worse disease in the beginning and later stages of RA. 
Such investigations can give insights into elucidating the pathological process and may 
give clues into the molecular pathways involved in the disease process as well as the 
progression of disease. 
 
4.1.1 Relationship of RA features and characteristics 
 
Initial comparative analyses of RA disease characteristics and features were performed for 
general assessment of the patients investigated in this study. RF and anti-CCP 
autoantibodies have been well documented to be associated with RA. Chi-square analysis 
revealed a significant association between RF and anti-CCP presence (p=0.0003), where 
nearly 90% of patients positive for RF were also positive for anti-CCP, and were over 6x 
more likely to be anti-CCP positive than RF negative patients (Table 4.1.1a). Interestingly, 
over 50% of patients were negative for RF but were positive for anti-CCP, whereas 11% of 
RF positive patients were negative for anti-CCP. This adds to the notion that anti-CCP 
develops first in RA disease and further demonstrates that it may be a better prognostic and 
diagnostic tool than RF (Greiner et al., 2005, van Gaalen et al., 2005, Nishimura et al., 
2007). 
Table 4.1.1a: Association between RF and anti-CCP 
 Anti-CCP n (%) Odds Ratio (95% CI) 
 Negative Positive  
RF negative 19 (46%) 22 (54%) Referent 
RF positive 5 (11%) 40 (89%) 6.38 (2.17-18.74) 
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χ2= 13.23 (df=1), p= 0.0003 
 
Analysis also revealed that patients negative for RF were twice as likely to present with an 
effusion of a knee joint than RF positive patients, although this was not significant (10/41 
(24%) v 6/45 (13%), OR=2.02, 95% CI 0.68-5.99, p=0.26). This was similarly found with 
anti-CCP negative patients who were also more likely to present with a knee effusion than 
anti-CCP positive patients (6/24 (25%) v 10/62 (16%), OR=1.75, 95% CI 0.57-5.34, 
p=0.36), which was also not significant. No significant association was found between 
erosive disease and patients positive for RF either (27/40 (67%) v 23/36 (64%), OR=1.17, 
95% CI 0.45-2.97, p=0.81). However a significant association was found with anti-CCP 
(p=0.01). Patients with anti-CCP were over 3x more likely to have erosive disease than 
patients negative for anti-CCP (Table 4.1.1b), which is consistent with previous studies 
which have shown anti-CCP has a stronger relationship to erosions than RF (Visser et al., 
2002, Shankar et al., 2006, Agrawal et al., 2007). 
 
Table 4.1.1b: Association between anti-CCP and erosive disease 
 Erosions n (%) Odds Ratio (95% CI) 
 Negative Positive  
Anti-CCP negative 12 (57%) 9 (43%) Referent 
Anti-CCP positive 14 (25.5%) 41 (74.5%) 3.76 (1.34-10.59) 
χ2= 6.78 (df=1), p=0.01 
 
 
Autoantibodies have been shown to be present in individuals years before the actual onset 
of RA disease and increase the risk of early RA development (Rantapää-Dahlqvist et al., 
2003). Patients who were positive for anti-CCP were more likely to have early disease 
onset than anti-CCP negative patients (17/61 (28%) v 1/24 (4.2%), OR=6.16, 95% CI 1.08-
35.13, p=0.01), which is in line with previous studies (Diaz et al., 2011). The presence of 
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RF however was not associated with early onset (p=0.60). This further contributes to the 
notion that anti-CCP is a risk factor for early RA development and also a better prognostic 
and diagnostic tool than RF (Vossenaar and van Venrooij, 2004, Niewold et al., 2007, Diaz 
et al., 2011). 
 
No significant association was found between synovial effusions and erosions (8/13 
(61.5%) v 42/63 (66.7%), OR=0.78, 95% CI 0.23-2.57, p=0.75), although this could be 
attributed to the relatively small numbers of patients with both synovial effusions and 
erosions available for comparison.
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4.1.2 EARLY RA 
 
RA patients with early disease (disease duration of <2 years) were investigated with 
respective baseline (first clinical admittance) clinical, laboratory and patient characteristic 
data. Such investigations can give insights into the development of disease and the 
pathological process in early disease before its progression into established disease, which 
may provide valuable clues to the pathways by which RA develops. 
 
4.1.2.1.1 Relationship of RA disease features and patient characteristics with disease 
activity and severity in early RA 
 
Initial analyses of baseline disease activity and severity measures with RA patient 
characteristics and clinical features were performed for general assessment of the patients 
investigated in this cohort. RF and anti-CCP have been well documented to be associated 
with more severe RA. Comparative analyses between positive and negative patients of 
both RF and anti-CCP revealed no significant differences in the level of disease activity 
and severity with either autoantibody (data not shown). This lack of difference may be 
because these particular patients are too early in their stage of RA development with ~60% 
(59/86) of patients having a disease duration of 6 months or less. Thus clear differences in 
severity may not have yet developed between positive and negative RF patients. 
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4.1.2.1.2 Influence of cigarette smoking 
 
Cigarette smoking has been documented to be associated with worse RA disease (Saag et 
al., 1997, Wolfe, 2000, Söderlin et al., 2011), which was similarly demonstrated in this 
early RA patient cohort. Patients who had ever smoked demonstrated a significantly higher 
WBC count (p=0.03), DAS44ESR (p=0.04), DAS44CRP (p=0.02), VAS (p=0.02) and 
HAQ score (p=0.01) plus a significantly lower grip strength (p=0.04) (Figure 4.1.2a). 
However 74% (20/27) of non-smokers are women, which could explain the lower grip 
strength. No other disease measure was found to be significantly different in patients who 
have ever smoked (n=59) than those who had never smoked (n=27). 
 
Figure 4.1.2a: Association of cigarette smoking with disease activity and severity 
 
 Green= never smoked, Red= ever smoked 
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Further analyses of the active smoking status of RA patients revealed however that the 
majority of disease activity and severity measures were not significantly different between 
never smokers, past smokers and current smokers, except for the number of swollen joints 
(p=0.04) and the HAQ score (p=0.02) (Figure 4.1.2b and c respectively). Past smokers 
were shown to have a significantly higher number of swollen joints than current smokers 
and never smokers, as well as higher HAQ scores compared to current smokers and never 
smokers, although this was only significant for the latter. 
 
Figures 4.1.2b and c: Comparison of the number of swollen joints and the HAQ according 
to patient smoking status 
 
 
 
The higher level of severity found in past smokers could possibly be attributed to the 
frequency and the amount of time patients have smoked (pack year history). However 
further analysis revealed that current smokers rather than past smokers (as well as never 
smokers) had the greatest number of smoking pack year history (30.0 (14.5-33.75) v 15.0 
(8.75-40) v 0 (0-0), p=<0.0001). Patient gender also did not explain these results as there 
was a similar frequency of both male and female patients amongst past smokers (49% and 
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51% respectively). Duration of RA disease also could not explain these results, as no 
significant difference was found between never, past and current smokers (p=0.51), 
although past smokers were found to be older than current smokers (mean age 58 and 53 
respectively). Differences in ages may have had a negative impact on measures of disease 
activity and severity as patients could have ceased smoking for other health related reasons 
(e.g. cardiovascular disease). In addition, the possibility of an immunosuppressive effect of 
current smoking may also contribute to the reduction of severity compared with past 
smokers (Geng et al., 1996, McCue et al., 2000, Ouyang et al., 2000, Singh et al., 2000). 
Interestingly, chi-square analysis also revealed RA patients who had never smoked were 
more likely to present with a synovial effusion than ever smokers, however this was not 
significant (7/27 (26%) v 9/59 (15.3%), OR=1.94, 95% CI 0.65-5.76, p=0.25). No 
significant association was found between smoking and erosive disease (35/51 (68%) v 
15/25 (60%), OR=1.45, 95% CI 0.55-3.87, p=0.60). Patients who had ever smoked were 
shown to be more likely to be positive for RF than patients who have never smoked (33/59 
(56%) v 12/27 (44%), OR=1.56, 95% CI 0.63-3.86, p=0.36), which is consistent with 
previous studies (Heliovaara et al., 1993, Mattey et al., 2002a, Morgan et al., 2009). 
Furthermore, RF was also found to be more likely in current smokers than in past smokers 
(Table 4.1.2d) which is also in line with past studies (Wolfe, 2000, Mattey et al., 2002a, 
Mattey et al., 2002c, Westhoff et al., 2008). Neither of these relationships were found to be 
significant, this may be due to the relatively small number of patients. 
 
Table 4.1.2d: Association between smoking status and RF 
Smoking status RF negative n (%) RF positive n (%) Odds Ratio (95% CI) 
Never smoked 15 (56%) 12 (44%) Referent 
Past smoker 18 (51%) 17 (49%) 1.17 (0.43-3.16) 
Current smoker 8 (33%) 16 (67%) 2.40 (0.79-7.32) 
χ2=2.84 (df=2), p=0.24 
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In addition, categorisation by pack year history showed patients who had smoked more 
than 30 pack years were nearly 4x more likely to be RF positive (Table 4.1.2e). 
Furthermore, a significant increasing trend between smoking and the presence of RF 
(p=0.04), suggests a time-dose quantitative relationship between RF and frequency and 
duration of smoking (Wolfe, 2000, Stolt et al., 2003). These findings show that current, 
frequent, long term smokers are more likely to be RF positive. 
 
Table 4.1.2e: Association between pack year category and RF 
Stratified pack year RF negative n (%) RF positive n (%) Odds Ratio (95% CI) 
0 15 (58%) 11 (42%) Referent 
0.1-15 12 (57%) 9 (43%) 1.02 (0.32-3.19) 
16-30 5 (50%) 5 (50%) 1.34 (0.33-5.50) 
>30 4 (25%) 12 (75%) 3.74 (0.99-14.01) 
χ2=5.03 (df=3), p-(trend)=0.04 
 
Patients who ever smoked were also found more likely to be positive for anti-CCP positive 
than anti-CCP negative (45/59 (76%) v 17/27 (63%), OR=1.88, 95% CI 0.71-5.00, p=0.21) 
which is in line with other studies (Linn-Rasker et al., 2006). This however did not reach 
significance, which may be due to the relatively small number of patients available. 
Furthermore, the presence of anti-CCP was more likely in current smokers than in past 
smokers, although this was not significantly associated (p=0.12) (Table 4.1.2f), suggesting 
that recent exposure to cigarette smoke may increase anti-CCP production. 
 
Table 4.1.2f: Association between smoking status and anti-CCP 
Smoking status Anti-CCP negative n (%) Anti-CCP positive n (%) OR (95% CI) 
Never smoked 10 (37%) 17 (63%) Referent 
Past smoker 11 (31%) 24 (69%) 1.27 (0.45-3.60) 
Current smoker 3 (12.5%) 21 (87.5%) 3.68 (0.94-14.42) 
χ2=4.16 (df=2), p=0.12 
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A significant distribution between the categories of pack year history with the presence of 
anti-CCP was found (p=0.02) where the likelihood of anti-CCP increased with the general 
increasing trend of pack years (Table 4.1.2g). 
 
Table 4.1.2g: Association between pack year category and anti-CCP 
Stratified pack year Anti-CCP negative n (%) Anti-CCP positive n (%) Odds Ratio (95% CI) 
0 9 (35%) 17 (65%) Referent 
0.1-15 10 (48%) 11 (52%) 0.73 (0.25-2.15) 
16-30 0 (0%) 10 (100%) 12.30 (0.66-228.2) 
>30 2 (12.5%) 14 (87.5%) 3.53 (0.77-15.99) 
χ2=10.18 (df=3), p-(trend)=0.3 
 
 
Cigarette smoking is commonly known to increase the risk of early RA development 
(Heliovaara et al., 1993, Silman et al., 1996, Symmons et al., 1997, Costenbader et al., 
2006), where the age of onset may be different between smokers and non-smokers 
(Hutchinson et al., 2001). However, analysis revealed that in patients categorised as having 
early onset (<40 years) a significantly smaller proportion of patients (8/58) were smokers 
than non-smokers (10/27) (14 v 37%, OR=0.28, 95% CI 0.10-0.80, p=0.02). 
 
4.1.2.1.3 Influence of DMARD treatment 
 
The majority of RA patients were receiving NSAIDs (60%) at time of first attendance to 
clinic. Only a small group were receiving DMARDs (14%), which had been administered 
prior to their initial attendance. Patients receiving DMARD therapy had a significantly 
higher PIPS (p=0.02), DAS44CRP (p=0.03) and Ritchie Index score (p=0.04) (Figure 
4.1.2h). Those patients on DMARDs were likely to have presented early with more active 
disease, hence the requirement of the administration of DMARDs to help alleviate disease. 
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No other disease measure was found to be significant, which could be due to the small 
number of patients on DMARDS to show any clear differences. 
 
Figure 4.1.2h: Association of DMARDs with the PIPS, DAS44CRP and the Ritchie Index 
 
Blue=DMARD negative, Purple=DMARD positive 
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4.1.2.2 BIOMARKER PROFILING IN EARLY RA 
 
A total of 36 mediators were investigated in this cohort of early RA patients. RANTES was 
excluded from analyses due to the majority of results being greater than the maximum 
threshold of detection. In addition, the majority of patient results for IL-17, FGF-β and 
MMP-12 were found to be below the minimum detection level and thus also excluded. 
Furthermore, the standard curves obtained with MIP-1β were considered to be 
unacceptable, and thus these results were also not included in analyses. 
 
4.1.2.2.1.1 Early RA Hierarchical clustering biomarker profiling 
 
Genesis hierarchical clustering analysis was used to identify RA patient groups based on 
their mediator expression. A heat map displaying the relative expression level of each 
mediator for every RA patient was generated (Figure 4.1.2i). After 2-dimensional 
hierarchical clustering, 4 distinct patient clusters denoted as C1, C2, C3 and C4 based on 
their mediator expression pattern similarities were identified, which further demonstrates 
that RA is an immunologically heterogeneous disease and may have various pathological 
routes. 
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Figure 4.1.2i: Heat map of the relative mediator expression in early RA patients 
 
y-axis=patient identification number, x-axis=mediators  
 
 
Clusters C1 and C3 displayed similar patterns of relatively high mediator expression. In 
contrast, clusters C2 and C4 displayed similar patterns of relatively low mediator 
expression, apart from some of the MMPs, TIMPs and endostatin, which suggests the 
possibility of immunological subtypes of varying grades of immune activity. The heat map 
showed the biggest differences between the high and low mediator expression clusters (C1 
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and C3 versus C2 and C4) were of the interleukins, as well as a number of other specific 
mediators (eotaxin, G-CSF, GM-CSF, MCP-1, IFN-γ, TNF-α and VEGF). This was 
confirmed with statistical comparisons (p=<0.05) (data not shown), although IL-8 was 
additionally found to be significantly higher in the high mediator expression clusters 
(31.46 (24-50.7) v 24.72 (12.7-41.6), p=0.03). This 20 mediator profile of interleukins, 
eosonophil and monocyte chemoattractants, granulocyte/macrophage growth factors, 
angiogenesis factor and pro-inflammatory mediators could largely explain the difference 
between these potential immunological subtypes. Discriminant stepwise selection and 
forward logistic regression analysis of this profile revealed that IL-6 alone (p=0.0001, 
model p=<0.0001, model r-squared=0.46), distinguished the high from the low mediator 
expression clusters in particular. 
 
4.1.2.2.1.2 Association with early RA disease activity and severity 
 
Chi-square analysis significantly demonstrated that the C1 and C3 patient clusters also had 
the highest frequencies of patients positive for RF, whereas the C2 cluster showed the 
lowest frequency of RF positive patients followed by cluster C4 (Table 4.1.2j). No 
significant difference was found between patient clusters and the distribution of anti-CCP 
autoantibody. However, similar to that of RF seropositivity, C1 and C3 clusters had the 
highest frequencies of anti-CCP positive patients (Table 4.1.2j). This suggests that the 20 
interleukin-prominent biomarker profile expressed in the high mediator expression clusters 
and particularly pro-inflammatory mediator IL-6 may be important in regard to the 
generation of autoantibodies as Th2 interleukin production have roles in stimulating 
antibody production (Janeway Jr et al., 2005). The difference of mediator expression 
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pattern and seropositivity between the relatively high and low expression levels could 
suggest the possibility of a disease subtype. 
 
Table 4.1.2j: Association between patient clusters and autoantibodies 
Patient Cluster RF negative n (%) RF positive n (%) 
Anti-CCP 
negative n (%) 
Anti-CCP 
positive n (%) 
C1 2 (13.3%) 13 (86.7%) 3 (20%) 12 (80%) 
C2 24 (68.6%) 11 (31.4%) 13 (37%) 22 (63%) 
C3 3 (20%) 12 (80%) 1 (6.7%) 14 (93.3%) 
C4 12 (57%) 9 (43%) 7 (33%) 14 (67%) 
χ2=18.57 (df=3), p=0.0003   χ2=5.62 (df=3), p=0.13 
 
No significant difference was found between patient clusters and the distribution of 
synovial effusions (p=0.74) or erosions (p=0.72). 
  
Comparison of disease activity and severity measures revealed that only the OSRA-D 
(p=0.05) plus indices of peripheral inflammation (CRP p=0.02, ESR p=0.01, WBC count 
p=0.02) were significantly different between patient clusters (Figure 4.1.2k). No other 
disease measure was found to be significantly different. Differences were mainly between 
patients of the C4 and the C2 cluster, with the C4 cluster demonstrating highest scores 
despite both displaying relatively low mediator expression patterns. 
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Figures 4.1.2k: Comparison between patient clusters and disease measures in early RA 
 
 
 
As clusters 2 (n=35) and 4 (n=21) showed the largest differences in terms of disease 
measures despite demonstrating relatively similar mediator expression patterns, 
comparisons were performed to determine expression differences between the 2 clusters. 
Mediators IL-1ra (p=0.005), IL-6 (p=0.01), IL-8 (p=<0.0001), G-CSF (=0.03), VEGF 
(p=<0.0001), MMP-1 (p=0.0001), -8 (p=<0.0001), -9 (p=0.0002), TIMP-1 (p=0.0004), -2 
(p=0.04), -3 (p=0.02), -4 (p=0.007), OPG (p=0.001), OPN (p=0.0002) and endostatin 
(p=<0.0001) were found to be significantly higher in the C4 patient cluster compared to 
cluster C2 (Figure 4.1.2l). This 15 mediator profile consists of pro-inflammatory cytokines, 
chemokines, angiogenesis and cell growth factors plus matrix remodelling mediators 
including ECM degrading enzymes and therefore could largely account for the worse 
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disease activity and severity found in the C4 cluster (Lawlor et al., 2004, Nishimoto, 2006, 
Knudsen et al., 2008, Yoo et al., 2008). However, IL-1ra an inhibitor of IL-1 and OPG an 
osteoclastogenesis inhibitor (bone growth stimulator) and a key regulator of immune 
responses (Lacey et al., 1998, Schiff, 2000, Feige, 2001, Cutolo, 2004), may be elevated to 
compensate for increased inflammation. Discriminant stepwise selection and forward 
logistic regression analysis of this profile revealed that a profile of high IL-8, MMP-1, 
MMP-8 and OPG expression in particular distinguished the C4 cluster from the C2 cluster 
(model p=<0.0001, model r-squared=0.54). Although the individual mediators were not 
separately significant (all mediators p=>0.057), their cumulative contribution as a profile is 
significant. This suggests that raised expression of these mediators collectively may 
contribute to worse disease activity and severity. 
 
Figure 4.1.2l Comparison of mediators between patient clusters C2 and C4 
 
Green=C2 cluster, Blue=C4 cluster 
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Interestingly, the distribution of early disease onset was significantly different between the 
patient clusters. Cluster C2 was shown to have the highest frequency of early onset disease 
whereas the C4 cluster demonstrated the lowest frequency of early onset disease (Table 
4.1.2m). This suggests that the elevated 15 mediator profile identified in the C4 patient 
cluster and in particular raised IL-8, MMP-1, MMP-8 and OPG expression may also be 
important in regard to delayed RA development. 
 
Table 4.1.2m: Association between patient clusters and early RA onset 
Patient Cluster Early Onset negative n (%) Early Onset positive n (%) 
C1 13 (86.7%) 2 (13.3%) 
C2 22 (63%) 13 (37%) 
C3 12 (85.7%) 2 (14.3%) 
C4 20 (95%) 1 (5%) 
χ2=9.68 (df=3), p=0.02 
 
4.1.2.2.1.3 Association with cigarette smoking 
 
Cigarette smoking has been well documented to be associated with severe RA and worse 
disease outcome. Chi-square analysis revealed the distribution of smokers was 
significantly different between patient clusters (Table 4.1.2n). The C2 patient cluster had 
the lowest frequency of smokers compared to the other clusters, whereas clusters C1, C3 
and C4 all had similarly high frequencies of smokers. This suggests that the elevated 15 
and 20 mediator profiles identified in these clusters may both be upregulated in smokers. 
This could also account for the low frequency of smokers in the C2 cluster with its 
relatively low mediator expression pattern. Interestingly, the C4 cluster demonstrated the 
highest frequency of smokers despite displaying a relatively low mediator expression 
pattern. This may be in part due to the elevated expression of immuno-regulatory 
mediators IL-1ra and OPG identified in this cluster. In addition, cigarette smoke has been 
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documented to have immunosuppressive properties which may also partially explain the 
pattern of low mediator expression in the C4 cluster (McCue et al., 2000, Ouyang et al., 
2000, Oltmanns et al., 2005, Lee et al., 2007). 
 
Table 4.1.2n: Association between patient clusters and smoking 
Patient Cluster Never smoked n (%) Ever smoked n (%) 
C1 4 (26.7%) 11 (73.3%) 
C2 17 (48.6%) 18 (51.4%) 
C3 3 (20%) 12 (80%) 
C4 3 (14.3%) 18 (85.7%) 
χ2=8.70 (df=3), p=0.03 
 
The smoking status of patients was also shown to be significantly different between patient 
clusters (p=0.04), where the C2 patient cluster had the lowest frequency of current smokers 
compared to the remaining clusters (Table 4.1.2o). This suggests that recent exposure to 
cigarette smoke may upregulate the expression of both the 15 and 20 mediator profiles in 
these clusters. Interestingly, the C4 cluster had the highest frequencies of past smokers 
which may partly account for the relatively low mediator expression pattern found in this 
cluster. 
 
Table 4.1.2o: Association between patient clusters and smoking status 
Patient Cluster Never smoked n (%) Past smokers n (%) Current smokers n (%) 
C1 4 (26.7%) 4 (26.7%) 7 (46.7%) 
C2 17 (48.6%) 13 (37.1%) 5 (14.3%) 
C3 3 (20%) 6 (40%) 6 (40%) 
C4 3 (14.3%) 12 (57.1%) 6 (28.6%) 
χ2=13.21 (df=6), p=0.04 
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Subsequent analysis with pack year history stratified by smoking intensity between patient 
clusters revealed no significant differences in the distribution between patient clusters. 
However, the C2 cluster was found to have the lowest frequency of patients that smoked 
more than 15 pack years, whereas clusters C1, C3 and C4 displayed similarly high 
frequencies (Table 4.1.2p). This indicates that frequent exposure and large quantities of 
cigarette smoke may upregulate the expression of both the 15 and 20 mediator profiles.  
 
Table 4.1.2p: Association between patient clusters and stratified pack year history 
Patient Cluster Never smoked n (%) 0.1-15 n (%) 16-30 n (%) >31 n (%) 
C1 4 (30.8%) 1 (7.7%) 3 (23.1%) 5 (38.5%) 
C2 17 (51.5%) 10 (30.3%) 3 (9.1%) 3 (9.1%) 
C3 3 (25%) 3 (25%) 2 (16.7%) 4 (33.3%) 
C4 2 (13.3%) 7 (46.7%) 2 (13.3%) 4 (26.7%) 
χ2=15.05 (df=9), p=0.09 
 
Chi-square analysis was also performed between patient clusters and current DMARD 
treatment, however no significant difference in the distribution of DMARD patients was 
found between the clusters (p=0.84). This may be possibly explained by the small number 
of patients on DMARDs. 
 
4.1.2.2.1.4 Early RA Hierarchical clustering results summary 
 
These results indicate that cigarette smoking may upregulate the expression of multiple 
mediators, especially in response to recent exposure. The upregulation of mediators, 
especially interleukins and MMPs, therefore could contribute to the generation of 
autoantibodies and influence the level of disease activity and severity found in RA 
smokers. This particular mediator profile-disease activity and severity relationship may 
therefore account for the relatively low expression of mediators in non-smokers and thus 
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explain the better level of RA disease found in patients of the C2 cluster. As cigarette 
smoke has been documented to have immunosuppressive properties (McCue et al., 2000, 
Ouyang et al., 2000, Oltmanns et al., 2005, Lee et al., 2007), as well as potentially 
upregulate immuno-regualtory mediators (IL-1ra and OPG) this may account for the 
delayed onset of disease found in RA smokers. These results also illustrate that smoking 
may suppress or promote expression of certain mediators, and that cessation of smoking 
may produce a different mediator expression profile compared with that of current 
smokers, which in turn may influence disease severity in a unique manner.
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4.1.2.2.2.1 Early RA Principal Component Analysis biomarker profiling 
 
Due to the large number of mediators investigated in this study, principal component 
analysis (PCA) was employed to reduce the large number (dimensionality) of interrelated 
(multicollinearity) variables. An exploratory PCA of all 36 mediators was initially 
performed that selected a set of 17 specific mediators which provided the maximum 
variance (Table 4.1.2q).  
 
Table 4.1.2q: Mediators selected for Principal Component Analysis 
Selected PCA Baseline Biomarkers 
IL-1β IL-8 TNF-α MMP-3 OPN 
IL-2 G-CSF VEGF MMP-8  
IL-4 GM-CSF MMP-1 MMP-9  
IL-6 IP-10 MMP-2 Dkk-1  
 
 
Principal component analysis identified 6 principal component (PC) biomarker profiles 
generated from correlation patterns of the 17 selected mediators which were then used for 
analysis. Table 4.1.2r displays the 6 PC generated biomarker profiles and their modified 
relative factor loadings after varimax rotation. Positive and negative factor loadings relate 
to high and low expression level respectively. 
 
Table 4.1.2r: PC profiles of 17 biomarkers and their relative factor loadings 
PC 1 PC 2 PC 3 PC 4 PC 5 PC 6 
IL-2 0.91 MMP-9 0.90 VEGF 0.77 G-CSF 0.95 IP-10 0.89 Dkk-1 0.81 
TNF-α 0.91 MMP-8 0.88 MMP-2 -0.72 IL-1β 0.82 MMP-2 -0.46 OPN 0.73 
IL-6 0.90 IL-8 0.71 MMP-3 0.63 GM-CSF 0.79   MMP-1 0.62 
IL-4 0.89           
GM-CSF 0.57           
IL-1β 0.51           
- negative factor loading 
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4.1.2.2.2.2 Association with early RA disease activity and severity 
 
Regression analyses revealed various PC profiles were associated with a number of disease 
activity and severity measures, particularly that of the PC 3 and 6 profiles which were 
highly associated with the majority of RA disease measures (Table 4.1.2s). The PC 3 
profile which consisted of high VEGF and MMP-3 expression, but a low level of MMP-2 
was strongly associated with a large number of pain and inflammatory measures. The PC 6 
profile which incorporated mediators Dkk-1, OPN and MMP-1 was shown also to be 
strongly associated with measures of inflammation. These matrix remodelling mediators 
including ECM degrading enzymes and an angiogenesis stimulator have multiple roles 
including chemotaxis, apoptosis, cell regulation (proliferation, migration, adhesion), 
inflammation etc. and may explain the worse disease activity and severity found in RA 
patients (Reinholt et al., 1990, Yamanaka et al., 2000, McCawley and Matrisian, 2001, 
Green et al., 2003, Stamenkovic, 2003, Clavel et al., 2007, Diarra et al., 2007, Glass and 
Karsenty, 2007, Nagasaka et al., 2008, Yoo et al., 2008, Ueland et al., 2009). 
 
The PC 3 profile was also shown to be associated with various measures, particularly 
relating to the joint; the number of swollen joints, synovial effusion, the OSRA-D and the 
HAQ. This profile may account for the higher degree of inflammation which is normally 
associated with synovial effusions and swollen joints (Reinholt et al., 1990, Yamanaka et 
al., 2000, McCawley and Matrisian, 2001, Green et al., 2003, Stamenkovic, 2003, Clavel 
et al., 2007, Diarra et al., 2007, Glass and Karsenty, 2007, Nagasaka et al., 2008, Yoo et 
al., 2008, Ueland et al., 2009). No other PC profile was found to be associated with any 
other measures for function or joint damage including erosions and the Larsen hand score. 
This may be because early RA patients may not show sufficiently large differences in joint 
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damage in early stages of the disease process to be able to link them to particular 
mediators. 
 
Furthermore, the PC 1 profile consisting of Th2 related interleukins IL-1β, IL-2, IL-4, IL-6 
(Janeway Jr et al., 2005), plus GM-CSF and TNF-α was found to be positively associated 
with RF autoantibodies alone. No profile was identified to be associated with anti-CCP. 
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Table 4.1.2s: Association between PC profiles and disease measures 
Disease  
Measure 
Variable PC 1 PC 2 PC 3 PC 4 PC 5 PC 6 
Model 
 p-value 
Model  
r-squared 
CRP   <0.0001   <0.0001 <0.0001 0.60 
ESR 0.02  <0.0001   <0.0001 <0.0001 0.40 
SJ >5  
(+/-) 
  0.03    0.02 0.06 
WBC  <0.0001    0.01 <0.0001 0.50 
Platelets  
(+/-) 
  0.004   0.004 <0.0001 0.20 
Anaemia  
(+/-) 
  0.02   0.01 0.001 0.15 
Synovial 
effusion  
(+/-) 
  0.004    0.002 0.10 
PIPS >5  
(+/-) 
      NS  
CGDA 0.008  0.001   0.01 0.0003 0.20 
OSRA-A   0.0006   0.02 0.0001 0.18 
SI 0.03 0.02 0.001   0.003 0.0002 0.23 
DAS44CRP   0.003    0.003 0.10 
Inflammation 
DAS44ESR   0.001    0.001 0.90 
RF (+/-) 0.04      0.008 0.07 
Autoantibody Anti-CCP 
(+/-) 
      NS  
VAS   0.004    0.004 0.09 
TJ >9  
(+/-) 
      NS  
Pain 
RI >10 (+/-)       NS  
Erosions 
(+/-) 
      NS  
OSRA-D   0.001    0.002 0.11 
Damage 
Larsen  
Hands score 
>28 (+/-) 
      NS  
EMS >60 
(+/-) 
      NS  
HAQ   0.001  0.04  0.002 0.14 
Function 
Grip 
strength 
<88.5 (+/-) 
      NS  
Other 
Ever 
Smoked  
(+/-) 
 0.006  0.13  0.02 0.0001 0.20 
N.B Non-parametric variables were dichotomised using the median value as the cut-off level, (-) negative 
association, NS=Not Significant. 
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As PC profiles PC 3 and PC 6 were both found to be associated with the majority of 
inflammatory measures, further investigation was performed with mediators from both 
profiles as separate independent variables to determine which mediators specifically within 
these profiles were most strongly associated with inflammation (Table 4.1.2t). Regression 
analyses revealed MMP-3 to be the most strongly associated independent mediator with 
the majority of inflammatory disease measures, with OPN following closely behind. 
 
Table 4.1.2t: Association between PC 3 and PC 6 derived mediators with measures of 
inflammation 
Inflammatory 
Disease 
Measure 
PC 3 PC 6 
Variable VEGF MMP-2 MMP-3 Dkk-1 OPN MMP-1 
Model 
p-value 
Model  
r-squared 
CRP 0.004  <0.0001  0.0006 0.004 <0.0001 0.67 
ESR 0.001  0.002  0.002  <0.0001 0.39 
Platelet (+/-)     0.03 0.0002 <0.0001 0.21 
Anaemia (+/-)   0.0007   0.03 <0.0001 0.27 
CGDA >47 
(+/-) 
 0.03 (-) 0.003    <0.0001 0.20 
OSRA-A   0.004  0.02  0.0003 0.18 
SI   <0.0001 0.007   <0.0001 0.27 
N.B Non-parametric variables were dichotomised using the median value as the cut-off level, (-) negative 
association. 
 
MMP-3 and OPN were also found to be associated with overall RA disease activity 
measure of the OSRA-A (Table 4.1.2t). In addition, MMP-3 and Dkk-1 were shown to be 
associated with another overall disease activity measure of the Stoke Index (Table 4.1.2t). 
Comparisons between Stoke Index disease activity categories revealed significant 
differences of expression between the phenotypes for both MMP-3 and Dkk-1 (p=<0.0001 
and p=0.005 respectively), with a significant increasing trend of worse disease (p-(trend) 
<0.0001 and p-(trend)=0.001 respectively) (Figures 4.1.2u). 
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Figures 4.1.2u: Association of Stoke Index categories with MMP-3 and Dkk-1 expression 
 
 
The PC 3 profile was also shown to be associated with additional overall disease activity 
measures of the DAS44CRP and DAS44ESR (Table 4.1.2s). Regression analyses were 
therefore also performed on the PC 3 mediators as separate independent variables to 
determine which mediators were most strongly associated with overall DAS activity. 
Analysis revealed MMP-3 to be associated with both DAS scores (p=0.001 and p=0.02 
respectively), with VEGF associating also with the DAS44ESR (p=0.02), although this 
was lost after adjusting for smoking. Subsequent comparisons of these mediators between 
DAS44 phenotypes revealed MMP-3 expression to be significantly different between the 
phenotypes in both the DAS44ESR and DAS44CRP (p=0.006 and p=0.002 respectively), 
with a significant increasing trend of worse disease activity in both DAS scores (p-
(trend)=0.001 and p-(trend)=<0.0001 respectively) (Figures 4.1.2v). This was similarly 
demonstrated with VEGF expression and the DAS44ESR (p=0.03, p-(trend)=0.005), 
although this seemed to be dependent on patient smokers (Figure 4.1.2w). 
 
 
 
 152 
Figures 4.1.2v: Association of MMP-3 expression with DAS44CRP and DAS44ESR 
phenotypes 
 
 
 
Figure 4.1.2w: Association of VEGF expression with DAS44ESR phenotypes 
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4.1.2.2.2.3 Association with cigarette smoking and DMARD treatment 
 
Profiles PC 2 (IL-8, MMP-8 and MMP-9) and PC 6 (Dkk-1, OPN and MMP-1) were found 
to be associated with cigarette smoking with PC 4 contributing to its overall significance 
(model p=0.0001, model r-squared=0.20) (Table 4.1.2s). The PC 6 profile was associated 
with DMARD treatment (p=0.01, model p=0.005, model r-squared=0.10). This suggests 
that both smoking and DMARD treatment may upregulate the expression of the mediators 
in this profile. No PC profile at baseline was found to be associated with early onset. 
 
4.1.2.2.2.4 Early RA Principal Component Analysis results summary 
 
These results suggest that cigarette smoking may upregulate various mediators that play a 
major role in neutrophil activation, angiogenesis and matrix remodelling. This may 
account for the high level of inflammation and worse overall disease activity found in early 
RA, as well as joint severity associated with this profile. Upregulation of these mediators 
may also account for the association with DMARD treatment, since patients presenting 
with higher levels of inflammation would have higher requirement for therapeutic 
intervention (Saag et al., 1997, Másdóttir et al., 2000, Wolfe, 2000, Mattey et al., 2002c, 
Finckh et al., 2007, Westhoff et al., 2008). 
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4.1.2.2.3 Composite Biomarker Profiles 
 
Using both hierarchical clustering and principal component analysis a biomarker profile of 
IL-1β, IL-2, IL-4, IL-6, GM-CSF and TNF-α was derived which was likely to be 
associated with RF. ROC analysis of this composite mediator profile revealed it to be 
“fairly” accurate in identifying patients positive for RF (AUC 0.74, 95% CI 0.62-0.84, SE 
0.05, p=<0.0001) (Figure 4.1.2x). 
 
Figure 4.1.2x: Accuracy of RF identified biomarker profile 
 
 
Hierarchical clustering and principal component analysis identified 2 distinct biomarker 
profiles that were predominantly associated with worse disease activity and severity in 
these RA patients. A composite of these 2 profiles therefore could create a profile that may 
maximally account for worse RA disease. ROC analysis of this profile (IL-8, VEGF, OPN, 
Dkk-1, MMP-1, MMP-3 and MMP-8) showed it to be “fair” in identifying a worse disease 
activity phenotype, defined by severe DAS (score >3.7) or high Stoke Index (score 12-17) 
disease activity scores (AUC 0.76, 95% CI 0.65-0.86, SE 0.05, p=<0.0001) (Figure 
4.1.2y). 
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Figure 4.1.2y: Accuracy of worse disease activity phenotype identified biomarker profile  
 
 
No biomarker profile from either analysis method was found to be associated with erosive 
disease, however PCA did reveal a biomarker profile associated with multiple joint 
specific disease measures (high VEGF, MMP-3 and low MMP-2 expression). ROC 
analysis of this profile was subsequently performed, but it “failed” to accurately identify 
the presence of erosions in early RA (AUC 0.48). 
 
4.1.2.2.4 Early RA Overall Summary 
 
This cohort of RA patients demonstrated biomarker profiles that were predominantly 
associated with markers of inflammation rather than outcome disease measures although a 
few biomarker profiles of interest from both analysis methods were derived. 
 
A biomarker profile of growth factors, pro-inflammatory cytokines and numerous 
interleukins was identified to be associated with RF production. This profile is consistent 
with previous studies where multiple interleukins and the same specific mediators were 
strongly associated with autoantibody presence (Hitchon et al., 2004, Alex et al., 2007, 
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Hueber et al., 2007, Jørgensen et al., 2008, Kokkonen et al., 2010, Meyer et al., 2010, 
Chandra et al., 2011, Hodkinson et al., 2011). Various interleukins may be involved in the 
generation of RF autoantibody, although IL-6 seems particularly important since it was 
identified in both hierarchical clustering and principal component analysis. This profile 
may also have the potential to predict a more severe phenotype in established RA as 
autoantibodies are associated with worse disease and poorer outcome (Reilly et al., 1990, 
Myllykangas-Luosuj~irvi et al., 1995, Másdóttir et al., 2000, Wolfe, 2000, Mattey et al., 
2001b, Vencovsky´ et al., 2003, Greiner et al., 2005, Lindqvist et al., 2005, Sihvonen et 
al., 2005, Mewar et al., 2006, Mattey et al., 2007, Turesson et al., 2007). 
 
A distinct matrix remodelling biomarker profile including mediators associated with 
chemoattraction and angiogenesis was associated with worse disease activity and severity. 
This profile is unique when compared with previous profiling studies. However, individual 
mediators of this profile in conjunction with other mediators have been similarly found 
associated with greater disease activity in previous studies (Moniem and Mohammad, 
2003, Kuryliszyn-Moskal et al., 2006, Angelo and Kurzrock, 2007, Ateş et al., 2007, 
Clavel et al., 2007, Rioja et al., 2008, Sennels et al., 2008, Bazzichi et al., 2009, Gaoya et 
al., 2009, Meyer et al., 2010, Ozgonenel et al., 2010). This profile therefore has the 
potential to become a novel assessment measure to complement current RA disease 
activity measures. 
 
Cigarette smoking may upregulate IL-6, IL-8, MMP-1, MMP-8, MMP-9, Dkk-1, OPN and 
OPG. Both hierarchical clustering and principal component analysis identified IL-8, MMP-
1 and MMP-8 which is consistent with previous studies where IL-8 and MMPs were 
upregulated in healthy non-RA smokers (Nakamuraa et al., 1998, Wang et al., 2000, 
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Knuutinen et al., 2002, Nordskog et al., 2003, Raitio et al., 2005, Karimi et al., 2006). This 
further demonstrates that smoking can alter the expression of mediators and thus influence 
immune activity. Mediators of neutrophil activation and matrix remodelling are 
particularly prominent in this profile, which suggests a major role for these molecules in 
the association between smoking and RA. 
 
This study demonstrates the importance of various chemoattractants, angiogenesis factors, 
growth factors, pro-inflammatory cytokines and matrix remodelling mediators in the 
pathological process of early RA, and identifies mediators which are likely to be involved 
in molecular pathways of the disease process during its development. Cytokines commonly 
accepted to be associated with RA development (e.g. IL-β, IFN-γ and TNF-α) did not 
provide any more information about disease activity in early RA than many of the other 
mediators. These findings highlight the heterogeneity of RA pathology and indicate that 
various markers of immune dysfunction influence the development of RA, which 
illustrates the complex network of mediators involved in disease. Some of these 
biomarkers could become novel targets for disease intervention, where specific targeting 
may help to lower inflammation and damage leading to reduced disease activity and 
severity.
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4.1.3 BIOMARKER PROFILING FOR RA PROGNOSIS 
 
RA is a long-term disease, therefore identifying biomarkers that predict its likely course 
and outcome would greatly aid in the management of the disease, and become a useful tool 
especially for newly diagnosed early stage RA patients. Such investigations can also give 
clues into the pathological process of RA and how it may develop. Biomarker clusters and 
PC profiles identified at baseline from hierarchical clustering and the PCA method 
respectively were analysed with measures of disease activity and severity at 5 year follow-
up to determine whether any specific profiles could predict disease outcomes in established 
RA. 
 
4.1.3.1.1 Hierarchical clustering prognostic biomarker profiling 
 
Analysis of baseline patient clusters with measures of disease at 5 year follow-up revealed 
the same few indices of peripheral inflammation (ESR, CRP and WBC count) to be 
significantly different between patient clusters as in early RA. No other measures of 
inflammation, pain, damage, or function at 5 year follow-up were found to be significantly 
different between baseline clusters. The C2 baseline patient cluster demonstrated the 
lowest levels of peripheral inflammation compared to the other clusters (Figure 4.1.3a). 
This suggests that high expression of the 15 biomarker profile especially that of IL-8, 
MMP-1 and MMP-8 identified from the C2 cluster at baseline may also be important in 
regard to peripheral inflammation in established disease as well as in early disease. 
Interestingly, the baseline C4 cluster no longer displayed the highest levels of peripheral 
inflammation compared to the other clusters at 5 year follow-up. This was now displayed 
by clusters C1 and C3 instead. This could suggest that the upregulated profile of 
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predominantly interleukins particularly that of IL-6 identified in the C1 and C3 clusters 
may account for the increased level of peripheral inflammation found in these clusters. 
This could also be due to the influence of the high frequencies of autoantibodies present in 
these patient clusters, as autoantibodies are documented to be strongly associated with 
worse RA disease (Mewar et al., 2006, Agrawal et al., 2007). Cigarette smoking may also 
in part explain this relationship as it also has been well documented to be strongly 
associated with worse disease severity (Saag et al., 1997, Wolfe, 2000, Finckh et al., 2007, 
Söderlin et al., 2011), as these patient clusters also had high frequencies of patients who 
have ever and currently smoke. 
 
Figure 4.1.3a: Comparison of baseline patient clusters and 5 year follow-up peripheral 
inflammation disease measures 
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4.1.3.1.2 Principal component analysis prognostic biomarker profiling 
 
Analysis of PC biomarker profiles identified at baseline with measures of disease at 5 year 
follow-up revealed only a few associations of significance (Table 4.1.3b). PC profiles 1 
and 2 consisting of IL-1β, IL-2, IL-4, IL-6, TNF-α, GM-CSF and IL-8, MMP -8 and -9 
respectively were found to be associated with the ESR, WBC count and the number of 
platelets. This relationship with indices of peripheral inflammation was similarly shown in 
early RA and suggests that these mediators may also be important in inflammation in 
established disease. 
 
Table 4.1.3b: Association between baseline PC biomarker profiles and 5 year follow-up 
disease measures 
 
Disease Measure Variable PC 1 PC 2 PC 3 PC 4 PC 5 PC 6 
Model 
p-value 
Model  
r-squared 
ESR >21 
(+/-) 
0.05   0.06   0.001 0.14 
WBC  0.0002     0.00032 0.14 Inflammation 
Platelets 
(+/-) 
0.03      0.01 0.06 
Damage OSRA-D  0.03 0.0001 0.03(-)   <0.0001 0.23 
Function 
HAQ >1.5 
(+/-) 
   0.02 0.10(-)    0.007 0.10 
N.B Non-parametric variables were dichotomised using the median value as the cut-off level, (-) negative 
association, NS=Not Significant. 
 
 
Analyses also revealed PC profiles 2, 3 and 4 were associated with both the OSRA-D and 
the HAQ, with PC 4 demonstrating an inverse relationship. The latter association suggests 
a possible protective effect of the PC4 profile (IL-1β, G-CSF and GM-CSF) in RA, which 
has also been demonstrated in a number of studies (Hartung et al., 1995, Hartung et al., 
1997, Boneberg et al., 1999, Fadok et al., 2001, Boneberg and Hartung, 2002, Jinushi et 
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al., 2007, Martins et al., 2011). Although these mediators have been associated with 
exacerbation of RA (Eastgate et al., 1988, Xu et al., 1989, Fiehn et al., 1992), an animal 
study revealed that exogenous G-CSF prevented adjuvant-arthritis in rats (Brendolan et al., 
2003), where it can switch immune activity to a Th2 humoral response and promote 
immunological tolerance (Rutella et al., 2005). Thus further investigation is required on 
the pleiotropic activity of these growth factors in RA and their ability to potentially reduce 
joint damage. 
 
Further investigation of mediators from profiles PC 2, 3 and 4 as separate independent 
variables were performed to determine which were most strongly associated with joint 
damage and function at 5 year follow-up. An independent profile of elevated MMP-8 
(p=0.03) and reduced MMP-2 (p=0.003(-)) expression were found to be most strongly 
associated with the OSRA-D at 5 year follow-up (model p=0.0004, model r-squared=0.15). 
Whereas, MMP-3 was the only mediator that was independently associated with the HAQ 
(p=0.02). MMP-3 and MMP-8 are known contributors to RA pathology and joint damage 
as they are ECM degrading enzymes with multiple pro-inflammatory activities (Yamanaka 
et al., 2000, Green et al., 2003), whereas MMP-2 although an ECM degrading enzyme has 
been shown to have pleiotropic functions with anti-inflammatory roles (McQuibban et al., 
2000, McQuibban et al., 2002). This could partly explain the worse joint damage and 
functional outcome in established stage of disease as found in patients at 5 year follow-up. 
However ROC analysis of this profile demonstrated that these biomarkers were poor (AUC 
<0.6) at predicting a worse outcome at 5 year follow-up for both erosive disease and worse 
disease activity characterised by a severe DAS44 (>3.7 score) phenotype or a high Stoke 
Index phenotype (score 12-17). This biomarker profile therefore would not be useful as a 
prognosis marker for established disease. 
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4.1.3.2 Prognostic biomarker profiling for disease remission 
 
Disease activity remission is a favourable aim to be achieved in RA patients, although a 
“low” disease activity phenotype (DAS44 >1.6-2.4 score) is also a desirable status for 
patients to achieve. The association of baseline biomarker profiles with better disease 
activity at 5 year follow-up was investigated to identify any biomarker profiles that could 
potentially predict better RA disease. The minimal disease phenotype of the Stoke Index 
(score 1-3) was also investigated, as it provides another indication of favourable outcome 
in RA. Baseline patient clusters C1 and C2 were found to have the highest frequency of 
disease activity favourable outcomes compared to the other clusters, however chi-square 
analyses revealed no significant differences between the clusters (p=>0.58). This could be 
due to the small numbers of remission and low disease phenotype patients within each 
cluster (data not shown). 
 
No baseline PC profiles were found to be associated with remission, low or minimal 
disease activity phenotypes of the DAS44CRP, DAS44ESR or Stoke Index at 5 year 
follow-up. Alternatively, the 17 mediators discerned as important biomarkers from the 
exploratory principal component analysis prior to their reduction into smaller components 
were used for analysis as independent variables. Logistic regression analyses revealed only 
a few baseline mediators from this 17 mediator selection were significantly associated with 
that of a favourable outcome at 5 year follow-up. In particular MMP-2 was shown to be 
positively associated with a minimal phenotype of the Stoke Index (p=0.04, model p=0.03, 
model r-squared=0.05) as well as the low phenotype of the DAS44ESR (p=0.05, model 
p=0.004, model r-squared=0.11). This was independently associated except after adjusting 
for DMARD treatment, where MMP-2 lost significance with the low DAS44ESR 
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phenotype. This suggests that MMP-2 may be elevated in response to DMARD treatment, 
especially as the majority of RA patients were receiving DMARD treatment (91%) at the 
time of follow-up. In addition, IL-2 an anti-inflammatory and regulatory cytokine was also 
significantly associated with a low DAS44ESR phenotype (p=0.02). No biomarker profile 
was found to be associated with a low phenotype of the DAS44CRP or the remission status 
of this disease activity measure. Discriminant regression however revealed a biomarker 
profile of IL-8 alone to be independently associated with remission status of the 
DAS44ESR (p=0.03, model p=0.03). This suggests that this chemotactic mediator may 
have a possible anti-inflammatory role in more established RA, as found in some studies 
where it inhibits the adhesion of leukocytes, especially neutrophils, to activated endothelial 
cells and thus possess immunosuppressive activities (Wheeler et al., 1988, Gimbrone et al., 
1989, Hechtman et al., 1991, Nourshargh et al., 1992). Further investigation is warranted 
to determine the true relationship of IL-8 with more favourable outcomes, if it indeed has 
anti-inflammatory properties in addition to its commonly accepted pro-inflammatory role 
(Vjeroslava Slavić1 et al., 2005). ROC analysis demonstrated that this small profile of 
MMP-2, IL-2 and IL-8 “poorly” (AUC 0.67) predicted a favourable outcome as 
characterised by either a minimal Stoke Index (score 1-3), low (>1.6-2.4 score) or 
remission (score <1.6) phenotype of the DAS44 at 5 year follow-up. This biomarker 
profile therefore would not be useful as a prognosis marker for established disease. 
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4.1.3.3 Summary 
 
These analyses could not identify any biomarkers that would be effective in predicting 
outcome in established disease, however a profile was found that may be important in the 
development and progression of RA disease. Hierarchical clustering and PCA biomarker 
profiling both identified similar baseline mediators of elevated interleukins, a 
chemoattractant, a cell growth factor and pro-inflammatory cytokines plus and MMPs 
which were associated with inflammation within the peripheral circulation in established 
disease. This type of relationship was similarly demonstrated at both early and established 
stages of disease and therefore could potentially become an inflammatory marker for use in 
long term targeting for a lower disease activity over a sustained period of time.
 165 
4.1.4 ESTABLISHED RA 
 
RA patients with established disease (disease duration of >5 years) were investigated with 
respective 5 year clinical, laboratory and patient characteristic data. The same cohort of 
patients from the early RA investigation was used. A total of 77 patients out of the original 
86 at baseline were investigated, as the sera from 9 patients were not available at 5 year 
follow-up. 
 
4.1.4.1.1 Relationship of RA disease features and patient characteristics with disease 
activity and severity in established RA 
 
Initial analyses of 5 year follow-up disease activity and severity measures with RA patient 
characteristics and clinical features were performed for general assessment of the patients 
investigated in this cohort. Autoantibodies have been well documented to be associated 
with worse disease in RA. Comparisons between positive and negative patients for both RF 
and anti-CCP with measures of disease activity and severity were performed. Analyses 
revealed RF and anti-CCP positive patients both had significantly higher CRP (p=0.0004, 
p=0.01), ESR (p=0.0005, p=0.02) and Stoke Index (p=0.003, p=0.04) respectively than 
negative patients. The PIPS was also shown to be significantly higher in patients positive 
for anti-CCP (1 (0-4.75) v 0 (0-1), p=0.02), whereas patients with RF had a significantly 
higher WBC count (p=0.01), number of platelets (p=0.008) and CGDA score (p=0.02) 
(Figure 4.1.4a). Furthermore, an increasing trend with the additional presence of 
autoantibodies of none, one or both in the CRP (p-trend=<0.0001), ESR (p-trend=<0.0001) 
and the Stoke Index (p-trend=0.001) was also demonstrated, illustrating a cumulative 
effect on disease activity and severity. These findings are in line with previous studies that 
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autoantibodies are associated with more severe RA (Másdóttir et al., 2000, Agrawal et al., 
2007). 
 
Figure 4.1.4a: Association of autoantibodies with disease activity and severity at 5 year 
follow-up 
 
Pink=RF negative, Orange=RF positive, Light blue=anti-CCP negative, Dark blue=anti-CCP 
positive 
 
 
4.1.4.1.2 Influence of cigarette smoking 
 
Cigarette smoking has been well documented to be associated with worse RA disease, 
which was similarly demonstrated in this established RA patient cohort (Saag et al., 1997, 
Wolfe, 2000, Söderlin et al., 2011). Analyses revealed the majority of disease measures 
were significantly higher in patients who had ever smoked than in never smokers (Table 
4.1.4b). The frequency of patients who had ever and never smoked did not alter by the time 
of 5 year follow-up, however two patients who had previously smoked became current 
smokers, while 6 patients became past smokers by having ceased smoking for more than 6 
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months. All other patients’ smoking status remained the same. Comparison of disease 
measures by smoking status revealed that past smokers had a significantly higher CRP, 
VAS, HAQ, OSRA-A, OSRA-D and overall Stoke Index and DAS44ESR disease activity 
(Table 4.1.4b). As patient smoking status did not alter greatly by the time of 5 year follow-
up, this relationship of worse disease in past smokers could not be accounted for by the 
frequency or duration of cigarettes smoked (pack year history), nor by their age, gender or 
disease duration. 
 
Table 4.1.4b: Association of cigarette smoking with disease activity and severity at 5 year 
follow-up 
Disease 
Measure 
Variable 
Never smoked 
(n=26) 
Past 
smokers 
(n=34) 
Current 
smokers 
(n=17) 
p-
value† 
Ever 
smoked 
(n=51) 
p-
value†† 
CRP 4.5 (3-14) 12 (6-35.5) 
10 (5.5-
3) 
0.03 
11.5 (6-
34.5) 
0.008 
WBC 6.6 (5.2-8.5) 
8.3 (6.5-
9.5) 
8.2 (7-
9.4) 
0.14 
8.3 (6.7-
9.5) 
0.05 
OSRA-A 2.00 +1.97 3.41 +2.14 
3.11 
+2.47 
0.04 3 (1-5) 0.01 
SI 2 (1-5) 4 (2-7) 3 (2-6) 0.04 3 (2-7) 0.01 
DAS44CRP 2.30 +0.97 2.93 +1.09 
2.74 
+0.99 
0.07 
2.86 
+1.05 
0.03 
Inflammation 
DAS44ESR 2.35 +1.00 3.03 +1.04 
2.88 
+1.04 
0.04 
2.98 
+1.03 
0.01 
VAS 24 (2.7-53.5) 
51 (33.7-
67.7) 
40 (17.5-
80) 
0.002 
50 (32-
73) 
0.001 
TJ 3 (0.7-7.2) 6.5 (2-11.2) 
7 (2-
11.5) 
0.07 7 (2-11) 0.02 Pain 
RI 3 (0.7-10.2) 8.5 (3-15.7) 9 (2-16) 0.09 9 (2-15) 0.03 
Damage OSRA-D 1 (0-3) 2 (1-3.2) 
2 (0.5-
3.5) 
0.05 2 (1-3) 0.01 
Function HAQ 0.87 +0.85 1.74 +0.81 
1.47 
+0.83 
0.0006 
1.65 
+0.82 
0.0002 
The Mean +SD for parametric data, the median (lower and upper interquartile range (IQR)) for non-
parametric data. † One-way ANOVA or Kruskal-Wallis test as appropriate. †† Two-sample T-test/Aspin 
Welch or Mann-Whitney U/Kolmogorov test as appropriate for equal/unequal variance. 
 
 
 
 
 168 
4.1.4.1.3 Influence of DMARD treatment 
 
By the time of 5 year follow-up, the majority of RA patients were receiving DMARD 
treatment (91%) compared to the 14% of patients at baseline. A significant difference was 
found only in the PIPS between DMARD positive and negative patients. Patients receiving 
DMARD treatment demonstrated a significantly higher PIPS than patients negative for 
DMARD treatment (0 (0-0) v 0 (0-3), p=0.02). No other significant differences were found 
in any of the other disease measures.
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4.1.4.2 BIOMARKER PROFILING IN ESTABLISHED RA 
 
A total of 35 mediators were investigated in this cohort of established RA patients. 
RANTES, IL-17, FGF-β, MIP-1β and MMP-12 were not included in these analyses as they 
were excluded at baseline. Endostatin was excluded from these analyses as it was not 
considered a mediator of high variability in principal component analysis at baseline, and 
thus was not investigated in 5 year follow-up patient serum. 
 
4.1.4.2.1.1 Established RA Hierarchical clustering biomarker profiling 
 
Hierarchical clustering analysis as described earlier (section 4.1.2.2.1.1) was similarly used 
and identified 5 distinct patient clusters denonted as C1, C2, C3, C4 and C5, further 
demonstrating that RA in an immunologically heterogenous disease and may have various 
pathological routes.
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Figure 4.1.4c: Heat map of the relative mediator expression in established RA patients 
 
 
 y-axis=patient identification number, x-axis=mediators 
 
Clusters C1, C2 and C3 displayed similar patterns of relatively low mediator expression. In 
contrast, cluster 5 displayed a relatively high mediator expression pattern particularly that 
of interleukins. It should be noted that the C5 patient cluster is not in the traditional sense a 
cluster as it separated into numerous smaller clusters. However, for the purposes of this 
investigation these were combined together due to their similar expression levels in 
comparison to the other patient clusters. The C4 cluster displayed a moderate expression 
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pattern of the investigated mediators. This heat map demonstrates the varying grades of 
immune activity and the possibility of immunological subtypes. The heat map showed the 
biggest differences between the high and low mediator expression clusters (C5 versus C1, 
C2 and C3) were that of the interleukins as well as a number of other specific mediators 
(IP-10, eotaxin, G-CSF, GM-CSF, MCP-1, IFN-γ, TNF-α and MMP-2). This was 
confirmed for the most part with statistical comparisons (p=<0.05), although IP-10 was not 
found to be significantly different between these specific clusters (p=0.23). However, MIP-
1α (14.8 (13-62.2) v 11.62 (0-14.04), p=0.002), OPN (18000 (13075-30825) v 12475 
(8175-20100), p=0.008) and MMP-9 (590184.3 (433641.7-749302.3) v 465523.4 
(332157.5-624322.9), p=0.04) were also found to be significantly higher in the C5 cluster. 
This 22 mediator profile could largely explain the difference between these potential 
immunological subtypes (Gruber et al., 1996, Isomäki and Punnonen, 1997, Mohammed et 
al., 2003, Stamenkovic, 2003, Lawlor et al., 2004). Discriminant stepwise selection and 
forward logistic regression analysis of this profile revealed IL-6 alone (p=0.003) with 
contribution of IL-9 (p=0.08) in particular distinguished the high from the low mediator 
expression clusters (model p=<0.0001, model r-squared=0.52). 
 
4.1.4.2.1.2 Association with established RA disease activity and severity 
 
Chi-square analysis significantly demonstrated that patient cluster C5 had the highest 
frequencies of patients positive for RF followed by cluster C4, whereas clusters C1 and C3 
displayed the lowest frequency of RF positive patients (Table 4.1.4d). The C2 cluster 
showed half RF positive and RF negative patients. No significant difference was found in 
the distribution of anti-CCP between patient clusters, although similar to that of RF 
seropositivity, clusters C5 and C4 had the highest frequencies of anti-CCP positive patients 
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(Table 4.1.4d). This suggests that the 22 interleukin-prominent mediator profile expressed 
in the high mediator expression cluster, and particularly pro-inflammatory Th2 humoral 
mediators IL-6 and IL-9, may be important in regard to the production of autoantibodies in 
established disease (Janeway Jr et al., 2005). 
 
Table 4.1.4d: Association between patient clusters and autoantibodies 
 
Patient Cluster RF negative n (%) RF positive n (%) 
Anti-CCP 
negative n (%) 
Anti-CCP  
positive n (%) 
C1 8 (80%) 2 (20%) 4 (40%) 6 (60%) 
C2 5 (50%) 5 (50%) 3 (30%) 7 (70%) 
C3 15 (68%) 7 (32%) 8 (36.4%) 14 (63.6%) 
C4 5 (35.7%) 9 (64.3%) 3 (21.4%) 11 (78.6%) 
C5 4 (19%) 17 (81%) 3 (14.3%) 18 (85.7%) 
χ2=15.6 (df=4), p=0.003   χ2=3.79 (df=4), p=0.43 
 
Chi-square analysis revealed no significant difference in the distribution of synovial 
effusions between patient clusters in established disease (p=0.37). Analysis of erosive 
disease revealed however a near significant difference between patient clusters (p=0.06) 
(Table 4.1.4e). The C5 patient cluster had the highest frequencies of patients with erosive 
disease. This suggests that the 22 mediator profile identified in the high C5 mediator 
expression cluster may also be important in regard to erosions in established disease 
(Gruber et al., 1996, Isomäki and Punnonen, 1997, Mohammed et al., 2003, Stamenkovic, 
2003, Lawlor et al., 2004). This profile consists of interleukins, eosonophil and monocyte 
chemoattractants, granulocyte/macrophage growth factors, matrix remodelling mediators 
and pro-inflammatory mediators and may explain for the high frequency of patients with 
erosive disease in this cluster (Xu et al., 1989, Koch et al., 1992, Seki et al., 1995, Garcia-
Zepeda et al., 1996, Gruber et al., 1996, McQuibban et al., 2000, McQuibban et al., 2002, 
Lawlor et al., 2004, Janeway Jr et al., 2005, Xu et al., 2005, Nishimoto, 2006, Li and 
Rostami, 2010). Interestingly, clusters C1, C3 and C4 demonstrated relatively similar high 
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frequencies of patients positive for erosions (62-69%), whereas the C2 cluster had the 
lowest frequency of erosive patients (30%), despite clusters C1 and C3 having a similar 
low mediator expression pattern to the C2 cluster. Subsequent comparisons between these 
clusters revealed Dkk-1 (4752+2798.2 v 2238.43+1260.3, p=0.02), TIMP-1 
(246897.6+100191.4 v 156825+28221.45, p=0.02) and TIMP-2 (166288.3+30961.1 v 
121143+13473.44, p=0.001) to be significantly higher in the C2 cluster in comparison to 
clusters C1 and C3, and distinct from the C5 cluster and may be important in protecting 
bones from erosions. This profile incorporates inhibitors of ECM tissue degrading enzymes 
which regulate bone destruction and could account for the lower frequency of patients with 
erosive disease in this cluster (Brew et al., 2000, Mannello and Gazzanelli, 2001, Baker et 
al., 2002, Clark et al., 2008, Murphy et al., 2009). 
 
Table 4.1.4e: Association between patient biomarker clusters and presence of erosions 
 
Patient Cluster Erosive negative n (%) Erosive positive n (%) 
C1 3 (37.5%) 5 (62.5%) 
C2 7 (70%) 3 (30%) 
C3 6 (31.6%) 13 (68.4%) 
C4 4 (31%) 9 (69%) 
C5 3 (16%) 16 (84%) 
χ2=8.80 (df=4), p=0.06 
 
Comparison of disease activity and severity measures revealed that the VAS (p=0.03), the 
Stoke Index (p=0.006) and peripheral inflammation measures (CRP p=0.0001, ESR 
p=0.0002, WBC count p=0.04, platelets p=0.01) were significantly different between 
patient clusters (Figure 4.1.4f). No other measures of disease were shown to be 
significantly different. Differences were mainly between patients of the C4 and the C1 
cluster, with cluster C4 demonstrating the highest scores. 
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Figure 4.1.4f: Comparison between patient clusters with disease measures in established 
RA 
 
 
 
Although cluster C4 demonstrated the highest scores of disease activity and severity, it 
displayed a moderate mediator expression pattern in comparison to the C5 cluster. Thus 
mediator comparisons against the C4 cluster were performed to determine which were 
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uniquely raised in this cluster. Analyses revealed a profile of 7 mediators in the C4 cluster 
which were significantly different from the C5 and C1 clusters. These were PDGF-bb 
(p=0.0006, p=0.0006), VEGF (p=0.01, p=0.002), OPG (p=0.04, p=0.005), Dkk-1 
(p=0.003, p=0.001), MMP-1 (p=0.02, p=0.04), MMP-3 (p=0.01, p=0.001) and TIMP-1 
(p=0.0006, p=<0.0001) (compared with C5 and C1 respectively, Figure 4.1.4g). This 
profile consisting of angiogenesis and cell growth factors plus matrix remodelling 
mediators including ECM degrading enzymes therefore could largely account for the 
worse disease activity and severity found in the C4 cluster (Paleolog, 2002, Alvarez et al., 
2006, Kuryliszyn-Moskal et al., 2006, Yoo et al., 2008). Interestingly, OPG a mediator 
responsible for bone growth and mineral deposition plus TIMP-1 a regulator for ECM 
degrading enzymes were also found to be significantly raised in cluster C4. These 
regulatory mediators may be upregulated as a compensatory response to the greater level 
of disease activity and inflammation. 
 
Figure 4.1.4g: Comparison of 7 biomarker profile between C1, C4 and C5 patient clusters 
 
Green=C1 cluster, Purple=C4 cluster, Red=C5 cluster 
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The Stoke Index score was found to be significantly different between patients clusters, 
however clusters demonstrated a score of no more than a median of 5 indicating that each 
patient cluster were of a mild or minimal overall disease activity phenotype. Chi-square 
analysis of Stoke Index phenotype categories showed a significant difference in 
distribution between patient clusters and demonstrated that patients of the C1 and C3 
clusters had the highest frequencies of a minimal phenotype followed by the C2 cluster 
(Table 4.1.4h). This suggests that low expression of the 22 mediator profile identified in 
the high mediator expression cluster may also be important in regard to less overall disease 
activity and severity in established disease (Gruber et al., 1996, Isomäki and Punnonen, 
1997, Mohammed et al., 2003, Stamenkovic, 2003, Lawlor et al., 2004). No significant 
difference in the distribution of DAS44CRP (p=0.88) or the DAS44ESR (p=0.33) disease 
activity phenotypes was found, nor was there any difference in remission status. 
 
Table 4.1.4h: Association of stoke index phenotypes with patient clusters 
 
5 Year Follow-up Stoke Index Phenotype 
Patient Biomarker Clusters Minimal n (%) Mild n (%) Moderate n (%) Severe n (%) 
C1 10 (100%) 0 (0%) 0 (0%) 0 (0%) 
C2 5 (50%) 2 (20%) 3 (30%) 0 (0%) 
C3 16 (72.7%) 5 (22.7%) 1 (4.5%) 0 (0%) 
C4 4 (28.6%) 6 (42.9%) 3 (21.4%) 1 (7.1%) 
C5 8 (38.1%) 9 (42.9%) 3 (14.3%) 1 (4.8%) 
χ2=21.71 (df=12), p=0.04 
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4.1.4.2.1.3 Association with cigarette smoking 
 
Cigarette smoking has been well documented to be associated with severe RA and worse 
disease outcome. Chi-square analysis revealed the distribution of smokers was 
significantly different between patient clusters, where cluster C5 was found to have the 
highest frequencies of smokers (Table 4.1.4i). This suggests that the elevated 22 mediator 
profile identified in this high mediator expression cluster may be upregulated in smokers. 
Interestingly, the C2 cluster demonstrated a similar frequency of smokers, despite this 
cluster displaying a relatively low mediator expression pattern. This suggests that raised 
expression of Dkk-1, TIMP-1 and TIMP-2 identified in this C2 cluster may also be 
important in regard to smoking in this set of patients. Furthermore, cigarette smoke has 
been documented to have immunosuppressive properties which may partly explain the 
pattern of low mediator expression in this cluster (McCue et al., 2000, Ouyang et al., 2000, 
Oltmanns et al., 2005, Lee et al., 2007). 
 
Table 4.1.4i: Association between patient clusters and smoking 
Patient Cluster Never smoked n (%) Ever smoked n (%) 
C1 7 (70%) 3 (30%) 
C2 2 (20%) 8 (80%) 
C3 9 (41%) 13 (59%) 
C4 5 (35.7%) 9 (64.3%) 
C5 3 (14.3%) 18 (85.7%) 
χ2=10.80 (df=4), p=0.03 
 
The smoking status of patients was also found to be significantly different between patient 
clusters in established RA (p=0.003), where cluster C5 demonstrated the highest frequency 
of current smokers (Table 4.1.4j). This suggests that recent exposure to cigarette smoke 
may upregulate expression of the 22 mediator profile. The C2 cluster however was found 
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to have the highest frequency of past smokers which may partly account for the relatively 
low mediator expression pattern displayed by this cluster. Furthermore, cigarette smoke 
has been documented to have immunosuppressive properties (McCue et al., 2000, Ouyang 
et al., 2000, Oltmanns et al., 2005, Lee et al., 2007), patients who no longer smoke 
therefore may express mediators without any inhibition. This may account for the raised 
Dkk-1 and TIMPs identified in this cluster of past smokers. TIMPs are natural MMP 
inhibitors and thus have roles in regulating inflammation which could also contribute to the 
low expression of mediators in this cluster (Brew et al., 2000, Mannello and Gazzanelli, 
2001, Baker et al., 2002, Clark et al., 2008, Murphy et al., 2009). 
 
Table 4.1.4j: Association of 5 year smoking status with patient clusters 
 
 Smoking Status 
Patient Cluster Non-smoker n (%) Past smoker n (%) Current smoker n (%) 
C1 7 (70%) 2 (20%) 1 (10%) 
C2 2 (20%) 7 (70%) 1 (10%) 
C3 9 (41%) 11 (50%) 2 (9%) 
C4 5 (35.7%) 7 (50%) 2 (14.3%) 
C5 3 (14.3%) 7 (33.3%) 11 (52.4%) 
χ2=23.0 (df=8), p=0.003 
 
Chi-square analysis did not reveal a significant association between patient clusters and 
pack year stratification (p=0.10), indicating that the difference between C2 and C5 patients 
was not due to intensity and length of time patients smoked. 
 
Chi-square analysis between patient clusters and those receiving DMARD treatment at 
time of 5 year follow-up also did not demonstrate a significant difference in distribution 
between the patients groups (p=0.40). 
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4.1.4.2.1.4 Established RA Hierarchical clustering results summary 
 
These results indicate that a mediator profile of multiple interleukins and various other 
mediators may be upregulated in response to smoking, especially after recent exposure. 
This upregulation of various mediators therefore could contribute to the increase of 
autoantibody production and bone erosion found in RA smokers as well as influence the 
level of disease activity and severity. This particular mediator profile-disease activity and 
severity relationship may therefore account for the relatively low expression of mediators 
in non-smokers and thus explain the better level of RA disease found in patients of the C1 
cluster. These results also illustrate that smoking may suppress or promote expression of 
certain mediators, and that cessation of smoking may produce a different mediator 
expression profile compared with that of current smokers, which in turn may influence 
disease severity in a unique manner. 
 
4.1.4.2.2.1 Established RA Principal Component Analysis biomarker profiling 
 
As at baseline, an exploratory PCA of all 36 mediators at 5 year follow-up was initially 
performed. This selected a specific set of 17 mediators which provided the maximum 
variance and were incorporated into the principal component analysis (Table 4.1.4k). 
 
Table 4.1.4k: Mediators selected for Principal Component Analysis 
 
Five Year Follow-up PCA Biomarkers 
IL-1ra TNF-α VEGF MMP-1 MMP-9 
IL-2 G-MCSF OPN MMP-2  
IL-6 IP-10 OPG MMP-3  
IL-8 PDGF-ββ Dkk-1 MMP-8   
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Principal component analysis identified 5 PC biomarker profiles generated from the 
correlation patterns of the 17 mediators selected which were then used for analysis. Table 
4.1.4l displays the 5 PC generated biomarker profiles and their modified relative factor 
loadings after variamax rotation. Positive and negative factor loading relate to high and 
low expression level respectively. 
 
Table 4.1.4l: PC profiles of 17 biomarkers and their relative factor loadings 
 
PC 1 PC 2 PC 3 PC 4 PC 5 
IL-1ra 0.96 MMP-8 0.86 PDGF-bb 0.70 MMP-3 0.75 IP-10 -0.77 
IL-2 0.94 MMP-9 0.82 MMP-1 0.67 OPG 0.60 Dkk-1 0.50 
GM-CSF 0.91 IL-8 0.67 VEGF 0.62 OPN 0.51 OPG -0.45 
IL-6 0.90 OPN 0.41 Dkk-1 0.56 MMP-2 0.43   
TNF-α 0.87     MMP-2 -0.44         
- negative factor loading 
 
4.1.4.2.2.2 Association with established RA disease activity and severity 
 
Regression analyses revealed only a few significant associations of PC profiles with 
measures of disease (Table 4.1.4m). Predominantly, the PC 4 profile consisting of OPG, 
OPN, MMP-3 and MMP-2 expression was found to be independently associated with the 
greatest number of disease activity and severity measures, especially inflammatory indices, 
the VAS for pain and various joint measures including the number of swollen joints and 
the OSRA-D. These mediators are well known for ECM remodelling and have roles in 
inflammation which would account for the association with systemic inflammation and for 
patients experiencing worse pain (Xu et al., 2005, Ateş et al., 2007, Bazzichi et al., 2009, 
Gaoya et al., 2009). In contrast, OPG has been shown to have roles in bone growth, 
mineral deposition and immune regulation and could be elevated as a response to 
compensate for worse disease severity (Lacey et al., 1998, Feige, 2001, Schoppet et al., 
2002). However, after adjusting for confounding factors disease duration, ever smoking 
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and DMARD treatment, PC 4 was no longer associated with the OSRA-D, suggesting that 
smokers present with worse severity, and thus have a higher need for DMARD treatment 
(Saag et al., 1997, Másdóttir et al., 2000, Wolfe, 2000, Mattey et al., 2002c, Finckh et al., 
2007, Westhoff et al., 2008). 
 
Furthermore this PC 4 profile was also found to be associated with patients who have ever 
smoked, which suggests that smoking may promote expression of certain mediators such 
as upregulation of OPG, OPN, MMP-2 and MMP-3. In addition, cigarette smoke may also 
have an anti-inflammatory protective role in RA as OPG, a mediator responsible for bone 
growth, mineral deposition and immune regulation was also elevated. However this profile 
lost its significance when adjusted for DMARD treatment at 5 year follow-up. Intriguingly, 
erosions and synovial effusions were found to be negatively associated with PC 3 and PC 4 
respectively. Further investigation is required to determine the true premise of this 
relationship. 
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Table 4.1.4m: Association between PC biomarker profiles with disease measures 
 
Disease 
Measure 
Variable PC 1 PC 2 PC 3 PC 4 PC 5 
Model 
 p-value 
Model 
r-squared 
CRP (+/-) 0.04   0.02  0.0001 0.20 
ESR >21 
(+/-) 
0.009   0.06  <0.0001 0.24 
SJ >3 (+/-)    0.05  0.04 0.05 
WBC  0.002  0.0003 0.0006 <0.0001 0.31 
Platelets   <0.0001   <0.0001 0.21 
Anaemia 
(+/-) 
 0.03  0.001  0.0002 0.20 
Synovial 
effusion 
(+/-) 
   0.02(-) 0.02 0.005* 0.12 
PIPS >0 
(+/-) 
0.11     0.04* 0.05 
CGDA >32 
(+/-) 
     NS  
OSRA-A 
>3 (+/-) 
   0.01  0.005 0.09 
SI >3 (+/-) 0.03   0.002  <0.0001 0.26 
DAS44CRP 
>2.60 (+/-) 
     NS  
Inflammation 
DAS44ESR 
>2.69 (+/-) 
     NS  
RF (+/-)      NS  
Autoantibody Anti-CCP 
(+/-) 
0.10     0.01 0.08 
VAS >47 
(+/-) 
   0.004  0.0008 0.13 
TJ >5 (+/-)      NS  Pain 
RI >8 (+/-)      NS  
Erosions 
(+/-) 
  0.05(-)   0.04 0.06 
OSRA-D    0.03  0.03 0.05 Damage 
 Larsen 
Hand score 
>28 (+/-) 
     NS  
EMS >30 
(+/-) 
 0.02    0.009 0.08 
HAQ >1.5 
(+/-) 
     NS  
Function 
Grip 
strength 
>107 (+/-) 
     NS  
Other 
Ever 
Smoked 
(+/-) 
   0.05  0.03 0.05 
N.B Non-parametric variables were dichotomised using the median value as the cut-off level, * Forward 
logistic regression only as discriminant stepwise selection unable to perform, (-) negative association, 
NS=Not Significant. 
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The Stoke Index for overall disease activity was also shown to be strongly associated with 
the PC 4 profile as well as the PC 1 profile which consists of granulocyte-macrophage 
growth factors and pro-inflammatory mediators (IL-1ra, IL-2, IL-6, GM-CSF and TNF-α) 
(Table 4.1.4m). Regression analyses were subsequently performed between PC profiles 
and the Stoke Index minimal disease phenotype (score 1-3). Analysis revealed profiles PC 
1 and PC 4 to be negatively associated with minimal disease activity (Table 4.1.4n). 
Furthermore, analyses were subsequently performed between PC profiles and better 
activity phenotypes of both the DAS44 -CRP and -ESR measures (remission (<1.6) and 
low (1.6-2.4)) (Table 4.1.4n). The PC 4 profile was similarly revealed to be negatively 
associated with a low DAS44CRP. Reduced mediator expression levels in this profile 
therefore may account for a more favourable disease activity. Interestingly, the PC 1 
profile demonstrated a positive association with a low DAS44ESR. This profile includes 
mediators which have anti-inflammatory activities including IL-1ra which is a well 
characterised inhibitor of the pro-inflammatory cytokine IL-1β, and IL-2 an immune 
response regulatory cytokine which could explain its association with less severe disease 
(Cutolo, 2004, Janeway Jr et al., 2005). Furthermore, PC 3 alone was found to be 
associated with remission status of the DAS44ESR. This profile predominantly consists of 
pro-inflammatory mediators and ECM degrading enzymes, plus MMP-2 which was 
negatively loaded within this profile and thus did not explain for being affiliated with 
remission in RA patients (McQuibban et al., 2000, McQuibban et al., 2002). 
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Table 4.1.4n: Association between PC profiles with low/minimal/remission overall disease 
activity phenotypes 
 
Disease Activity 
Phenotype  
PC 1 PC 2 PC 3 PC 4 PC 5 
Model 
 p-value 
Model  
r-squared 
Stoke Index 
Minimal (+/-)  
0.03(-)   0.002(-)  <0.0001 0.26 
DAS44CRP 
Low (+/-) 
   0.06(-)  0.04 0.05 
DAS44CRP 
Remission (+/-) 
     NS  
DAS44ESR 
Low (+/-) 
0.02     0.003 0.10 
DAS44ESR 
Remission (+/-) 
  0.04   0.04 0.05 
(-) negative association, NS=Not significant 
 
 
4.1.4.2.2.3 Established RA Principal Component Analysis biomarker profiling results 
summary 
 
These results suggest that cigarette smoking may upregulate OPN, MMP-2 and MMP-3 
expression, which could explain why these mediators were also shown to be associated 
with worse disease activity and severity measures in established RA. A low expression of 
these mediators plus elevated expression of anti-inflammatory activity IL-1ra, IL-2 and 
OPG would therefore be associated with better RA disease. This was demonstrated by the 
negative association of this mediator profile with favourable disease activity phenotypes 
(minimal/low) of the Stoke Index and DAS44CRP scores. 
 
 
 
 
 185 
4.1.4.3 Composite Biomarker Profiles 
 
Hierarchical clustering alone identified a biomarker profile of elevated IL-6, IL-9 plus low 
expression of TIMP-1 and TIMP-2 was derived which was likely to be associated with 
erosive disease. ROC analyses however of this profile revealed that both AUCs were 
“poor” at identifying erosive RA patients (AUC 0.61 and 0.60 respectively). 
 
Principal component analysis could not identify a biomarker profile associated with RF or 
anti-CCP, however hierarchical clustering identified numerous interleukins and specific  
mediators (growth factors, chemoattractants and pro-inflammatory cytokines) which were 
associated with RF. Interleukin -6 and IL-9 were particularly shown to be associated with 
seropositivity, however ROC analysis revealed it to “poorly” identify RF positive patients 
(AUC 0.70). Consequently, ROC analysis of all investigated interleukins identified this 
profile to be “good” at accurately identifying patients positive for RF (AUC 0.87, 95% CI 
0.81-0.95, SE 0.036, p=<0.0001) (Figure 4.1.4o) and indicates that multiple interleukins in 
collaboration are associated with RF production. 
 
Figure 4.1.4o: Accuracy of RF identified biomarker profile 
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A biomarker profile incorporating PDGF-bb, VEGF, Dkk-1, MMP-1, MMP-3 and OPN 
which was likely to be associated with worse disease activity and severity was also derived 
from both the hierarchical clustering and principal component analysis. ROC analysis of 
this biomarker profile however showed it to “poorly” identify worse disease (defined by 
either a severe DAS44-CRP, -ESR (score >3.7) or high Stoke Index (score 12-17) 
phenotype) (AUC 0.67). 
 
In contrast, a biomarker profile of low IL-6, IL-9, GM-CSF, TNF-α, OPN, MMP-3 
expression which was likely to be associated with a better disease outcome was derived 
from both hierarchical clustering and principal component analysis. ROC analysis revealed 
this profile to be “good” at accurately identifying favourable disease activity (defined by 
either a minimal Stoke Index (score 1-3), low (>1.6-2.4 score) or remission (score <1.6) 
DAS44 phenotype (AUC 0.83, CI 95% 0.70-0.94, SE 0.05, p=<0.0001) (Figure 4.1.4p). 
 
Figure 4.1.4p: Accuracy of disease activity and severity composited biomarker profile for 
favourable disease activity 
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4.1.4.4 Established RA Overall Summary 
 
This cohort of RA patients, although considered to be at an established stage of disease, 
demonstrated biomarker profiles that were found to be associated with only a few 
measures of disease activity and severity. These were mainly markers of inflammation, 
rather than outcome disease measures although a few biomarker profiles of interest from 
both analysis methods were derived. 
 
A biomarker profile of growth factors, chemoattractants, pro-inflammatory cytokines and 
especially numerous interleukins was associated with RF. This profile is in line with 
previous studies where multiple interleukins and the same specific mediators were strongly 
associated with autoantibody presence (Hitchon et al., 2004, Alex et al., 2007, Hueber et 
al., 2007, Jørgensen et al., 2008, Kokkonen et al., 2010, Meyer et al., 2010, Chandra et al., 
2011, Hodkinson et al., 2011). 
 
These results identified a biomarker profile of low IL-6, IL-9, GM-CSF, TNF-α, OPN, 
MMP-3 expression which was associated with a better level of disease activity. This 
profile is unique when compared with previous profiling studies, although individually 
these mediators have been previously described with pro-inflammatory roles in RA. Thus a 
reduction in their expression would likely be associated with reduced RA disease activity 
and severity, as well as potentially a new assessment measure for disease activity. 
 
Cigarette smoking may upregulate IL-6, IL-9, OPG, OPN and MMP-3 which is consistent 
with previous profiling studies that smoking can alter expression of a variety of MMPs and 
cytokines and thus influence immune activity (Nakamuraa et al., 1998, Knuutinen et al., 
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2002, Nordskog et al., 2003, Raitio et al., 2005). This profile provides further insight into 
the mechanisms involved in the effects of cigarette smoking in RA. 
 
This study further demonstrates the importance of various interleukins, growth factors, 
matrix remodelling mediators and pro-inflammatory cytokines in the pathological process 
of established RA, and identifies mediators which are likely to be involved in molecular 
pathways of the disease process. Commonly accepted mediators of RA pathology (IL-β, 
IFN-γ and TNF-α) again did not provide any more information about disease activity in 
established disease than many of the other serum biomarkers. These findings further 
demonstrate the heterogeneity and the complex network of mediators involved in RA 
pathology and suggests that these markers of immune dysfunction could become novel 
targets for disease intervention.
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4.1.5 BIOMARKER PROFILING RA DISEASE PROGRESSION 
 
This study investigated biomarker profiling in both early and established RA in the same 
cohort of patients, which allowed the investigation of mediator expression changes with 
progression of the disease. Such investigations can determine whether any biomarker 
profiles may explain the change in activity and/or severity over the 5 year period and give 
possible insights into the disease process as the disease progresses. This type of 
investigation can further help elucidate the pathological process in RA and may give clues 
of the molecular pathways involved in disease progression. 
 
Comparison of disease measures between early and established RA revealed a significant 
decrease in the majority of indices by the time of 5 year follow-up (p=<0.05) (Figure 
4.1.5a and b). In particular, the level of disease activity was shown to be reduced whereas 
disease severity did not generally change during the 5 year period as no significant 
difference was found in the OSRA-D (p=0.50) or HAQ (p=0.76). However a significant 
improvement in function was shown in the EMS score and grip strength. The data 
demonstrate that these RA patients generally had a lower level of active disease at 5 year 
follow-up than when they first attended the clinic but only a slight or no improvement in 
severity measures. 
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Figure 4.1.5a: Comparison of disease activity and severity between early and established 
RA 
 
 
Yellow=Early RA, Green=Established RA 
 
 
 
Figure 4.15b: Change in disease activity and severity from early to established RA 
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The expression of mediators also changed between baseline and 5 year follow-up, where 
half of the mediators either increased or decreased during the 5 year period (Figure 4.1.5c). 
Half of these mediators were found to be significantly different between baseline and 5 
year follow-up. In particular IL-4, IL-5, IL-6, IL-8, G-CSF, MCP-1, OPG and TIMP-3 
were found to be significantly lower at 5 year follow-up (p=<0.03), whereas IL-1β, IL-7, 
IL-10, IL-13, eotaxin, IP-10, MIP-1α, MMP-2 and TIMP-2 were shown to be significantly 
higher at 5 year follow-up (p=<0.01) (Figure 4.1.5d). 
 
Figure 4.1.5c: Changes in mediator expression from baseline to 5 year follow-up 
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Figure 4.1.5d: Comparison of mediator expression between baseline and 5 year follow-up 
 
Orange=Baseline, Brown=5 year follow-up 
 
 
4.1.5.1 Association of mediator expression changes and changes in disease activity and 
severity 
 
Changes in mediator expression and their relationship to disease activity and severity 
changes were analysed to determine their association with progression of RA. Various 
mediator expression changes were associated with changes in disease measures, in 
particular a decrease in IL-8, PDGF-bb, OPN, MMP-1 and MMP-3 were found to be the 
most associated with decreased disease activity as well as a decrease in EMS (Table 
4.1.5e). PDGF-bb, OPN and MMP-1 were associated with the greatest number of disease 
measures, with MMP-1 predominantly associated with measures of peripheral 
inflammation whereas OPN was associated with measures of overall disease activity 
(CGDA, OSRA-A). PDGF-bb however was associated with a range of inflammatory 
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disease activity measures (WBC, PIPS, OSRA-A) as well as the VAS. In contrast, eotaxin 
and TIMP-4 were negatively associated with decreased disease activity (CGDA, OSRA-A, 
DAS44ESR, VAS, tender joints, Ritchie Index) indicating that elevated expression would 
result in an increase of overall disease activity, joint tenderness and pain. These mediators 
are known inflammatory chemoattractants, growth factors and matrix remodelling 
mediators respectively, so a reduction in their expression would likely be associated with a 
less active disease which may explain the lower level of disease activity displayed 
(Baggiolini and Clark-Lewis, 1992, Garcia-Zepeda et al., 1996, Clark and Parker, 2003, 
Mohammed et al., 2003, Stamenkovic, 2003, Vjeroslava Slavić1 et al., 2005, Xu et al., 
2005, Alvarez et al., 2006, Holmbeck and Szabova, 2006, Bazzichi et al., 2009, Gaoya et 
al., 2009). Interestingly TIMP-4 demonstrated an association with greater disease activity, 
although it is characterized as an inhibitor of ECM degrading enzymes (Brew et al., 2000, 
Mannello and Gazzanelli, 2001, Clark et al., 2008, Melendez-Zajgla et al., 2008). This 
could be due to this mediator being upregulated as a means of regulating increased 
inflammatory activity. These relationships were largely independent of confounding 
factors, although reduced WBC counts was no longer associated with reduced OPN after 
adjusting for DMARD treatment (91% of patients positive). 
 
Autoantibodies, erosions, the Larsen hand score and synovial effusions were recorded only 
once in this cohort, and therefore change over time was not recorded. 
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Table 4.1.5e: Association of mediator expression changes with disease measure changes 
 Inflammation Pain Damage Function 
Mediator 
CRP 
>0 
ESR WBC 
Platelets 
>0 
PIPS 
>0 
SJ CGDA 
OSRA 
-A 
Stoke 
Index 
DAS 
44 
ESR 
>0 
VAS 
TJ 
>0 
RI 
>0 
OSRA 
-D 
EMS 
>0 
HAQ 
>0 
IL-1β                 
IL-1ra   0.001(-)    0.02          
IL-2                 
IL-4                 
IL-5                 
IL-6         0.004        
IL-7           0.01      
IL-8  0.05       0.05      0.04  
IL-9              0.01(-)   
IL-10   
<0.0001 
(-) 
     0.0004        
IL-12         0.003(-)        
IL-13                 
IL-15       0.03          
Eotaxin   0.01    0.01(-)   
0.04 
(-) 
   0.008(-)   
G-CSF         
0.0006 
(-) 
       
GM-CSF              <0.0001   
IFN-γ   <0.0001              
IP-10      0.005           
MCP-1                 
MIP-1α                0.15(-) 
PDGF-bb   0.04  0.02   0.01   0.0005      
TNF-α   
<0.0001 
(-) 
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Mediator 
CRP 
>0 
ESR WBC 
Platelets 
>0 
PIPS 
>0 
SJ CGDA 
OSRA 
-A 
Stoke 
Index 
DAS 
44 
ESR 
>0 
VAS 
TJ 
>0 
RI 
>0 
OSRA 
-D 
EMS 
>0 
HAQ 
>0 
VEGF           0.01(-)      
MMP-1 0.002 <0.0001  0.0002     <0.0001       0.03 
MMP-2 0.02(-) 0.01(-)               
MMP-3  0.004      0.004   0.0006      
MMP-8                 
MMP-9  0.02(-) 0.0006              
OPG                 
OPN   0.04    0.01 0.007 0.04(-)     0.03   
Dkk-1                 
TIMP-1                 
TIMP-2                 
TIMP-3         0.02        
TIMP-4   0.02     0.03(-)   0.03(-) 
0.01 
(-) 
0.03 
(-) 
   
Model p-value <0.0001 <0.0001 <0.0001 <0.0001 0.006 0.005 0.005 0.0001 <0.0001 0.02* 0.0005 0.007 0.02 0.0003 0.006 0.005* 
Model r-squared 0.25 0.51 0.60 0.35 0.10 0.10 0.20 0.27 0.46 0.07 0.26 0.08 0.07 0.25 0.10 0.13 
>0 an improvement, (-) negative association. * Forward logistic regression only as discriminant stepwise selection unable to perform. N.B DAS44CRP and Grip strength 
were not significant and thus not included in table.
Table 4.1.5e: Association of mediator expression changes with disease measure changes continued 
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4.1.5.2 Association of mediator changes with cigarette smoking and DMARD 
treatment 
 
Regression analysis of mediator expression changes in patients who had ever smoked 
revealed a positive association with an increase in TIMP-2 level (p=0.01). In addition, a 
decrease in TIMP-3 level was found to be negatively associated with ever having smoked 
(p=0.005(-)). An increase in MMP-9 level was also found to be negatively associated with 
ever having smoked (p=0.052(-)), and this contributed to the overall model (model 
p=0.001, model r-squared=0.17). This indicates that cigarette smoking may upregulate the 
expression of TIMP-2 and TIMP-3 as well as possibly down-regulating MMP-9. This 
suggests that smoking may promote or suppress the expression of certain mediators which 
has been similarly demonstrated in previous studies (Knuutinen et al., 2002, Nordskog et 
al., 2003, Raitio et al., 2005). In contrast to this study, another study found MMP-9 to be 
upregulated in smokers (Nakamuraa et al., 1998). This provides some insight into the 
mechanisms involved in the effects of cigarette smoking in RA. 
 
Little difference in the changes of mediator expression was shown in patients treated with 
or without DMARDs, although the small number of patients not receiving DMARDs had 
increased expression of IP-10 (1388.5 (423-3094.6) v 481 (-745.4-1334.115), p=0.05), 
TIMP-1 (33695 (22502.6-45149.4) v 8943.96 (-14897.4-34908.3), p=0.04) and TIMP-2 
(30024.1 (20972.5-31394.14) v 13476.7 (-470.46-22568), p=0.01) compared to those 
receiving treatment. However, the numbers of patients not receiving DMARDs was small, 
so the significance of these results is unclear. 
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4.1.5.3 Summary 
 
This cohort of RA patients displayed a less active disease by the time of 5 year follow-up, 
with no overall improvement in disease severity. The improvement in the level of disease 
activity was shown to be associated with a biomarker profile of reduced eotaxin, IL-8, 
PDGF-bb, OPN, MMP-1, MMP-3. This particular profile is unique to this study, although 
specific mediators of this profile including MMP-1 and MMP-3 have been identified to be 
associated with joint damage progression (Yamanaka et al., 2000, Constantin et al., 2002, 
Green et al., 2003, Tchetverikov et al., 2003, Ateş et al., 2007, Mamehara et al., 2010). In 
contrast to this study, eotaxin has been found to be associated with less radiographic 
progression, although this was only 12 months after diagnosis of early RA which may 
account for this discrepancy (Syversen et al., 2008). The reduction of these 
chemoattractants, growth factors and matrix remodelling mediators appears to be 
independent of any effect of cigarette smoking and DMARD treatment. These mediators 
therefore could potentially become novel targets for inhibition of disease activity as well as 
the potential to be clinical markers for long term disease assessment.
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4.2 COMPARISON OF BIOMARKERS IN THE PERIPHERAL CIRCULATION 
AND THE SYNOVIAL FLUID IN RA 
 
RA biomarker profiling has been commonly investigated in the serum due to its ease of 
procurement, despite the main site of inflammation occurring at the synovial joint. The 
peripheral circulation may not necessarily reflect the same level of immune activity as 
within the joint. Thus, RA biomarker profiling of paired serum and joint synovial fluid 
collected at the same time were investigated for comparison between the 2 environments. 
This type of investigation can also determine whether any biomarker profiles from either 
location are particularly associated with disease activity and severity which may provide 
further clues into the disease process. In addition, this investigation can also determine 
whether any biomarker profiles from either environment are associated with joint damage. 
This can elucidate the respective systemic and articular contribution, since the active 
inflamed joint recruits mediators from the peripheral circulation. These type of 
investigations can help further understand the pathological process of RA as well as give 
clues to the molecular pathways involved and insights into the systemic nature of RA.  
 
Thirty-nine mediators in total were investigated in both the serum and the synovial fluid 
with the exclusion of MMP-12 and endostatin as they were excluded from the first RA 
cohort. Within the sera, the level of RANTES was usually greater than the maximum 
threshold of detection and thus was not included in analyses. However levels were within 
the detection range in the synovial fluid and so were still included in specific analyses. 
Dkk-1 was barely detected within the synovial fluid, and so was also excluded from 
analyses involving synovial fluid but was included in serum analyses. It should be noted 
that RA patients of this cohort were extremely varied in terms of disease duration (0.16-36 
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yrs, median 1.5 years, mean 6.63 years), and thus patient disease duration was taken into 
account in analyses wherever possible. 
 
Initial comparisons of mediator expression in the serum and the synovial fluid were 
performed to investigate immunological activity within the 2 environments. In line with 
previous studies, paired t-tests revealed that the majority of mediators were significantly 
higher in the synovial fluid than in the serum (Figure 4.2a) (Steiner et al., 1999, 
Tchetverikov et al., 2004, van den Ham et al., 2009, Moura et al., 2010). A few mediators 
(IL-2 p=0.008, IL-7 p=<0.0001, IL-9 p=0.01, PDGF-bb p=<0.0001, eotaxin p=<0.0001, 
and TIMP-4 p=<0.0001) however were found to be significantly higher in the serum 
(Figure 4.2a). In contrast, no significant differences were shown for IL-4, IL-5, FGF-β, G-
CSF, GM-CSF, IFN-γ and TNF-α between the 2 sites. This demonstrates that immune 
activity in general is greater at the site of inflammation (the active joint), although the 
separate sites do display some similarity in immune activity. 
 
Figure 4.2a: Comparison of mediator expression between the peripheral circulation and 
synovial joint 
 
SF=Synovial fluid 
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Correlation analyses demonstrated a relationship between the 2 environments as a 
significant positive correlation was found in the majority of mediators (excluding IL-1ra, 
IL-6, MIP-1β, PDGF-ββ, OPG, MMP-1, MMP-2, TIMP-1 and TIMP-2) (Appendix figure 
4.2b). Interestingly, MMP-2 and OPG were found to be negatively correlated, although this 
did not reach significance (Spearman’s Rank r-correlation -0.18 and -0.02, p=0.24 and 0.84 
respectively) (Appendix figure 4.2b). This suggests that the peripheral circulation may to 
an extent reflect the joint immunologically. 
 
4.2.1 Comparison of synovial joint and peripheral circulation biomarker profiles for 
disease activity and severity 
 
Combined biomarker profiling of the serum and the synovial fluid was investigated to 
determine whether any mediators from a specific environment are associated with disease 
activity and severity. Regression analyses revealed a biomarker profile of high IL-13, IL-
17 and MMP-8 plus low IL-5, IL-12 and IP-10 expression from the synovial fluid was 
associated with disease activity and severity, whereas a profile of high IL-13, IL-15, IP-10, 
MIP-1α and TIMP-4 plus low PDGF-bb and MMP-2 from the serum was shown to be 
associated with RA activity and severity (Table 4.2c). This illustrates that no specific 
environment is closer in reflecting disease activity than the other, in fact both sites show 
associations with disease activity. However, these biomarker profiles are distinct from each 
other, indicating that specific mediators from both environments are associated with 
disease activity and severity. Only IL-13 (an inducer of the Th2 humoral response) and IP-
10 from both environments were found to be associated with disease activity (Wynn, 
2003), although interestingly IP-10 demonstrated a negative association in the synovial 
fluid. This could suggest a possible anti-inflammatory role in RA as this chemokine also 
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has pleiotropic activities which include inhibiting angiogenesis (Angiolillo et al., 1995, 
Neville et al., 1997, Yates-Binder et al., 2012). 
 
Table 4.2c: Combined serum and synovial fluid biomarker profiling for disease activity 
and severity 
Mediator 
CGDA 
>56 (+/-) 
OSRA-A 
>5 (+/-) 
SI >9 
(+/-) 
DAS44ESR 
>3.6 (+/-) 
DAS44CRP 
>3.53 (+/-) 
HAQ >1.5 
(+/-) 
IL-5       
IL-5 SF 0.05(-)      
IL-12       
IL-12 SF    0.05(-)   
IL-13    0.04   
IL-13 SF      0.01 
IL-15 0.01      
IL-15 SF       
IL-17       
IL-17 SF 0.02      
IP-10    0.002 0.006  
IP-10 SF     0.02(-)  
PDGF-bb      0.03(-) 
PDGF-bb SF       
MIP-1α  0.04     
MIP-1α SF       
MMP-2     0.03(-)  
MMP-2 SF       
MMP-8       
MMP-8 SF    0.06   
TIMP-4 0.06      
TIMP-4 SF       
Model p-value <0.0001 0.02 NS <0.0001 <0.0001 <0.0001 
Model r-squared 0.36 0.10  0.40 0.34 0.32 
NS=Not significant, (-)=negative association. N.B All analyses were performed with discriminant stepwise 
selection followed by forward logistic regression of selected variables. 
 
Intriguingly, a single mediator, IL-2 an inducer of the Th2 humoral response (p=0.003) 
from the serum was found to be associated with RF (n=19/44 (43%)) (model p=<0.0001), 
whereas IP-10 (p=0.008) from the sera and TIMP-3 (p=0.006) from the synovial fluid were 
positively associated with anti-CCP positivity (n=35/52 (67%)) (model p=<0.0001). 
However, one study identified IL-2 as stimulating the production of antibodies, but not the 
production of RF autoantibodies (Callaghan et al., 1993). Further investigation of these 
  202 
autoantibody biomarker profiles in both the serum and the synovial fluid therefore is 
needed to determine the influence of both environments on autoantibody production.  
 
4.2.2 Comparison of synovial joint and peripheral circulation biomarker profiles for 
joint damage and disability 
 
Combined biomarker profiling of the serum and the synovial fluid was investigated to 
determine whether any mediators from either environment are associated with damage and 
destruction of the joint. Regression analyses revealed that mediators from both the 
peripheral circulation and the synovial joint were associated with joint disease activity and 
severity (SF profile: IL-2, IL-13 IL-15, IL-17 and G-CSF, serum profile: IP-10, Dkk-1 and 
MMP-2) (Table 4.2d). However, the synovial joint environment seems to positively reflect 
joint disease severity more than that of the serum, especially since MMP-2 and Dkk-1 from 
the serum demonstrated a negative association to joint disease activity and severity. In 
addition, these environment specific profiles are distinct from one another, since no 
mediator was found to be commonly associated in both environments. This suggests that 
specific mediators from both the synovial joint and the peripheral circulation are associated 
with joint damage and severity. Intriguingly, serum IP-10 was found to be positively 
associated with more joint disease indices than any other mediator from either 
environment. This is consistent with previous studies where an association with increased 
damage in the joint was shown in animal experimental arthritis, and therefore could be a 
potential target for RA treatment (Salomon et al., 2002, Kwak et al., 2008).  
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Table 4.2d: Combined serum and synovial fluid biomarker profiling for joint disease 
activity and severity 
  Inflammation  Pain Damage Function 
Mediator 
SJ >5 
(+/-) 
PIPS >3 
(+/-) 
TJ >7 
(+/-) 
RI >11 
(+/-) 
OSRA-D 
>2.5 (+/-) 
Larsen 
Hand 
score >50 
(+/-) 
Erosion 
(+/-) 
EMS  
>60 
(+/-) 
Grip 
strength 
>98 
(+/-) 
IL-2          
IL-2 SF         0.06 
IL-13          
IL-13 SF    0.009      
IL-15          
IL-15 SF         0.008(-) 
IL-17          
IL-17 SF         0.02(-) 
G-CSF          
G-CSF SF         0.03 
IP-10 0.01  0.002 0.004      
IP-10 SF          
Dkk-1      0.01(-)    
Dkk-1 SF X X X X X X X X X 
MMP-2    0.01(-)      
MMP-2 SF          
Model  
p-value 
0.003 NS <0.0001* <0.0001 NS 0.0001 NS NS <0.0001 
Model  
r-squared 
0.14  NA 0.35  0.41   0.45 
SF=Synovial Fluid, X=excluded mediator, NS=Not Significant, NA=Not Applicable, (-)=negative 
association. N.B All analyses were performed with discriminant stepwise selection followed by forward 
logistic regression of selected variables. *Discriminant regression alternatively used as logistic regression 
unable to perform. 
 
ROC analysis of this biomarker profile of positively associated IL-13, IL-15, IL-17 from 
the synovial fluid and sera IP-10 were analysed with the presence of erosions (n=28/37 
(75.7%)) but “failed” in accurately identifying patients with erosive disease (AUC 0.59). In 
contrast, ROC analysis of negatively associated IL-2 and G-CSF from the synovial fluid 
and Dkk-1 and MMP-2 from the serum was “fairly” accurate (AUC 0.74, 95% CI 0.55-
0.93, SE 0.1, p=0.007) in identifying the presence of erosions (Figure 4.2e). This 
biomarker profile is unique to that of previous biomarker profiling studies and could 
potentially provide new strategies for disease intervention since IL-2 is a known immuno-
regulatory mediator, and G-CSF and MMP-2 have been shown to have anti-inflammatory 
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activities (Hartung et al., 1995, Boneberg et al., 1999, McQuibban et al., 2000, Boneberg 
and Hartung, 2002, McQuibban et al., 2002, Martins et al., 2011). Interestingly, Dkk-1 was 
negatively associated with joint severity despite being characterised as a matrix 
remodelling mediator (Diarra et al., 2007). ROC analysis excluding Dkk-1 in the 
biomarker profile demonstrated “poorer” accuracy in identifying erosive disease (AUC 
0.68). Further investigation of Dkk-1 in both the serum and synovial fluid is therefore 
required to determine its relative effects on joint damage. 
 
Figure 4.2e: Accuracy of erosive disease identified biomarker profile 
 
 
4.2.3 Association with cigarette smoking 
 
Biomarker profiling and the influence of cigarette smoking in both the peripheral 
circulation and synovial fluid were investigated to determine whether cigarette smoking is 
associated with any effects on immune activity in either environment. As regression 
analyses could not be performed using patients who had ever smoked due to the limited 
range of patients, current smokers (n=14/49 (28%)) and past smokers (n=10/40 (25%)) 
were investigated. TIMP-3 alone from the sera was shown to be positively associated with 
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current smoking (p=0.02, model p=0.01, model r-squared=0.11), although no mediator 
from the sera was found to be associated with previous smoking. Interestingly, IL-10 alone 
from the synovial fluid was shown to be associated with current smoking as well as with 
past smoking (p=0.03, model p=0.01, model r-squared=0.12 and p=0.02, model p=0.01, 
model r-squared= 0.14 respectively). However, this mediator was found to be negatively 
associated with current smoking whereas it was shown to be positively associated with past 
smoking. This suggests that recent exposure to cigarette smoke may upregulate TIMP-3 in 
the peripheral circulation but downregulate IL-10 expression in the joint, which may be 
upregulated after smoking cessation. This demonstrates that smoking may promote or 
suppress expression of different mediators as other studies have described with various 
mediators (Madretsma et al., 1996a, Madretsma et al., 1996b, Ouyang et al., 2000, Lee et 
al., 2007, Choi et al., 2008). Although these results indicate that smoking is able to 
influence immune activity distinctly within the 2 environments, only a small number of 
mediators were identified which were affected by smoking. This could be due to the 
limited number and range of patients available for analysis. This profile is distinct from 
that of the biomarker profile identified in the early RA cohort of IL-6, IL-8, MMP-1, 
MMP-8, MMP-9, Dkk-1, OPN and OPG. Further investigation therefore would be useful 
to understand the role and mechanisms of cigarette smoking in RA in both the peripheral 
circulation and the synovial fluid. 
 
4.2.4 Association with DMARD treatment 
 
Biomarker profiling and the influence of DMARD treatment in both the peripheral 
circulation and synovial fluid were investigated to determine whether drug treatment is 
associated with any effects on immune activity at either environment. Analysis revealed 
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IP-10 alone from the sera was found to be significantly associated with DMARD treatment 
(p=0.05, model p=0.003, model r-squared=0.20). No mediator from the synovial fluid was 
found to be associated with drug treatment. This suggests that DMARDs may upregulate 
an angiogenesis inhibitor in the peripheral circulation (Angiolillo et al., 1995, Yates-
Binder et al., 2012). Although these results indicate that DMARDs are able to influence 
immune activity differently between the 2 environments, only a small number of mediators 
once again were identified which were affected by drug treatment. This could be due to the 
limited number and range of patients available and therefore additional investigation is 
needed. This profile is different to that of the biomarker profile identified in the early RA 
cohort which consisted of Dkk-1, OPN and MMP-1, although this may be upregulated by 
cigarette smoking and its association with DMARDs is one of response to worse disease 
associated with smoking. This also may be due to the fact that within this cohort, (n=23/51 
(45%)) of patients were receiving DMARD treatment whereas only 14% of patients were 
receiving treatment in early RA. 
 
4.2.5 Summary 
 
The level of inflammatory mediators was generally higher in the synovial fluid than the 
peripheral circulation reflecting a greater immune activity in the environment of the 
synovial joint which is in line with previous studies (Steiner et al., 1999, Tchetverikov et 
al., 2004, van den Ham et al., 2009, Moura et al., 2010). For these particular mediators the 
synovial joint is likely to be the primary site of production, although a significant 
correlation between the levels of many of the mediators in the 2 environments reflects a 
close relationship between these sites (Tchetverikov et al., 2004). However in some cases 
the level of particular mediators is higher in the peripheral circulation than the joint and is 
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more likely to reflect systemic production of these mediators (Moura et al., 2010). The 
association of particular disease characteristics with specific mediators at one and/or both 
sites is an indication of the systemic nature of RA. Thus both environments are important 
in the RA pathological process with mediators from both the peripheral circulation and 
synovial fluid involved in the disease process contributing to overall disease activity and 
severity, although mediators from the synovial fluid are those of most importance for joint 
damage and severity. 
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4.3 RA BIOMARKER PROFILING IN COMPARISON WITH OTHER 
ARTHRITIDES 
 
Biomarker profiling of RA (using early disease patients from the first cohort) in 
comparison with other arthritic diseases (psoriatic arthritis (PsA), reactive arthritis (ReA) 
and osteoarthritis (OA)) was carried out to determine if differences in biomarker levels 
could distinguish between the separate arthritides. Such investigations will allow for better 
understanding of the pathology of the different arthritides and may give clues to the 
different pathways involved in the various arthritides. A total of 35 mediators were 
investigated in ReA, PsA and OA patient sera (n=80) for comparison with RA. RANTES, 
IL-17, FGF-β, MIP-1β, MMP-12 and endostatin were not included in the analyses as they 
were excluded from analysis in the first RA cohort. 
 
Initial comparisons of disease activity and severity between the different arthritides 
revealed significant differences in the majority of disease measures except for the WBC 
count and the VAS (Appendix Table 4.3a). Patients with RA demonstrated worse activity 
and severity compared to patients with other arthritic diseases, which reflects the 
characteristic inflammatory and destructive type of disease pathology in RA. ReA patients 
closely followed RA in terms of worse activity and severity, with OA patients displaying 
the lowest level of disease activity and severity overall. This is not surprising since OA is 
characterised as a non-inflammatory arthritis (Appendix Table 4.3a). It should be noted 
that many disease measure indices were not recorded or present in the other arthritides, 
such as nodules, erosions, Larsen hand score, RF, anti-CCP, and thus were not included. In 
addition, disease measures specific to particular arthritides (e.g. WOMAC in OA, PASI in 
PsA, DAS44, Stoke Index, OSRA-D, Ritchie Index and PIPS in RA) were not included 
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and only general measures of disease were analysed. As such, damage measure indices 
were excluded. 
 
Comparison of mediator expression levels between the different arthritides also 
demonstrated RA patients to have the highest expression of mediators, characteristic of a 
more immunologically active type of arthritis (p=<0.05, Appendix figure 4.3b) (Stabler et 
al., 2004, Alex et al., 2007, Hueber et al., 2007). ReA patients closely followed RA with 
elevated expression of numerous mediators, while PsA and OA patients demonstrated the 
lowest levels of mediators. Interestingly, MMP-2 (p=0.0001), TIMP-1 (p=0.04), TIMP-2 
(p=<0.0001) and TIMP-4 (p=0.003) were found to be significantly lower in RA patients in 
comparison to the other arthritides, particularly that of OA and PsA patients. These 
particular mediators have well known anti-inflammatory and regulatory activities and 
therefore it is not surprising that their expression is limited in RA (McQuibban et al., 2000, 
Hoegy et al., 2001, Mannello and Gazzanelli, 2001, Itoh et al., 2002, McQuibban et al., 
2002). 
 
4.3.1 Arthritides differentiation 
 
Genesis hierarchical clustering analysis was used to determine if any biomarker profiles 
could be identified to distinguish between the different arthritides. A heat map was 
generated displaying the relative expression level of each mediator for every individual 
arthritic patient (Figure 4.3c). After 2-dimensional unsupervised hierarchical clustering, 3 
distinct patient clusters denoted as C1, C2 and C3 based on their mediator expression 
pattern similarities were identified. No clear separations between the arthritides were 
revealed, as each cluster had a mixture of each of the different arthritides. A degree of 
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separation was found between a proportion of RA patients and the other arthritides. Thirty-
six percent of RA patients grouped together in a distinct cluster (C1, n=32) of extremely 
high expression of half of the investigated mediators incorporating all of the interleukins 
and other specific mediators (eotaxin, IFN-γ, G-CSF, GM-CSF, TNF-α and MCP-1) with 
only 1 misclassified OA patient. Despite the C1 cluster being composed completely of RA 
patients bar one, it doesn’t create a useful biomarker profile in terms of aiding differential 
diagnosis as it did not include the remaining 64% of RA patients. Elevated expression of 
numerous mediators is also suggestive of RA and is in line with previous studies (Alex et 
al., 2007, van den Ham et al., 2009), and therefore this cluster could indicate a RA subtype 
that is more immunologically aggressive. 
 
  211 
Figure 4.3c: Heat map of the relative mediator expression in all arthritic patients 
 
y-axis=patient identification number, x-axis=mediators 
 
As extremely elevated mediators can skew clustering analysis in relation to the rest of the 
mediators, another unsupervised hierarchical clustering analysis on all the arthritides 
patients excluding the high mediator expression C1 RA patient cluster (plus the 
misclassified OA patient) was performed (Figure 4.3d). This can determine if any 
biomarker profiles are able to differentiate between the arthritides in patients who are 
  212 
phenotypically more immunologically similar. Similar to the previous hierarchical 
clustering analysis performed, each identified cluster denoted as C I, C II, C III and C IV 
incorporated a mixture of each of the arthritides revealing no distinct separation between 
the different arthritic diseases. However, one cluster (C IV) grouped just under half of RA 
patients (47%) with only 1 misclassified ReA patient. 
 
Figure 4.3d: Heat map of the relative mediator expression in all arthritic patients excluding 
the immunologically aggressive RA subtype 
 
 
y-axis=patient identification number, x-axis=mediators 
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Comparison of mediator expressions between the C IV cluster and the remaining clusters 
collectively were subsequently analysed to determine a biomarker profile which could 
potentially identify a large proportion of RA patients. The C IV RA prominent cluster 
demonstrated significantly lower IL-9, IL-12, IL-13, IL-15, PDGF-bb, MMP-2, TIMP-1, -
2 and -4 as well as significantly higher IL-1ra, IL-2, IL-4, IL-5, IL-6, eotaxin, G-CSF, IFN-
γ, IP-10, MCP-1, MIP-1α, TNF-α and Dkk-1 in comparison to the remaining clusters 
(p=<0.05, data not shown). This 22 mediator profile could largely explain the distinction of 
the RA prominent cluster from the remaining patient clusters. Discriminant stepwise 
selection and forward logistic regression analysis of this profile revealed a biomarker 
profile of high IL-2 (p=0.0003) and G-CSF (p=<0.0001) expression plus low IL-9 
(p=0.01(-)) and TIMP-4 (p=0.02(-)) which particularly distinguished the C IV cluster 
(model p=<0.0001, model r-squared=0.37). This cluster is different from the C1 RA 
prominent cluster as it displays a low expression of IL-9, IL-12, IL-13, and IL-15 which 
could suggest a different pathway in the development of RA pathology. 
 
As there was no clear separation between OA, PsA and ReA in either hierarchical 
clustering analysis, a separate unsupervised hierarchical clustering analysis of OA, PsA 
and ReA excluding RA patients was additionally performed (in case all RA patients skew 
arthritides differentiation) (Appendix figure 4.3e). This also failed to adequately 
differentiate the arthritides into separate clusters. There is the possibility that the specific 
mediators responsible for OA, PsA and ReA pathology were not investigated in this study 
and therefore could not be distinguished. The diverse patterns of mediator expression 
displayed on the heat maps not only demonstrate the heterogeneous immunological activity 
between arthritides but also the immunogenic heterogeneity between individuals in each of 
the arthritides as well as RA. 
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Regression analyses were also performed to gain a statistical approach for identifying 
arthritis distinguishing biomarker profiles. Analysis between RA patients and the other 
arthritides grouped together revealed a unique 6 biomarker profile of high IL-6 (p=0.05), 
MMP-1 (p=0.03), MMP-3 (p=0.02) and TIMP-3 (p=<0.0001) plus low TIMP-1 
(p=<0.0001(-)) and TIMP-4 (p=0.001(-)) expression which distinguished patients with RA 
(model p=<0.0001, model r-squared=0.36). Similar analyses were performed comparing 
each individual type of arthritis (ReA, PsA and OA) with the other arthritides grouped 
together. A small biomarker profile of elevated OPN (p=<0.0001) and low TIMP-3 
(p=0.003(-)) expression distinguished ReA patients from all other arthritides (model 
p=<0.0001, model r-squared=0.16). Another small biomarker profile of low VEGF 
(p=0.01(-)) and high TIMP-2 (p=0.02) expression distinguished patients with PsA from all 
other arthritides (model p=0.0003, model r-squared=0.11). Patients with OA demonstrated 
a profile of elevated TIMP-4 (p=<0.0001) plus low MMP-1 (p=0.05(-)) and TIMP-3 
(p=0.05(-)) expression which distinguished OA patients from the remaining arthritides 
(model p=<0.0001, model r-squared=0.17). The overall results demonstrate the important 
association of matrix remodelling mediators with a more inflammatory type of arthritis 
whereas ECM degrading enzyme inhibitors are associated with less/non-inflammatory 
types of arthritis. Interestingly, OA and RA distinguishing profiles display similar 
biomarker signatures containing MMP-1, TIMP-3 and TIMP-4 but the level of expression 
of these mediators is reversed in the two diseases. 
 
Using both hierarchical clustering and regression analysis and excluding the extremely 
elevated mediators identified in the RA prominent cluster (C1), a composite biomarker 
profile of high IL-2, IL-6, G-CSF, MMP-1, MMP-3 and TIMP-3 plus low TIMP-1 and 
TIMP-4 was collated. ROC analysis of the elevated mediator profile revealed it to be 
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“excellent” in accurately identifying RA disease (AUC 0.91, 95% CI 0.86-0.96, SE 0.024, 
p=<0.0001) (Figure 4.3f). These mediators in combination with low expression of TIMP-1 
and -4 could potentially become a specific profile to assist in RA diagnosis as well as have 
important roles in RA pathology. This biomarker profile in addition to a general elevated 
expression of numerous mediators therefore may be able to potentially identify a large 
proportion of RA patients. 
 
Figure 4.3f: Accuracy of RA distinguishing composited biomarker profile 
 
 
4.3.2 Disease activity and severity biomarker profiling between the different 
arthritides 
 
As RA is characterised as a severe and destructive type of arthritis, analyses of mediators 
with disease measures between the arthritides were performed to determine whether any 
biomarker profiles may explain the more damaging arthritis in comparison to the other 
arthritides. As regression analyses could not be adequately performed due to the limited 
number of the other arthritic patients, Spearman’s Rank correlation analysis was performed 
to compare with RA PCA data from the early cohort. 
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Numerous mediators were found to be significantly associated with various disease activity 
and severity measures in both ReA and RA patients. In contrast a relatively minimal 
number of mediators correlated with indices in OA patients and only a moderate number in 
PsA patients (Table 4.3g, h and i). This illustrates that numerous mediators are involved in 
RA pathology which reflects its characterisation as an inflammatory, immunologically 
active severe disease, whereas OA seems to have fewer inflammatory mediators involved 
in its pathology which reflects its characterisation as a non-inflammatory arthritis.
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Table 4.3g: Correlations between mediators and disease measure indices in OA patients 
 Inflammation Pain Function 
Mediator ESR CRP Platelets WBC CGDA SJ VAS TJ EMS HAQ 
Grip 
strength 
IL-6 0.54/0.02           
IL-9 0.61/0.006           
IL-13     0.47/0.04   0.44/0.04    
eotaxin           (-)0.55/0.02 
IP-10 0.57/0.01        (-)0.63/0.002   
MCP-1       (-)0.51/0.01     
MIP-1α        0.44/0.04   (-)0.51/0.03 
PDGF-bb  0.48/0.04          
VEGF  0.58/0.01  0.56/0.01 0.62/0.005 0.44/0.05  0.47/0.03    
MMP-8  0.58/0.01     (-)0.46/0.03     
MMP-9  0.53/0.02  0.47/0.03        
TIMP-1   0.59/0.007         
TIMP-2   0.57/0.01      (-)0.47/0.03   
TIMP-4   0.47/0.04       0.49/0.02  
OPG          0.54/0.01  
Values: Spearman’s Rank r correlation/p-value. (-) negative relationship.
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Table 4.3.h: Correlations between mediators and disease measure indices in PsA patients 
 
 Inflammation Pain Function 
Mediator ESR CRP Platelets WBC CGDA SJ VAS TJ EMS HAQ 
Grip 
strength 
IL-1β     0.36/0.03       
IL-5   0.35/0.03     0.36/0.03    
IL-6 0.54/0.0009 0.64/0.00005 0.39/0.02 0.59/0.0001  0.40/0.01    0.37/0.03  
IL-7   0.36/0.03 0.34/0.04 0.43/0.01       
IL-9     0.42/0.01       
IL-10         0.36/0.03   
IL-13  0.35/0.04          
IL-15   0.45/0.006       0.39/0.02  
IP-10      0.36/0.03      
MCP-1     0.38/0.02       
PDGF-bb   0.42/0.01         
MMP-1    0.38/0.03   0.39/0.01     
MMP-2  0.39/0.02       (-)0.35/0.03   
MMP-3  0.41/0.01   0.36/0.04      0.39/0.03 
MMP-8 0.44/0.009 0.36/0.03 0.40/0.01         
TIMP-1  0.40/0.01 0.34/0.04 0.44/0.007      0.41/0.01  
TIMP-2      0.34/0.04      
TIMP-4          0.35/0.04  
Dkk-1    0.37/0.03        
OPG       0.53/0.001  0.66/<0.0001 0.66/<0.0001  
Values: Spearman’s Rank r correlation/p-value. (-) negative relationship.
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Table 4.3i: Correlations between mediators and disease measure indices in ReA patients 
 Inflammation Pain Function 
Mediator ESR CRP Platelets WBC CGDA SJ VAS TJ EMS HAQ 
Grip 
strength 
IL-1β           0.55/0.004 
IL-6 0.72/0.00002 0.85/<0.0001 0.61/0.0007 0.56/0.002  0.48/0.01      
IL-7       (-)0.42/0.03     
IL-8    0.63/0.004  0.46/0.01      
IL-10 0.40/0.04 0.39/0.04  0.42/0.03       0.44/0.02 
IL-12 0.61/0.0008 0.54/0.005 0.48/0.01 0.62/0.0006  0.46/0.01      
IL-13 0.57/0.001 0.50/0.009 0.39/0.04 0.47/0.01        
IL-15    0.39/0.04       0.47/0.01 
eotaxin           0.39/0.04 
IFN-γ       (-)0.40/0.042  (-)0.40/0.04  0.49/0.01 
IP-10 0.54/0.003 0.43/0.03 0.44/0.02  0.44/0.02 0.39/0.04  0.39/0.04    
MCP-1           0.51/0.008 
VEGF 0.64/0.0003 0.54/0.005 0.52/0.006 0.50/0.008  0.45/0.02      
MMP-1 0.39/0.04 0.55/0.003 0.41/0.03         
MMP-3 0.49/0.009 0.44/0.02 0.48/0.01 0.39/0.04        
MMP-8 0.60/0.001 0.54/0.004  0.69/<0.0001  0.60/0.001    0.43/0.02  
MMP-9 0.55/0.003 0.43/0.02  0.56/0.002  0.46/0.01      
TIMP-1 0.69/0.0001 0.60/0.001 0.74/<0.0001 0.63/0.0005  0.42/0.03      
TIMP-3 0.61/0.0009 0.46/0.02 0.62/0.0008 0.52/0.006  0.52/0.007      
TIMP-4   0.40/0.04 0.39/0.04        
OPN 0.55/0.003 0.59/0.001 0.40/0.03 0.46/0.01  0.44/0.02      
OPG       (-)0.39/0.04     
Values: Spearman’s Rank r correlation/p-value. (-) negative relationship.
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Mediator profiles were found to be distinctly different between the individual arthritides 
for each of the disease measures, illustrating the varying pathological processes between 
arthritides (Tables 4.3g, h and i). ReA patients interestingly demonstrated approximately 
half of investigated mediators (IL-6, IL-10, IL-12, IL-13, IP-10, VEGF, OPN plus all the 
MMPs and TIMPs barring MMP-2 and TIMP-2) to be particularly correlated with 
peripheral inflammatory measures (ESR, CRP, swollen joints, platelet and WBC count), as 
well as the number of swollen joints, VAS and the HAQ to a degree (Table 4.3i). This 
profile, particularly the MMPs, OPN and VEGF similarly resembles a PCA derived profile 
of peripheral inflammation identified in early RA patients (early RA cohort section 4.1.3). 
These 2 arthritides seem to have some of the same pathological processes in common and 
therefore could suggest that ReA and RA may have similar disease developmental 
pathways. These mediators of ECM degrading enzymes, bone remodelling and 
angiogenesis factors also have roles in immune function (inflammation, chemotaxis, 
apoptosis regulation, effector cell and cytokine stimulation, etc.) (Mohammed et al., 2003, 
Xu et al., 2005, Clavel et al., 2007, Van Lint and Libert, 2007, Wang and Denhardt, 2008, 
Yoo et al., 2008, Candelario-Jalil et al., 2009), which in conjunction with the cytokines 
incorporated in the profile could explain the higher level of peripheral inflammation seen 
in both ReA and RA patients (Appendix table 4.3a). Although these disease activity 
indices are shown to be quite comparable between RA and ReA patients (Appendix table 
4.3a), RA patients still displayed the highest levels of peripheral inflammation. This could 
be attributed partly to Dkk-1 an indirect inducer of bone remodelling (Diarra et al., 2007, 
Ueland et al., 2009), which was uniquely associated to these indices in RA compared to the 
other arthritides (early RA cohort section 4.1.3). Furthermore, ReA patients and to a 
certain extent PsA and OA patients, showed significant correlations of IL-10, IL-12, IL-13, 
IP-10 and TIMPs with peripheral inflammation which were not reflected in RA patients 
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(Table 4.3g, h and i) (IL-10, IL-12, IL-13 and TIMPs were not included in the final PCA 
analysis of early RA patients due to their limited variance influence). These interleukins 
and IP-10 have been found to have pleiotropic actions with anti-inflammatory roles and 
angiogenesis inhibition (Angiolillo et al., 1995, de Vries, 1995, Marie et al., 1996, Xing et 
al., 1998, Chang and Radbruch, 2007, Yates-Binder et al., 2012), In addition, TIMPs are 
well known ECM degrading enzyme inhibitors as well as angiogenesis inhibitors and both 
suppress as well as induce apoptosis (Brew et al., 2000, Mannello and Gazzanelli, 2001). 
Such counteractive activities from these mediators may explain the reduced level of 
peripheral inflammation in ReA patients and the remaining arthritides in comparison to RA 
patients (Appendix table 4.3a). ROC analysis of this biomarker profile (low IL-10, IL-12, 
IL-13, IP-10, TIMP-1, -3 and -4 plus high VEGF, OPN, Dkk-1, MMP-1, -3, -8 and -9 
expression) revealed both the low and high profiles to be ‘fairly’ accurate in identifying 
worse RA disease (defined by either a severe DAS44-CRP, -ESR (score >3.7) or high 
Stoke Index (score 12-17) phenotype) (AUC 0.70, 95% CI 0.59-0.83, SE 0.06, p=0.0002, 
AUC 0.77, 95% CI 0.68-0.89, SE 0.05, p=<0.0001 respectively) (Figures 4.3j). As both 
these individual profiles were fairly accurate in identifying worse disease, their 
combination could potentially be useful in identifying severe RA. 
 
Figures 4.3.j: Accuracy of low and high biomarker expression biomarker profile for worse 
disease activity 
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4.3.3 Summary 
 
The specific biomarker profile that distinguished RA from other arthritides identified in 
this study is a unique signature compared to that of previous biomarker profiling studies. 
However, individual mediators within the profile have been identified in profiles from 
previous studies. Raised IL-2 and IL-6 were similarly found in studies which distinguished 
RA disease from PsA and OA respectively (Schlaak et al., 1996, Partsch et al., 1997, Raza 
et al., 2005, Moura et al., 2010). Therefore this biomarker profile could potentially assist in 
the diagnosis of undifferentiated arthritis where patients have an unconfirmed type of 
arthritis and would usually have to wait until symptoms further develop to make an 
accurate determination. 
 
Past studies have usually investigated RA in comparison with other arthritides in attempt to 
aid in the diagnosis of RA rather than discerning worse activity and severity. Thus the 
biomarker profile identified in this study is especially unique in comparison to other 
arthritides. This biomarker profile incorporates well characterised mediators prominently 
involved in RA inflammation and worse disease (Mohammed et al., 2003, Clavel et al., 
2007, Diarra et al., 2007, Van Lint and Libert, 2007, Wang and Denhardt, 2008, Yoo et al., 
2008, Ueland et al., 2009), and therefore has the potential to become be a novel assessment 
measure to complement current RA disease activity measures. 
 
The mediators identified in this investigation may be important in the pathways involved in 
the development of RA disease as well as the pathological process, and therefore could 
become potential targets for therapeutic intervention, such as MMPs which were 
prominently identified or possibly through the use of their natural inhibitors (TIMPs) as a 
novel treatment approach. 
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4.4 Conclusion 
 
The purpose of this research was to investigate the relationship between markers of 
immune dysfunction and RA. This study identified numerous interleukins, matrix 
remodelling mediators and pro-inflammatory biomarkers including chemoattractants, 
angiogenesis and cell growth factors as being involved in the pathological process, 
including its development and progression, and enabled its differentiation from other 
arthritides. These multiple biomarkers may be important in the molecular pathways of the 
complex cellular-mediator network involved in RA. The study illustrated and further 
contributed to the notion that RA is an extremely heterogeneous disease involving multiple 
mediators, with various possible routes of pathology. Many of the biomarkers identified in 
this study were shown to be associated with disease activity and severity, both systemically 
and from within the joint. In addition, cigarette smoking influenced biomarker expression 
in both environments and was associated with a biomarker profile which in turn was 
associated with worse disease. Thus, smoking could potentially alter immune regulation 
and stimulate RA development and progression. 
 
Therapies targeted specifically at some of these biomarkers have already been developed 
and have proved to be important in the treatment of RA. However, this study highlights the 
heterogeneity of the disease process and indicates that other markers of immune 
dysfunction may have the potential to become novel targets for therapeutic intervention as 
well as creating alternative approaches to treatments. This has already been preliminary 
demonstrated with specific biomarkers identified in this study, where VEGF gene knock-
out and OPN deficient, arthritis animal experimental models displayed reduced arthritis 
and were protected from joint destruction (Yumoto et al., 2002, Brendolan et al., 2003, 
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Mould et al., 2003). Such studies could ultimately lead to development of strategies for 
manipulating immune function, leading to remission or reduction in the severity of RA. 
Furthermore, profiles of markers of immune dysfunction may also have the potential to 
become useful clinical tools as new assessment measures for the disease process as well as 
aid in the diagnosis of arthritides. 
 
4.5 Limitations of the investigations 
 
In this study, some of the data were incomplete for individual patients i.e. data on the 
presence of erosions, autoantibodies, smoking and disease measures. In some cases 
therefore, this decreased the number of patients available for analyses and limited 
statistical significance. 
 
Within the first cohort, 9 patients were lost to 5 year follow-up. These 9 patients were 
therefore removed in comparative analysis of baseline and 5 year follow-up. The number 
of patients was also limited within the 2nd and 3rd cohorts of this study, and thus restricted 
statistical analyses. In particular, principal component analysis could not be performed to 
create specific PC profiles of important biomarkers. These were therefore analysed as 
individual markers. Furthermore, due to insufficient numbers in each of the different 
arthritic patient groups of the 3rd cohort, regression analyses of biomarkers with disease 
measures could not be performed. Alternative analyses had to be employed, and thus 
possible confounding factors could not be taken into consideration. It is evident that 
sufficient numbers of patients are required for the creation of profiles, and allowance needs 
to be made for patient loss and other factors when investigating multiple biomarkers using 
the new methodology. 
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Another limitation of this study was found when comparing patients between baseline and 
5 year follow-up RA within the first cohort. Information was unavailable at what time 
point during the 5 year period patients changed their status from past to current smoking. 
However, it should be noted that this occurred in only 3 patients, and therefore would not 
dramatically alter the results in this cohort. Such information should be recorded for future 
studies of this nature. This type of limitation was also found with DMARD treatment, 
where it was not known exactly when patients started receiving DMARDs. Furthermore, it 
can take up to 6 months for DMARDs to have any effect, while some patients do not 
respond at all to this treatment. Therefore, it should be recorded at what time point patients 
started receiving DMARD treatment, and whether they responded to treatment. 
 
Paired serum and synovial fluid samples of RA patients were procured at the same time as 
their joint flare. As a synovial effusion can occur at any time, the disease duration for each 
patient therefore varied considerably in the second cohort. The median disease duration of 
this cohort is 1.5 years, though the actual range of this cohort was from 0.16-36 years. 
Thus this cohort consisted of both early and established RA patients. Analysis was adjusted 
for disease duration wherever possible. However, this could only be performed in 
regression analyses, while other analyses, such as t-tests, could not incorporate this 
confounding factor. 
 
Two methods for measuring mediators were used in this project: bead based multiplex 
assays and ELISAs. However, comparing the modern multiplex array technology with 
traditional ELISAs, revealed a high variability between the methodologies, as IL-17 and 
FGF-β levels were significantly different between the two approaches. Although these 
particular mediators were excluded in analysis, it does give cause for concern to the 
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validity of this new bead array technology system. Differences between the two methods 
have been previously identified (duPont et al., 2005, Elshal and McCoy Jr., 2006), and 
although a significant correlation was demonstrated in measured mediators, the actual 
concentration levels differ considerably. This may be due to the different monoclonal 
antibodies, diluents, reagents and buffers used between the different assays, as this was 
also demonstrated between different kits of ELISAs (duPont et al., 2005, Elshal and 
McCoy Jr., 2006). Limiting material variability between the assays could therefore reduce 
the difference of concentration levels. Furthermore, an upgrade to magnetic beads in the 
Luminex system from the original but now discontinued polystyrene bead system, shows 
significant differences between the 27 plex data. It should be pointed out that investigation 
between the paired samples was performed by the use of magnetic beads, while the other 
27 plex assays were performed by the traditional polystyrene bead system. As a 
consequence, we have kept these two bead approaches separate in the analysis. Although, 
there are overlapping samples between the paired RA cohort and the early first cohort RA 
data set, these were then performed with both polystyrene and magnetic bead assays and 
analysed appropriately. 
 
4.6 Further suggested work 
 
A repeat of this study using additional patients plus complete database information would 
allow for larger detailed patient cohorts and thus provide more valid and confident 
findings. In particular it would be most valuable to repeat those investigations that were 
close to significance or suggested possible associations.  
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Possible future work could include the investigation of paired RA serum and synovial fluid 
samples in separate cohorts of patients with early or established disease. A comparison 
between early and late stages of disease at different time points could give useful clues as 
to how the disease progresses within the joint, and which biomarkers are responsible for 
bone damage and persist throughout the progression of the disease. 
 
Another aspect for possible further investigation would be the relationship between 
markers of immune dysfunction in the synovial fluid and the disease process in OA, ReA 
and PsA patients, in comparison with RA synovial fluid biomarker profiles. This could 
provide unique insights into the pathological process at the primary site of attack (i.e. the 
joint) in the different forms of arthritis. 
 
Further understanding of the mediator-cellular networks in RA may identify potential new 
molecular targets, and thus enable development of strategies for manipulation of immune 
function. This may include altering cell function by targeting immune regulatory 
molecules. A greater understanding of the multiple mediators involved in the inflammatory 
response may provide the opportunity to develop novel therapies for RA, as well as other 
arthritic diseases and autoimmune disorders. 
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Appendix figure 3.1.2: The patient smoking questionnaire 
 
                 Hospital number 
 
SMOKING QUESTIONNAIRE 
 
 
Surname    First name    Age 
 
Gender    Occupation 
          
           
1. Do you currently smoke cigarettes?     Yes No  
 
2. If not, have you ever smoked?      Yes No 
 
3. If you answered yes to question 1 or 2, at what age did you start smoking?  
 
4. How many cigarettes per day? 
 
5. If you answered yes to question 2, at what age did you stop smoking? 
 
6. Does your partner currently smoke?     Yes No 
 
7. If not, have they ever smoked?      Yes No  
 
8. Have you ever worked in a smokey atmosphere (e.g. pub)?  Yes No 
 
9. If yes to question 8, for how long? 
 
 
 
Thank you for your time.  
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Appendix figure 3.1.3.4: The Health Assessment Questionnaire 
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Appendix figure 3.2.3: Flow chart summarizing the rationale and the statistical analyses 
used in each cohort. 
Flow Chart: 4.1 Biomarker profiling in early and established RA 
 
Initial analyses were primarily performed for general assessment of the cohort. 
↓ 
Chi-square analysis and odds ratios between disease features (ie. early onset, 
autoantibodies, erosions and synovial effusion) were performed to determine potentially 
associated distributions and its presentation likelihood. 
 
4.1.2 Early RA 
4.1.2.1.1 Relationship of RA disease features and patient characteristics with disease 
activity and severity in early RA 
 
Preliminary assessment of the cohort was performed with RA features, patient 
characteristics and disease measures to determine their influence on disease activity and 
severity. 
↓ 
Two sample T-tests of disease measures were performed with autoantibodies, cigarette 
smoking and DMARD treatment to determine their association to the level of disease 
activity and severity. 
↓ 
Additional analyses of cigarette smoking with patients’ active smoking status and disease 
measures were performed by one-way ANOVA to compare the level of disease activity 
and severity to current and past smoking.  
↓ 
Further analysis of cigarette smoking (including patients’ active smoking status and 
stratified pack year history) with disease features were performed by chi-square analysis 
and odds ratio to determine potentially associated distributions and its presentation 
likelihood. 
 
4.1.2.2 Biomarker profiling in early RA 
4.1.2.2.1.1 Early RA Hierarchical clustering biomarker profiling 
 
Hierarchical clustering analysis (HCA) of mediators was performed to determine if 
mediator expression patterns could potentially identify biomarker profiles. 
↓ 
Two sample T-tests between the high & low HCA identified mediator expression patient 
groups and mediators were performed to identify potentially associated biomarkers. 
↓ 
Subsequently, discriminant analysis for initial biomarker selection followed by logistic 
regression of selected biomarkers were performed to identify a potentially associated 
biomarker profile. 
 
4.1.2.2.1.2 Association with early RA disease activity and severity 
 
Chi-square analysis of the HCA identified groups and disease features were performed to 
determine potentially associated distributions. 
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↓ 
One-way ANOVA of baseline disease measures between the HCA identified groups were 
performed to compare the level of disease activity and severity. 
↓ 
Two sample T-tests of mediators between HCA patient groups identified with the largest 
difference in disease activity and severity were performed to determine potentially 
associated biomarkers. 
↓ 
Discriminant analysis for initial biomarker selection followed by logistic regression of 
selected biomarkers were subsequently performed to identify a potentially associated 
biomarker profile. 
 
4.1.2.2.1.3 Association with cigarette smoking 
 
Chi-square analysis of the HCA identified groups and cigarette smokers (including ever 
smokers, patients’ active smoking status and stratified pack year history) were performed 
to determine potentially associated distributions. 
↓ 
Chi-square analysis of the HCA identified groups and DMARD treatment was also 
performed to determine potentially associated distributions. 
 
4.1.2.2.2.1 Early RA Principal Component Analysis (PCA) biomarker profiling 
 
An exploratory PCA of all mediators was performed to select specific mediators that 
provided the maximum variance and reduced the dimensionality of interrelated mediators. 
↓ 
A second PCA was performed using selected mediators to identify specific PC biomarker 
profiles based on their correlation patterns. 
 
4.1.2.2.2.2 Association with early RA disease activity and severity 
 
Multiple and logistic regression analyses (parametric and non-parametric data respectively) 
of PC biomarker profiles with disease measures and features plus patient characteristics 
(ie. cigarette smoking and DMARD treatment) were performed after initial PC biomarker 
selection with multivariate and discriminant selection (parametric and non-parametric 
respectively) to identify potentially associated biomarker profiles. 
↓ 
Similar regression analyses were performed on highly associated PC biomarker profiles as 
separate independent variables to identify potentially associated specific mediator 
biomarker profiles. 
↓ 
Since specific biomarkers were associated with overall disease activity measures (ie. 
DAS44CRP/ESR and Stoke Index), comparisons between disease activity phenotype 
categories by one-way ANOVA were performed to determine disease activity trends. 
 
4.1.2.2.3 Composite biomarker profiles 
 
ROC analyses of composite biomarker profiles collated from both the HCA and PCA 
biomarker profiling methods were performed to determine its potential for accurately 
identifying RA features, worse disease activity and erosive disease. 
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4.1.3 Biomarker profiling for RA prognosis 
 
4.1.3.1.1 Hierarchical clustering prognostic biomarker profiling 
 
One-way ANOVA between identified HCA patient groups and 5 year follow-up disease 
measures were performed to identify potentially associated prognostic biomarker profiles. 
↓ 
No ROC analysis was performed since no unique biomarker profile was identified for 5 
year follow-up disease severity. 
 
4.1.3.1.2 PCA analysis prognostic biomarker profiling 
 
Multiple and logistic regression analyses after initial discriminant or multivariate selection 
were performed with PC biomarker profiles and 5 year follow-up disease measures to 
identify potentially associated prognostic biomarker profiles. 
↓ 
Similar regression analyses were performed on baseline PC biomarker profiles that were 
highly associated to 5 year follow-up disease measures as separate independent variables, 
to identify potentially associated mediator specific biomarker profiles. 
↓ 
ROC analyses of the identified prognostic biomarker profile were performed to determine 
its potential for accurately predicting worse disease activity and erosive disease. 
 
4.1.3.2 Prognostic biomarker profiling for disease remission 
 
Chi-square analysis between baseline HCA identified groups and 5 year follow-up overall 
disease activity phenotype categories were performed to determine potentially associated 
distributions for predicting favourable outcomes (ie. remission, minimal and low 
phenotype statuses). 
↓ 
Logistic regression of baseline PC profiles and 5 year follow-up favourable outcomes 
failed to identify potentially associated prognostic biomarker profiles. 
↓ 
Discriminant analysis for initial selection of the baseline mediators identified from the 
exploratory PCA with 5 year follow-up favourable outcomes was alternatively performed. 
Logistic and discriminant regressions (when required) of selected biomarkers was 
performed to determine potentially associated prognostic biomarker profile. 
↓ 
ROC analysis of the identified prognostic biomarker profile were performed to determine 
its potential for accurately predicting favourable outcomes. 
 
 
4.1.4 Established RA 
 
4.1.4.1.1 Relationship of RA disease features and patient characteristics with disease 
activity and severity in established RA 
 
Preliminary assessment of established RA cohorts’ patient characteristics, disease 
measures and features were similarly performed as early RA cohorts’ initial assessment as 
previously described (Flow Chart 4.1.2.1.1) with two sample T-tests, one-way ANOVAs, 
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chi-square analyses and odds ratios to determine their influence on disease activity and 
severity. 
 
4.1.4.2 Biomarker profiling in established RA 
 
4.1.4.2.1.1 Established RA Hierarchical clustering biomarker profiling 
 
HCA biomarker profiling as previously described (Flow Chart 4.1.2.2.1.1) with two-
sample T-tests, discriminant analysis and logistic regression were similarly performed in 
established RA to identify potentially associated biomarker profiles. 
 
4.1.4.2.1.2 Association with established RA disease activity and severity 
 
Chi-square analysis of the HCA identified groups and disease features were performed to 
determine potentially associated distributions. 
↓ 
Two-sample T-test was performed with HCA patient groups identified with greatest 
frequency of erosions to determine potentially associated erosive biomarker profile. 
↓ 
One-way ANOVA of baseline disease measures between the HCA identified groups were 
performed to compare the level of disease activity and severity. 
↓ 
Two sample T-tests of mediators between HCA patient groups identified with the largest 
difference in disease activity and severity were performed to determine potentially 
associated biomarkers. 
↓ 
Since an overall disease activity measure was associated between HCA groups, a chi-
square analysis of HCA groups and overall disease activity phenotype categories were 
performed to determine potentially associated distributions. 
 
4.1.4.2.1.3 Association with cigarette smoking 
 
Chi-square analysis of the HCA identified groups and cigarette smokers (including ever 
smokers, patients’ active smoking status and stratified pack year history) were performed 
to determine potentially associated distributions. 
↓ 
Chi-square analysis of the HCA identified groups and DMARD treatment was also 
performed to determine potentially associated distributions. 
 
4.1.4.2.2.1 Established RA Principal Component Analysis (PCA) biomarker profiling 
 
An exploratory PCA of all mediators was performed to select specific mediators that 
provided the maximum variance and reduced the dimensionality of interrelated mediators. 
↓ 
A second PCA was performed using selected mediators to identify specific PC biomarker 
profiles based on their correlation patterns. 
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4.1.4.2.2.2 Association with established RA disease activity and severity 
 
Multiple and logistic regression analyses of PC biomarker profiles with disease measures 
and features plus patient characteristics were performed after initial PC biomarker 
selection with multivariate and discriminant selection to identify potentially associated 
biomarker profiles. 
↓ 
Since specific biomarkers were associated with specific overall disease activity measures, 
discriminant analysis and logistic regression were performed with disease activity 
favourable phenotypes (ie low, minimal, remission) to determine potentially associated 
biomarker profiles for better disease. 
 
4.1.2.2.3 Composite biomarker profiles 
 
ROC analyses of composite biomarker profiles collated from both the HCA and PCA 
biomarker profiling methods were performed to determine its potential for accurately 
identifying RA features, worse and favourable disease activity. 
 
4.1.5 Biomarker profiling RA disease progression 
 
Comparisons between early and established RA were performed to determine changes in 
disease and identify potentially associated biomarker profiles. 
↓ 
Two-sample T-tests of baseline and 5 year follow-up disease measures were performed to 
compare the level of disease activity and severity between early and established RA. 
↓ 
Mathematical calculations between baseline and 5 year follow-up disease measures were 
performed to determine the level of disease activity and severity change from early to 
established disease. 
↓ 
Mathematical calculations were similarly performed with mediators to determine the 
change in expression level from early to established RA. 
↓ 
Two-sample T-tests of mediators were similarly performed to compare the level of 
mediator expression between the 2 stages. 
 
4.1.5.1 Association of mediator expression changes and changes in disease activity and 
severity 
 
Discriminant analysis of mediator expression changes with disease measure changes for 
initial biomarker selection followed by logistic regression of selected biomarkers were 
performed to determine potential associated biomarkers. 
 
4.1.5.2 Association of mediator changes with cigarette smoking and DMARD 
treatment 
 
Discriminant analysis of mediator expression changes with ever smokers for initial 
biomarker selection followed by logistic regression of selected biomarker were performed 
to determine the potential influence of cigarette smoking on mediator changes. 
↓ 
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Discriminant analysis and logistic regression of mediator expression changes were 
similarly performed with DMARD treatment to determine the potential influence of 
DMARDs on mediator changes. 
 
 
Flow Chart: 4.2 Comparison of biomarkers in the peripheral circulation and the 
synovial fluid in RA 
 
Initial comparisons between the serum and the synovial fluid were preformed for 
preliminary assessment of the peripheral circulation and the joint. 
↓ 
Paired T-tests of mediators were performed to compare the level of immune activity 
between the 2 environments. 
↓ 
Spearman’s rank correlation analyses of mediators were consequently performed to 
determine the relationship between the 2 sites since the joint recruits mediators from the 
peripheral circulation. 
 
4.2.1 Comparison of synovial joint and peripheral circulation biomarker profiles for 
disease activity and severity 
 
Analyses were performed to determine whether biomarkers from a particular environment 
were associated with disease activity and severity in comparison to the other site. 
↓ 
Discriminant analysis of both serum and synovial fluid mediators together for initial 
biomarker selection followed by logistic regression of selected biomarkers were performed 
to identify associated biomarkers from a specific site. 
↓ 
No ROC analysis was performed since no specific environment was closer in reflecting 
disease activity and severity than the other. 
 
4.2.2 Comparison of synovial joint and peripheral circulation biomarker profiles for 
joint damage and disability 
 
Analyses were performed to determine whether biomarkers from a particular environment 
were associated with joint activity and severity in comparison to the other site. 
↓ 
Discriminant selection of both serum and synovial fluid mediators together followed by 
logistic regression (or discriminant regression as an alternative when required) of selected 
biomarkers were performed to identify associated biomarkers from a specific site. 
↓ 
Since both environments were associated with joint damage, in particular the synovial 
joint, ROC analysis of the collated biomarker profile were performed to determine its 
potential for accurately identifying erosive disease. 
 
4.2.3 Association with cigarette smoking and 4.2.4 Association with DMARD 
treatment 
 
Analyses were performed to determine whether cigarette smoking were associated with 
any effects on immune activity in either environment. 
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↓ 
Discriminant selection of the serum and the synovial fluid mediators (separate analyses) 
followed by logistic regression of selected biomarkers in both current and past smokers 
were alternatively performed (ever smokers could not be performed due to limited patient 
range) to identify potentially associated biomarkers at both environments. 
↓ 
Analyses were similarly performed to determine whether DMARD treatment were 
associated with any effects on immune activity in either environment. 
↓ 
Discriminant selection and logistic regression of selected biomarkers in both the serum and 
the synovial fluid of DMARD patients were performed to identify potentially associated 
biomarkers at both environments. 
 
 
Flow Chart: 4.3 RA biomarker profiling in comparison with other arthritides 
 
Initial comparisons of RA and the other arthritides were preformed for preliminary 
assessment. 
↓ 
One-way ANOVA’s of disease measure indices were performed to compare the level of 
activity & severity between the arthritides. 
↓ 
Mediators were subsequently compared by one-way ANOVA to determine potentially 
associated biomarkers. 
 
4.3.1 Arthritides differentiation 
 
Analyses were performed to identify potentially associated biomarker profiles for 
distinguishing RA from the other arthritides. 
↓ 
Hierarchical clustering analysis (HCA) of mediators was performed to determine if 
mediator expression patterns could differentiate the arthritides. 
↓ 
 Another HCA excluding a RA subgroup with high mediator expression identified from the 
previous HCA was performed since extreme expression patterns can skew HCA. 
↓ 
HCA identified a RA prominent subgroup that was analysed with two-sample T-tests with 
remaining patients to determine potentially associated biomarkers. 
↓ 
Subsequently, discriminant analysis for initial biomarker selection followed by logistic 
regression of selected biomarkers were performed for identification of a potentially 
associated RA biomarker profile. 
↓ 
A separate HCA excluding all RA patients was also performed to determine if mediator 
expression patterns could differentiate between the other arthritides. 
↓ 
A statistical approach was also employed, where discriminant analysis of all mediators 
followed by logistic regression of selected biomarkers for each arthritis were also 
performed, for identification of a potentially associated biomarker profile for each of the 
arthritides. 
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↓ 
ROC analysis of the composite biomarker profile collated from the 2 profiling methods 
were performed to determine its potential for accurately distinguishing RA and as a 
diagnosis profile. 
 
4.3.2 Disease activity and severity biomarker profiling between the different 
arthritides 
 
Analyses were performed to identify a potential biomarker profile for worse RA in order to 
identify more severe and damaging type of arthritis. 
↓ 
Since initial analyses identified no biomarker profiles for severity, Spearman’s rank 
correlation of mediators & disease measure indices were performed on each arthritis 
excluding RA (regression analyses could not be performed due to small patient numbers)  
to identify potentially associated biomarker profiles. 
↓ 
Correlated biomarker profiles and early RA PCA biomarker profiles were manually 
compared to identify a biomarker profile potentially associated with RA disease severity. 
↓ 
ROC analysis of the identified RA severity biomarker profile was performed to determine 
its potential for accurately identifying worse disease. 
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Appendix figure 4.2b: Correlation matrix of mediators (logged) (excluding Dkk-1 and 
RANTES) 
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Appendix Table 4.3a: Comparison of disease measures between the different arthritides 
Disease Measure Variable OA PsA ReA RA p-value† 
ESR 17 (7-29.7) 24 (13-37) 33.5 (7.5-71.5) 41 (19-66.7) 0.0008 
CRP 5 (2.7-11) 13 (6-25) 18 (3-110) 29 (6-69) 0.001 
Platelets 259 (244-312) 300.5 (266.7-350.2) 349 (260.2-481) 339 (286.5-429.5) 0.004 
WBC 7.1 (6.2-9.3) 8.3 (7.1-9.6) 8.75 (7.2-9.6) 8.5 (6.6-10.5) 0.25 
CGDA 23.5 (8.7-50.2) 35 (21-56.5) 35 (24-53) 47 (26.7-71) 0.006 
Inflammation 
SJ 2 (1-3) 3 (1.75-5) 2 (1-4) 5 (3-9) <0.0001 
VAS 37.5 (13.2-62.7) 65 (33-78.2) 50.5 (31.5-74.5) 55 (39-72) 0.16 
Pain 
TJ 3 (1-4.7) 6 (1.7-10) 2.5 (1.7-5.2) 9 (4.5-13) <0.0001 
EMS 10 (0-75) 45 (3.7-120) 30 (0-75) 60 (30-120) 0.009 
HAQ 0.93 (0.3-1.5) 0.87 (0.3-1.5) 0.56 (0.21-1.4) 1.5 (0.7-2) 0.0004 Function 
Grip strength 212.5 (120-289.5) 135 (89-260) 300 (232.5-300) 88.5 (65-120.2) <0.0001 
The Mean +SD for parametric data, the median (lower and upper interquartile range (IQR)) for non-parametric data. † One-way ANOVA or Kruskal-Wallis test as 
appropriate. 
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Appendix figure 4.3b: Comparison of mediator expression levels between the different arthritides 
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Appendix figure 4.3e: Heat map of 35 biomarkers in OA, PsA and ReA patients 
 
 
y-axis=patient identification number, x-axis=mediators 
